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Abstract
Smoking-related lung diseases including chronic obstructive pulmonary disease (COPD)
and lung cancer are projected to have claimed the lives of more than 30,000 Canadians in
2010. The poor prognosis and lack of new treatment options for lung diseases associated
with smoking are largely due to the inadequacy of current techniques for evaluating lung
function. Hyperpolarized 3He magnetic resonance imaging (MRI) is a relatively new
technique, and quantitative measurements derived from these images, specifically the
ventilation defect volume (VDV) and ventilation defect percent (VDP) have the potential
to provide new sensitive measures of lung function.

Here, we evaluate the

reproducibility of VDV, and explore the sensitivity of these measurements in healthy
young and elderly volunteers, and subjects with smoking-related lung disease (COPD and
radiation-induced lung injury (RILI)). Our results show that 3He MRI measurements of
ventilation have high short-term reproducibility in both healthy volunteers and subjects
with COPD. Additionally, we report that these measurements are sensitive to age-related
changes in lung function. Finally, in RILI we show that measurements of lung function
derived from 3He MRI are sensitive to longitudinal changes in lung function following
treatment, while in COPD we report that using VDP in conjunction with structural
measurements of disease (using the apparent diffusion coefficient (ADC) derived from
diffusion-weighted images) may provide a new method for phenotyping this smokingrelated lung disease.
Keywords: Hyperpolarized 3He magnetic resonance imaging, functional lung imaging,
ventilation defect, chronic obstructive pulmonary disease, lung cancer, radiation-induced
lung injury
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CHAPTER 1: INTRODUCTION
1.1 Overview and Motivation
More than 30,000 Canadians are projected to have died from smoking-related lung
diseases in 20101,2, which include both chronic obstructive pulmonary disease (COPD)
and lung cancer. The staggering mortality rate for lung diseases that can be attributed to
smoking continues to rise3, while current treatments remain largely unsuccessful and
potential new treatments fail in clinical trials.4-7 Currently, symptom management is the
only available treatment option for COPD aside from smoking cessation3,8, while current
treatments for lung cancer have a dismal 10-15% survival rate.9 Moreover, radiation
treatment for lung cancer causes further damage to the lung in more than 30% of patients,
a condition known as radiation-induced lung injury (RILI).10-12 These dismal mortality
statistics and the lack of new treatment options are likely a consequence of the
fundamental inadequacy of the current tools used to monitor and evaluate lung function.
Spirometry is the current gold standard for measuring lung function and is also used as an
intermediate endpoint for evaluation of new therapies in clinical trials, despite evidence
that its measurements do not to correlate well with patient outcomes.13 Established
measurements of lung function provide only global measures of largely regional diseases,
cannot differentiate between true functional impairment and various underlying structural
pathologies, and are largely insensitive to early disease-related changes, disease
progression and response to therapy.14-16 Thus, there is an urgent need for new tools that
can provide sensitive measures of lung function, probing regional lung function
independent of underlying pathology. Imaging tools have the potential to play a key role
in the development of new sensitive measurements of lung function, though they are not
yet fully developed.
This thesis focuses on the development and application of novel quantitative
measurements of lung function derived from hyperpolarized helium-3 (3He) magnetic
resonance imaging (MRI), and evaluates 3He MRI measurements of lung function in
healthy volunteers and subjects with smoking-related lung disease (COPD, lung cancer
and RILI). In order to validate new metrics aimed at quantifying lung function the
sensitivity and reproducibility of these measurements must first: 1) be characterized in

2
healthy individuals across a variety of ages, and, 2) be evaluated in the context of
currently available tools. Finally, these measurements can then be extended to evaluate
lung function in the context of COPD, lung cancer and RILI. To provide a foundation for
these concepts, Chapter 1 addresses the current understanding of lung function in healthy
young and elderly individuals. This chapter reviews the literature related to COPD, lung
cancer and RILI, outlines the current tools and imaging methods for evaluating lung
function, and describes hyperpolarized 3He MRI. Finally, an overview of the hypotheses
tested in this thesis related to a novel metric for evaluating lung function in young and
elderly healthy volunteers, as well COPD, lung cancer and RILI, derived from
hyperpolarized 3He MRI are described.

1.2 Lung Function: Delivery and Exchange of O2
On average, a person takes a breath once every five seconds, breathing more than 8,600 L
of air per day.17 The act of breathing continually introduces oxygen into the body and
expels carbon dioxide from the body. Thus, the continuous function of the respiratory
system, which is responsible for breathing, is vital for human life. The respiratory system
can be divided into two parts; the lung, the site of gas exchange, and the ventilatory
pump, comprised of the components that facilitate breathing including the chest wall,
diaphragm, inspiratory and expiratory muscles, the respiratory centres in the brain stem,
and the neural connections between the brain and respiratory muscles.18 The ventilatory
pump works by a mechanical process to expand the lung, whereby the muscles of the
thorax and abdomen work together under the control of the brain.19 In order to increase
the volume of the lungs the respiratory muscles must produce a pressure great enough to
overcome the natural tendencies of the lung and chest wall to recoil.19 When this
pressure is achieved the lung expands, and the increase in lung volume creates a negative
pressure within the lung relative to atmospheric pressure, resulting in an influx of air
from the environment (Figure 1-1). Within the lung, air flows through many generations
of airways, finally reaching alveoli; the site of gas exchange, where passive diffusion of
oxygen and carbon dioxide across the blood-gas barrier occurs.

The constant,

synchronous functioning of the ventilatory pump and the lungs allows for gas delivery
and gas exchange to occur.
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The lung, as the site of gas exchange, has a unique structural design that maximizes its
overall functional capacity. Normal lung function requires ventilation of the more than
300 million alveoli.20 The architecture necessary for gas delivery and homogenous
ventilation throughout the lungs is provided by over 2400 km of large and small airways,
with more than 20 generations of dichotomous branching as shown in Figure 1-1.20
Designed to maximize function, the dichotomous branching structure of the large
airways, from the trachea to the terminal bronchioles, and small airways (<2mm in
diameter) rapidly expand the total cross-sectional area of the airways, thereby providing a
low-resistance path for airflow.20-22 In total, the airway tree takes up a mere 3% of the
total lung volume, minimizing the anatomic dead space in the lungs, and maximizing the
volume available for gas exchange.23

Figure 1-1: Lung Function.
In the young healthy adult lung, expansion of the lungs results in airflow through approximately
2400 km of large and small airways. The airways provide a pathway for ventilation of more than
300 million alveoli, where gas exchange across the blood-gas barrier occurs.

1.3 Established Tests of Lung Function
There are an array of methods for evaluating lung function; some are commonly used in
the clinic, while others are more often performed in research studies as primary or
secondary outcome measures. Methods for evaluating lung function include quantitative
tests such as spirometry, plethysmography and diffusing capacity of carbon monoxide
(DLCO), and qualitative tests such as the modified Medical Research Council (mMRC)
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dyspnea scale. Despite the fact that these tests are either subjective or highly effort
dependent, they are for the most part inexpensive and readily accessible making them
ideal tools for clinical use. The various measurements of lung function that can be
derived from these tests are described here.

1.3.1 Pulmonary Function Tests
Pulmonary function tests (PFT) directly measure overall lung function using three
different sets of coached breathing maneuvers, which allow for the evaluation of, 1)
dynamic flow rates, 2) static lung volumes, and 3) gas exchange. Spirometry, which
measures flow rates using a spirometer (Figure 1-2A), is regarded as the gold standard for
measuring lung function. Spirometry captures two specific measurements; the forced
expiratory volume in one second (FEV1), the maximal volume of air that can be
forcefully expired from the lungs in one second and the forced vital capacity (FVC), the
total volume of air that can be forcefully expired from the lungs, as shown in Figure 12B. Static lung volumes can be measured using plethysmography (Figure 1-2C), which
requires an individual to perform a series of breathing maneuvers in a closed system
where pressure changes are measured, followed by the application of Boyle’s Law to
compute lung volumes. Lung volumes that can be measured are shown in Figure 1-2D,
and include total lung capacity (TLC), the total volume of gas in the lungs following
maximum inspiration; functional residual capacity (FRC), the lung volume at the end of
normal expiration; inspiratory capacity (IC), the volume inspired from FRC; tidal volume
(TV), the volume of gas inhaled and exhaled as during normal respiration; residual
volume (RV), the volume of gas remaining in the lungs following maximum expiration;
expiratory reserve volume (ERV), the volume of gas remaining in the lungs at the end of
normal expiration that could be expired on maximum effort; and, vital capacity (VC), the
maximum volume of gas inspired from RV. Both flow rates and lung volumes measured
are commonly expressed as a percent predicted (%pred) value that depends on age, height,
gender and ethnicity.3,24 Finally, diffusion of gases across the alveolar membrane can
also be measured using DLCO.

DLCO is measured during a breath-hold technique,

whereby alveolar volume and alveolar concentrations of carbon monoxide are derived
from measurements of the concentration of tracer gas in the inhaled and exhaled air and

5
the carbon monoxide concentration in the inspired gas.25 Closing capacity is the lung
volume at which the small airways in the dependent part of the lung close, and can be
measured using a single-breath nitrogen wash-out test.29

Figure 1-2: Pulmonary Function Testing.
A hand-held spirometer is shown in (A) with a corresponding sample airflow curve in (B),
depicting both the forced expiratory volume in one second and the forced vital capacity. (C)
displays a subject in a plethysmography body box, where plethysmography and measurement of
gas diffusion can be performed. Note that for plethysmography, the door of the body box is
closed and sealed. Lung volumes that can be measured using plethysmography are shown in (D),
and include vital capacity, tidal volume, expiratory reserve volume, residual volume, inspiratory
capacity, functional residual capacity, and total lung capacity.

PFTs are the most commonly performed lung function tests in the clinic, largely due to
the low cost associated with hand-held spirometers and their relative ease of use. Despite
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the wide-spread use of PFTs, studies have shown they are highly effort dependent, may
not be reproducible, and give a single global measurement of lung diseases that are
thought to be highly regionally variable.16 The variability in pulmonary function test
results, primarily due to inconsistency in patient effort, have been found to be higher than
for most other clinical laboratory tests.26 The American Thoracic Society (ATS) has
created acceptability and repeatability criteria to minimize the variability of these
measurements, which dictates that a minimum of three technically acceptable spirometry
maneuvers must be completed (free from artifacts and leaks, good start, acceptable
exhalation), with the two largest FEV1 and FVC measurements within 150mL of each
other.27,28 This criteria can be challenging for patients with lung disease, and many tests
are often performed before the criteria is reached. Additionally, the ability to measure
DLCO relies on the subjects’ ability to perform a breath-hold ten seconds in duration,
which is often not possible for patients with severe lung disease. Thus, pulmonary
function testing, although inexpensive and easily accessible, can be difficult to execute
properly, especially in patients with advanced lung disease. Furthermore, these tests do
not provide specific measures of underlying disease in the lung parenchyma or airways.

1.3.2 Clinical Measurements of Breathlessness
Clinical measurements of breathlessness aim to evaluate lung function by measuring
dyspnea (shortness of breath) both qualitatively and quantitatively. The mMRC scale is a
survey of respiratory symptoms that has been well validated in the literature.29 This scale
requires the subject to select one of five statements that best describes the type of
physical task that usually leaves them feeling breathless, such as ‘I get short of breath
when hurrying on level ground or walking up a slight hill’.30 Advancing on the mMRC’s
single component system, the St. George’s Respiratory Questionnaire (SGRQ) addresses
three areas of concern, including symptoms, activities that relate to breathlessness and
disturbances to daily life.29

This self-administered questionnaire includes 76 items

weighted by the distress associated with each.29 Another, more objective test used to
evaluate breathlessness is the six minute walk distance (6MWD), whereby the distance
that an individual can walk in six minutes on a hard flat surface is measured.31 Results of
the 6MWD test have been correlated to quality life and ability to complete daily
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activities, and used to predict morbidity and mortality.31

In fact, both mMRC and

6MWD have been shown to be better predictors of mortality in COPD than FEV1.32
Overall, these tests are inexpensive, highly accessible, and despite their subjective nature
appear to correlate well with disease outcomes.

1.3.3 Inflammatory Markers
Inflammation is heavily associated with the development of COPD, and subsequent
decline in lung function.

Inflammatory markers that may be related to COPD

development and/or progression can be measured using bronchoalveolar lavage (BAL)
and induced sputum measurements.31 BAL is an invasive method using bronchoscopy to
collect cells and proteins found in pulmonary secretions for evaluation.31 While the
patient is sedated a flexible bronchoscope is used for direct visualization and guidance
through the airways to a location where the pulmonary secretion is sampled, generally at
the level of the subsegmental bronci (4th-6th generation).31 At the location to be sampled,
a saline solution is flushed into the airway, and then drawn back out for analysis. This
technique allows for assessment of eosinosphils, neutrophils, lymphocytes, mast cells,
machrophages, histamine and subcellular protein components.31
Induced sputum measurements of inflammatory markers can also be made.

In this

procedure an individual inhales nebulized hypertonic saline that induces sputum
production, specifically from the lower airways for sampling.31

Due to the highly

invasive nature of these procedures, coupled with the costs associated BAL, the widespread use of these techniques is limited.

1.3.4 Other Tests
Other tools have been developed to evaluate lung function, including the BODE index.
This test combines four measures of lung function that have the strongest association
with mortality – body mass index (BMI), airflow obstruction, dyspnea, and exercise
capacity.33

In this test measurements of these four parameters, BMI, post-

bronchodialator FEV1 %pred value, mMRC dypnea score and 6MWD, are each scored on
a scale of zero to three (zero or one for BMI) and summed to compute a total BODE
index score out of ten.33

8
Another approach to evaluate lung function is to evaluate exertional dyspnea.
Cardiopulmonary exercise testing (CPET) allows for the simultaneous study of responses
of the respiratory system to a known exercise stress through the measurement of gas
exchange with the airway.34 In addition to measuring gas exchange, oxygen uptake
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electrocardiography, heart rate and blood pressure can also be measured.34,35 There are a
number of different protocols for CPET, using either a treadmill or cycle ergometer.
Protocols are classified according to how the work rate is applied, and include 1)
progressive incremental exercise, 2) a multi-stage exercise protocol, 3) a constant work
rate protocol, and 4) a discontinuous protocol.35

1.4 Functional Decline of the Lung
There is a natural decline in lung function that occurs due to aging and this decline occurs
at an accelerated rate in individuals with lung disease. Accelerated functional decline
occurs with smoking-related lung diseases, including COPD, lung cancer and RILI.
Section 1.4 of this thesis provides an overview of the functional lung changes that occur
with age, COPD, lung cancer, and RILI, as well as the underlying pathology thought to
cause lung function impairment, and commonly presented symptoms that lead to COPD,
lung cancer and RILI diagnosis.

1.4.1 The Aging Lung: Normal Functional Decline
During the first two decades of life the lungs grow and mature, reaching maximal
functional capacity at the age of approximately 20 for females and 25 for males.36
Beyond this age, four basic physiological changes associated with aging begin to occur,
including: 1) a decrease in the elastic recoil of the lung, 2) a decrease in compliance of
the chest wall, 3) a decrease in strength of the respiratory muscles, and, 4) a change in
shape and structure of the lung.36-38 The decreases in static elastic recoil pressures that
occur with age are most evident at high lung volumes (above 40-50% of TLC), which
results in increased lung compliance (ability of the lungs to increase in volume with
applied change in pressure) at these lung volumes.39 The decline in lung elastic recoil
can be attributed to changes in connective tissue; specifically elastin and collagen,
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although conflicting evidence exists as to the exact changes that occur.39 Stiffening of
the chest wall occurs as its rigidity increases due to other age-related changes including
decalcification of the ribs, costal cartilage calcification, changes in shape of the chest, and
narrowing of the intervertebral disk spaces.39 During normal breathing, the lung volume
increase that results from rib cage expansion is 40% of the total volume increase. This
drops by 10% to 30% in the elderly, while the energy required for chest wall movement
is 70% of the total elastic work required to breathe, as compared to 40% in a 20 yearold.39 Additionally, the diaphragm muscles have been shown to decline in strength in the
elderly, which may be due to an overall decline in muscle mass with age.40 With age, the
lung changes shape due to the increase in kyphotic curvature of the spine and
anteroposterior diameter of the chest wall.39 The large airways are not generally affected
by aging, other than calcification of the bronchial cartilage, which results in a slight
increase in anatomic dead space.39 In contrast, the small airways decrease in diameter
due to a decrease in tethering, which would normally maintain patency at a given lung
volume, leading to premature airway closure.39,40 These changes in the small airways
result in air-trapping and ventilation-perfusion mismatching.40 There is an increase in
distal airspace size with aging, resulting from loss of supporting tissue, along with a loss
in the number of capillaries per alveolus.38,41 Overall, the total alveolar surface area of
the lung decreases by 0.27 m2/year, from 70m2 at age 20 to 60 m2 at age 70.39 These agerelated changes do not alter day-to-day lung function, as assessed by blood oxygenation
and ventilation, although the respiratory system of elderly individuals has a diminished
ventilatory response to hypercapnia, making them more vulnerable to respiratory failure
and hypoxia when compromised (i.e. pneumonia).41,42
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Figure 1-3: Normal Decline in Pulmonary Function with Age.
The functional decline of the healthy aging lung, as measured by FEV1 is shown in this
schematic. In the healthy elderly adult the decline in lung function does not amount into
clinically relevant airflow obstruction. Adapted from reference (43).

The underlying physiological changes that occur in the lung with increasing age effect
lung function, and the aging effect has been well characterized in cross-sectional studies
using PFTs. The classic study by Fletcher and Peto in 1977 was the basis for our current
understanding of functional lung decline that results from aging.43 This study showed a
continuous decline in FEV1 beginning at the age of 25, at a rate of approximately 42
ml/year43, but this decline did not reach the threshold of clinically relevant airflow
obstruction (Figure 1-3). The effects of age on lung function can also be detected with
other PFT measurements, with results indicating that increased age is associated with an
increase in RV, RV/TLC, and FRC (due to increased lung compliance), a decrease in
FVC, and IC while TLC shows no change with age.36,38,41,44 Additionally, VC declines
by approximately 26mL/year in men and 21mL/year in women.39

Interestingly, a

longitudinal study using pulmonary function testing in fit, healthy elderly subjects (in
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their sixth and seventh decades) showed that the longitudinal rate of change in VC, RV
and FEV1 is significantly greater than would be predicted from cross-sectional data.45
The authors of this study hypothesized that the accelerated rate of decline reported in this
longitudinal study may reflect non-linear changes in lung function in a subset of the
population, which may be averaged out in cross-sectional studies.45 Finally, the effects of
age on gas diffusion across the blood-gas barrier have also been evaluated using the
DLCO, with results indicating that there is a decline in DLCO with age, corrected for
alveolar volume.46 The reported decrease in DLCO correlates well with the decrease in
internal surface area of the lung.39
Overall, physiological changes associated with aging can be quantified using PFTs, and
these measurements show a decline in lung function in healthy adults as they age, with
longitudinal studies showing that the rate of decline may be greater than previously
thought.

1.4.2 Chronic Obstructive Pulmonary Disease: Accelerated Functional
Decline
COPD is defined by the ATS as a preventable and treatable disease state characterized by
airflow limitation that is not fully reversible, and usually progressive.47

Airflow

limitation in COPD is associated with an abnormal inflammatory response in the lungs to
inhaled noxious particles or gases – most commonly cigarette smoke.3,8,47 COPD is the
fourth leading cause of death worldwide, with morbidity and mortality rates expected to
increase in the coming years.8 At least 750 000 Canadians are currently living with
COPD, and as much as 10% of the population worldwide has the disease.48,49 COPD
results in thousands of hospitalizations in Canada every year, with the average hospital
stay lasting 10 days and costing $10,000.50,51 Additionally, 18% of patients will be
readmitted within the year.50,51 Given that COPD is largely underdiagnosed, the true
prevalence of this disease is not known.8 Although current prevalence data is thought to
largely underestimate the burden of COPD, historically the data has suggested that COPD
occurs more commonly in men, but more recently the prevalence of COPD appears close
to equal between the genders, with the latest data suggesting women may be more
susceptible to developing COPD.49,52
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COPD is caused by the inhalation of cigarette smoke and other toxic particles, which
invoke a local and systemic inflammatory response.53 In the subset of smokers that
develop COPD this inflammatory response is persistent54 and amplified.55

The

inflammatory reaction leads to pathological changes in four specific areas of the lung; the
central airways, small airways, lung parenchyma and pulmonary vasculature47 resulting
in chronic bronchitis, small-airway obstruction, emphysematous destruction and
pulmonary hypertension respectively.53 Emphysema is characterized by the dilation and
destruction of lung tissue beyond the terminal bronchioles (Figure 1-4A).22 As shown in
Figure 1-4B, chronic bronchitis is associated with inflammation in the central airways
resulting in increased mucus production, defective mucociliary clearance and thickening
of the bronchial walls22, while small-airway obstruction is associated with a remodeling
of the airways leading to a thickening of all compartments of the airway wall and a
malfunctioning of the mucociliary clearance apparatus resulting in an accumulation of
inflammatory exudates in the airway lumen.22,56,57

The occurrence of pulmonary

hypertension in COPD is likely caused by hypoxic vasoconstriction.58
Spirometric measurements are used to diagnose COPD, as the disease is characterized by
irreversible airflow limitation.

The current ATS guidelines state that a post-

bronchodialator FEV1/FVC < 0.7 dictates a diagnosis of COPD, with disease severity
determined based on the FEV1 %pred values (stage I FEV1 ≥ 80%pred, stage II 50%pred ≤
FEV1 < 80%pred, stage III 30%pred ≤ FEV1 < 50%pred, stage IV FEV1 < 30%pred).3 The
seminal cross-sectional study by Fletcher and Peto showed that the rate of decline in
FEV1 in smokers with COPD is significantly greater than age-matched healthy
volunteers, although smoking cessation slows the rate of decline to that of normal healthy
aging (Figure 1-4).43 COPD is also associated with increases in TLC due to loss of
elastic recoil, RV due to the premature closing of narrowed airways at higher lung
volumes, and RV/TLC, especially in advanced COPD.59 A decrease in IC in COPD
patients is indicative of hyperinflation.59 A decline in DLCO is measured in patients with
COPD, reflective of the loss in alveolar surface area.60
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Figure 1-4: COPD Pathology and Decline in Lung Function.
Emphysematous destruction and chronic bronchitis are shown in A and B respectively. The
functional decline of the lung likely releated to these underlying conditions is shown in panel C,
where Ci shows the natural decline in lung function due to age, Cii shows the decline associated
with smokers susceptible to lung disease and Ciii and Civ show the decline in lung function
associated with smoking cessation at 45 and 65 years respectively. Adapted from references (22),
(43), and (212).

Those with COPD may experience a wide variety of symptoms including chronic cough,
sputum production, dyspnea, wheezing, and chest tightness.3

Generally, the first

symptom to develop is coughing, followed by sputum production.8 The primary reason
medical attention is sought is for dyspnea, which is also the major cause of disability
associated with COPD.3,8 Symptoms are often related to smoking history as defined by
pack-years; the number of years smoked multiplied by the number of packs smoked per
day. These symptoms often result in a significant interference with normal activities of
daily living and a decline in quality of life, which are assessed in research studies using
quality of life metrics including the SGRQ61, the 6MWD62-64, mMRC65 and the BODE
index.33,66 Quality of life measures including the mMRC scale, the 6MWD, and BMI are
all better predictors of mortality than FEV1.32 The BODE index predicts mortality in
COPD patients better than any of its components taken independently.33
COPD is well described as a complex and heterogeneous disease in terms of clinical
presentation, underlying pathology, physiology, imaging, response to therapy, decline in
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lung function, and survival, which may be reflective of distinct underlying phenotypes.67
The identification of elements that could be used to group COPD patients into clinically
meaningful subgroups, providing prognostic information useful for guiding current
treatments, and developing new therapies is necessary.67 Although many studies have
proposed potential COPD phenotypes68-71, large-scale longitudinal clinical studies aimed
at identifying COPD phenotypes are needed to begin to enhance our understanding of the
disease in this regard.67

Studies of this nature, collecting clinical, physiological,

radiological, biological and genetic data, aimed at evaluating COPD phenotypes are
currently underway.14,72

1.4.3 Lung Cancer
Lung cancer is the leading cause of cancer related death, as shown in Figure 1-5, and
responsible for more than 1 in 4 of all projected deaths from cancer.2 In 2010 it is
projected that 24,200 Canadians will have been newly diagnosed with lung cancer, an
incidence rate second only to prostate cancer, and an additional 20,600 currently
diagnosed Canadians will die from the disease.2

Figure 1-5: Canadian Incidence and Mortality in Cancer for 2010.
Projected incidence and mortality rates for cancer in Canada in 2010. Lung cancer is projected to
be the second most commonly diagnosed cancer, and cause more than one in four of all cancerrelated deaths. Adapted from reference (2).
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The first classification system for lung cancer was proposed in 1924 by Marchesani and
co-workers, and is the basis for World Health Organization (WHO) classification used
today.9,73 According to the current WHO classification, lung cancer can be divided up
into four major histological subtypes; squamous cell carcinoma, adenocarcinoma, smallcell carcinoma and large-cell carcinoma.74,75 Squamous cell carcinomas are generally
larger than 4 cm in diameter, display cavitation, and are centrally located, often causing
segmental or lobar collapse due to their location.9,76 Adenocarcinoma on the other hand
are usually located in peripheral regions of the lung, are typically less than 4 cm in
diameter, and rarely cavitate.9,76 Squamous cell and adenocarcinomas each comprise
about 30% of all lung cancers seen in the clinic.75

Small cell carcinomas are

characterized by small tumour cells that are densely packed with limited cytoplasms and
no nucleoli77, while large-cell lung cancers are usually poorly differentiated9, grow
rapidly and metastasize quickly.78 Squamous cell carcinoma, adenocarcinoma and largecell lung cancer are frequently grouped into one category called non-small cell lung
cancer (NSCLC) because of similar treatment options79, while small-cell lung cancer
(SCLC) is treated with a different approach due to its chemosensitivity and mode of
metastatic spread.
Lung cancer is treated according to the stage of the disease. Staging occurs according to
the International System for Staging Lung Cancer; the T- primary tumour, N- regional
lymph nodes, M- distant metastasis (TNM) classification.

The primary tumour is

classified on a scale of one to four according to its size (diameter) and location with
respect to the chest wall, carina (ridge separating openings of right and left main
bronchi), diaphragm, mediastinum and pericardium.80

Regional lymph nodes are

classified according to metastasis – either not present (0), present in the ipsilateral
peribronchial and/or ipsilateral hilar nodes (1), present in the ipsilateral mediastinal
and/or subcarinal lymph nodes (2), or metastasis mediastinal or supraclavicular lymph
nodes (3).80 Distant metastases are either not detected (0), or present (1).80 The overall
stage of a lung cancer is then determined by the combination of T, M and N stages. For
example stage IIIA lung cancer can be any one of the following combinations: T3N1M0,
T1N2M0, T2N2M0, or T3N2M0. Each overall stage has similar treatment options and
survival expectancies.80 Stage I and II (and occasionally IIIA) lung cancers are operable,
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and surgery is performed as it has the highest long-term survival rates.75 Stage III
generally means that the tumour is non-resectable due to its location along the
mediastinum and presence of positive nodes not having spread beyond the lung.81 In this
stage curative treatment combining chemotherapy and radiation therapy is the most
common approach.75,79 Stage IV lung cancer indicates that the tumour has metastasized
beyond the lungs, and therefore in this late stage, palliative treatment is most commonly
provided.75
Many lung tumours result in occlusion of the major airways causing breathlessness.
Dyspnea is an early symptom in 60% of lung cancer cases, and accompanies other
symptoms, including chronic cough and sputum production or hemoptysis.75,82 Patients
with lung cancer frequently have co-existing lung disease that adversely impacts lung
function, and limits options for cancer therapy.82,83 In a retrospective study of 294 newly
diagnosed lung cancer patients with previously collected pulmonary function tests,
findings revealed that 73% of men and 53% of women had airflow obstruction fitting the
definition of COPD.84 The prevalence of COPD in this study is potentially overestimated
due to the impact of tumour burden of airflow measurements, and therefore highlights the
difficulty in evaluating undiagnosed underlying lung disease in patients with lung cancer.
Thus, the interaction between underlying lung disease, lung cancer onset, treatment, and
survival outcomes are unclear.

1.4.4 Radiation-induced lung injury
Radiation treatment for lung cancer can be curative, but it can also be fatal. Damage to
the lung can be incurred from radiation treatment leading to a significant decline in lung
function accompanied by symptoms that degrade quality of life.10 RILI is the major
dose-limiting toxicity of lung cancer radiation.

The lung is extremely sensitive to

radiation, with RILI occurring in an estimated 5-35% of patients undergoing thoracic
radiation, and the incidence of moderate to severe radiation injury between 10-20%.12
With increasing severity, survival rates decrease dramatically, and studies show 3-year
survival rates of 0% in subjects with severe injury.85
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Figure 1-6: Stages of Radiation-induced lung injury.
The acute phase of radiation pnuemonitis followed by the chronic late phases encompassing radiation fibrosis are shown in this schematic, along
with the associated complications commonly arising in each phase. Adapted from reference (87).
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RILI occurs in a series of stages, as depicted in Figure 1-6 - an early latent phase
followed by an intermediate acute phase, a subacute phase, a late phase, and a chronic
phase.86,87

The intermediate acute phase – radiation pneumonitis, is marked by an

inflammatory response during which leukocytes, plasma cells, macrophages, and
fibroblasts invade the alveoli causing capillary obstruction and septal thickening.10,88
Radiation fibrosis (late and chronic phases) is marked by further septal thickening and
obliteration of the alveolar space.88 This immune response is manifested in the form of
clinical symptoms which include dyspnea and a productive or non-productive cough in
the pneumonitis phase, and may develop into more severe dyspnea, reduced exercise
tolerance, orthopnea (difficulty breathing when not upright), cyanosis (bluish colour of
the skin due to insufficient oxygen), chronic cor pulmonale (a complication of pulmonary
disease leading to enlargement of the right ventricle), and finger clubbing as the injury
moves to the fibrotic stage.89
Many potential predictors of RILI have been examined including age, gender, histology,
stage, tumour lobe, lung involved, performance status, weight loss, chemotheraphy drugs,
chemoradiation schedule, pulmonary function tests, radiation dose, daily dose delivered
and volume irradiated, with the majority showing no significant relationship to RILI
risk.11,90 Robnett et al. indicated that low pre-treatment absolute FEV1 was significantly
associated with the development of severe radiation pneumonitis, and all patients in this
study with severe RILI had a pre-treatment FEV1 of less than 2.0 litres.91 Recently,
Rodrigues and co-workers have shown that elevated dose-volume parameters including
the percentage of lung volume receiving greater than 20Gy and mean lung dose remain as
the main correlation risk factors but with very low predictive value as an ensemble.11

1.5 Imaging Measurements of Lung Function
Pulmonary imaging has evolved over many decades, with a large focus in recent years on
structural techniques, specifically with the development of high resolution x-ray
computed tomography (HRCT). Imaging techniques including nuclear medicine and
MRI, aimed at evaluating lung function in COPD, lung cancer and RILI, have lagged
behind structural lung imaging methods, and although in the last two decades some major
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advances in functional lung imaging have been made, the clinical translation of these
techniques has yet to be seen.

1.5.1 Chest x-ray
The chest radiograph (Figure 1-7) is the most commonly acquired image for the
evaluation of the lung.92 The standard method for acquiring chest x-rays is for the subject
to stand with their back to the x-ray source and their hands placed on the posterior aspects
of the hips with the elbows rolled forward such that the scapulae are not in the lung field,
referred to as a postero-anterior (PA) x-ray.93

The PA x-ray is acquired at full

inspiration to capture the greatest possible area of lung structure A lateral projection is
often acquired in addition to the PA projection, with the median sagittal plane of the
subject parallel to the film and the subjects arms folded across their head.93,94

In a chest

x-ray of a healthy young individual x-rays travel from the x-ray source on the posterior
side, and through the lung parenchyma with relatively little attenuation or scatter, as
compared to other bony thoracic structures such as the ribs or clavicles. The x-rays
interact with the detector on the anterior side of the subject, generating an image in which
the lung tissue appears predominantly black.95 The branching of the pulmonary vessels
can be seen; the fissures separating the lobes of the lungs may be visible; the trachea is
centered; and the diaphragm appears as a smooth curve with acute and clearly defined
costophrenic angles.93,95 The radiation dose associated with a typical chest x-ray is
0.02mSv, which is equivalent to approximately three days background radiation.96 This
transmission-based imaging method is fast, widely available, and deposits relatively low
radiation doses as compared to other lung imaging modalities used clinically.97
A longitudinal study of chest x-rays acquired in a group of healthy men initially 48±13
years, and followed for 17±3 years, showed a doubling in hyperinflation, increased
markings, a three fold increase in the presence of enlarged pulmonary arteries and a
dramatic increase in the presence of Kerley B lines (thickened interlobular septa visible
in the subpleural region).98 The width of the cardiac silhouette also increases with age.95
COPD can be difficult to detect on chest x-ray due to poor contrast of the twodimensional (2D) projection image99, and detectability is related to overall severity of
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COPD (stage III and IV are most easily detected), rather than specific underlying
pathology such as emphysema or small airways disease.60,100

Patients with COPD

usually exhibit some degree of hyperinflation due to emphysema or airways disease,
which presents as a flattened diaphragm, a large lucent retrosternal air space, a narrow
vertical heart, and an overall increase in the anterior-posterior diameter of the chest
(Figure 1-7B).60,100,101 Focal areas that are hyper-lucent (darker than normal) within the
lung parenchyma may be indicative of bullous disease.101

Figure 1-7: Chest x-ray of healthy volunteer, COPD and lung cancer.
Chest x-rays are shown for a healthy individual in A, a subject with COPD in B, and a subject
with lung cancer in C. B displays hyperinflation and the presence of flattened diaphragm (as
indicated by arrows) common on chest x-rays of COPD. The arrow in C points to a tumour in the
right upper lung.

Chest x-rays continue to be the imaging modality used for the diagnosis of lung cancer
(Figure 1-7C), despite their inaccuracy, largely due to the wide-spread availability and
low cost relative to CT and MRI.102,103 Chest x-ray is not a reliable method for detecting
lung cancer, and many small tumours are missed.103,104 Failure to detect lesions at
favourable and even larger sizes can occur because the lesions can be obscured by the
mediastinum and other aspects of the thorax.104 In the context of lung radiotherapy,
treatment plans were made using x-ray films until the 1980’s.105 These films provided
only two-dimensional information with high levels of uncertainty surrounding precise
tumour location, necessitating large planning target volume (PTV) margins (2-3cm in all
directions) to account for this.105
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Chest x-ray in RILI is critical for diagnosis, as symptoms are non-specific and pulmonary
function tests are not routinely performed in follow-up evaluation. Changes in chest xray are usually first detected 2-3 months following radiation therapy, and include
increased ground glass opacity, indistinctness of the usual pulmonary markings.89 The
appearance of acute radiation pneumonitis on chest x-ray widely varies, ranging from
minimal changes (slight indistinctness of the pulmonary vasculature or slight increase in
the thickening of the pleura) to complete consolidation of the irradiated area.106 If
fibrosis follows the pneumonitis phase, it commonly appears on chest x-ray as apical
thickening, a slight retraction or elevation of a hemidiaphragm, minimal retraction or
elevation of the hilum or minor fissure, linear strand-like densities in the area where
pneumonitis was present.86,106 Retraction secondary to radiation fibrosis follows the
typical appearance of fibrosis of any other etiology.106

1.5.2 X-ray Computed Tomography
In recent years, x-ray computed tomography (CT) has become the imaging modality of
choice for evaluating the lung, providing highly detailed images with isotropic voxel size,
all captured in a ten-second breath-hold.107,108 The development of CT in the 1970’s
brought about many changes in terms of lung imaging. Through the acquisition and
reconstruction of multiple projections of data, cross-sectional images of the body can be
obtained.102 Each image slice is a matrix of pixels representing a voxel of tissue, and
specific to CT, each pixel is assigned a CT number based on the attenuation of signal in
that pixel in relation to the attenuation of water.102 CT is generally taken to be the best
imaging modality for the evaluation of lung parenchyma, with HRCT providing
morphological detail of the lung and generally accepted as the gold standard for structural
assessment of the lung.109

Despite the excellent morphological detail of the lung that

thoracic CT provides, concerns remain regarding the radiation dose associated with these
scans. A typical thoracic CT has an effective dose of 8 mSv, which is the equivalent of
approximately 400 chest x-rays or 3.6 years of background radiation.96
Although CT is generally regarded as a structural imaging technique, recent research has
evaluated the potential to extract functional information from inspiratory and expiratory
CT and four-dimensional CT.110-112 This emerging field of research has shown that

22
registration, thresholding and subtraction of pixel values at maximum inspiration and
expiration may yield information regarding ventilation by evaluating density changes in
registered pixels.110-112

Research is continuing in this area, and studies aimed at

evaluating the reproducibility, sensitivity, and correlates with currently accepted markers
of lung function are required.
Cross-sectional CT studies of healthy young and elderly subjects have been performed to
identify characteristics on CT that can be attributed to the normal aging process, in order
to differentiate features associated with aging from those associated with potential
disease. Findings suggest that in older healthy subjects there is a statistically significant
increase in the prevalence of reticular pattern, cysts, bronchial dilation and bronchial wall
thickening in elderly subjects, while no difference between ground glass opacity,
interlobular septal thickening or centrilobular emphysema was found.113 Another study
examining age-related differences apparent on CT found that mean lung attenuation
values decreased significantly with increasing age, while mean lung volumes showed no
significant change with increasing age.114
CT imaging of COPD patients is routinely used to qualitatively detect emphysema, as
shown in Figure 1-8A. Centrilobular emphysema (CE) is the most common form and
strongly associated with cigarette smoking. CE is characterized by focal regions of
decreased attenuation that are confined to the center of the secondary lobule, and is most
commonly located in the upper lobes.109 Two methods for quantifying emphysema from
CT have been developed based on areas of low attenuation. The first is a threshold cutoff
based on Hounsfield units (HU) to separate emphysematous tissue from normal tissue,
with the most common threshold being -950 HU.108,115 The second method uses a
percentile point on the frequency distribution curve of attenuation values to compare
subjects or groups of subjects.108 The 15th percentile is most commonly used, and is the
preferred method for longitudinal analysis.108,115 Quantitative CT analysis of COPD
patients commonly show an increase in low attenuation areas116-119 and increases in
airway wall area dimemsions119-123 reflective of emphysema and airways disease
respectively. Although a number of algorithms exist to evaluate airway wall dimensions,
the small airways cannot be well resolved on current resolution of CT.108 Given that
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these airways, <2mm in diameter, are the main site of airflow obstruction in COPD it is
likely that current measurements of airways disease using CT largely underestimate the
true burden of this underlying pathology in COPD.108 Despite the limitations of CT
airway measurements, Nakano and co-workers used measurements of emphysema and
airways disease derived from CT in an effort to understand their relative contribution in
COPD. They were the first to use CT as a tool for phenotyping COPD, and reported a
single dominant phenotype in 40% of subjects.121 A longitudinal study using CT by
Ohara et.al. showed that surrogate measures of airways disease did not correlate with
FEV1 at baseline, but changes in airway measurements over four years were significantly
inversely correlated to the change in FEV1 over the same time period.123 The change in
percentage of low attenuation areas in this same study did not correlate with the decline
in FEV1.123

Figure 1-8: CT of Smoking-related lung disease.
COPD is identifiable on CT by the areas of decreased signal intensity and flattened diaphragm as
indicated by the arrows in A. Arrows in B show stage IIIB lung cancer with the presence of
underlying COPD, while the arrow in C points to RILI as evidenced by the marked increase in
lung density in the irradiated portion of the lung.

CT is the modality of choice for evaluating lung cancer (Figure 1-8B), and is used for
guidance of transthoracic needle biopsies of lung nodules.124 Perhaps more importantly,
CT is critical for staging lung cancer in terms of identifying tumour size, location, local
extent of the primary tumour, including the presence or absence of atelectasis, pleural
effusion, the status of the mediastinum, and lymph node abnormalities.125 In recent
years, given the dismal outcomes of the disease, the benefits of CT screening for lung
cancer have been debated, amid concerns regarding radiation dose.126 The National Lung
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Screening Trial (NLST), a multi-centre randomized control trial, is evaluating spiral CT
against standard chest x-ray for detection of lung cancer.126,127

Results released in

December 2010 from the NLST show a significant decrease of 20% in the number of
deaths in the group screened with low-dose helical CT.128 The appearance of thoracic
tumours on chest radiography and CT differ based on the histological classification of the
tumour.

On chest radiography approximately half of all adenocarcinomas display

mediastinal lymphadenopathy129, while on CT these tumours are characterized by either a
localized ground glass opacity with a doubling time greater than one year, or a solid mass
with a fast doubling time, less than one year.130 In regard to radiation treatment planning,
three-dimensional information for the purposes of target definition and treatment
planning became widely available in the 1990’s when CT largely replaced
radiography105, and is now viewed as the minimum standard of care in the treatment of
thoracic tumours.131
Radiographic evidence of RILI is frequently observed following radiotherapy, although
only a fraction patients presenting with radiological evidence of RILI complain of
symptoms.132 CT evidence of RILI is shown in Figure 1-8C, and was described by
Libshitz et al133 as: 1) homogenous, with a slight increase in density uniformly involving
the irradiated portions of the lung, 2) patchy consolidation contained within the irradiated
lung, but not conforming to the shape of radiation portals, 3) discrete consolidation
conforming to the shape of radiation portals, but non-uniformly, 4) solid consolidation
conforming to and totally involving the irradiated portions of the lung. Radiation fibrosis
has also been described on CT as well defined areas of atelectasis with parenchymal
distortion, traction bronchiectasis, mediastinal shifting and pleural thickening.10,134,135 In
comparison to chest x-ray, CT is more sensitive to RILI-related changes in the lung and
demonstrates changes sooner following treatment.133,136-138

1.5.3 Nuclear Medicine Methods
Scintigraphy, single photon emission computed tomography (SPECT) and positron
emission tomography (PET) have all been used in the context of functional lung
imaging.139 Planar scintigraphy images are still acquired clinically, however, research
studies of lung function using nuclear medicine now focus on SPECT and PET
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approaches.139 Ventilation and perfusion are commonly imaged using these nuclear
medicine techniques.
Ventilation images are generated using a gamma camera, which detects gamma rays
released following radionuclide decay, with scintigraphy capturing a single 2D
projection, and SPECT images reconstructed from multiple 2D projections.140,141
Ventilation imaging using scintigraphy or SPECT can be performed with radioactive
gases (133Xe,

127

Xe,

81m

Kr) or radiolabeled aerosols (i.e. Technegas).139

Radioaerosols

can be used as an alternative to radioactive gases, although their distribution is not always
ideal.139,142 When an aerosol such as Technegas is used, the deposition and distribution
depend on its aerodynamic properties – primarily the particle size, with particles larger
than 2µm tending to deposit in the large airways of the lung.143 Ventilation patterns of
the lung are studied using an array of protocols that largely depend on the half-life of the
radioisotope used.144 Ventilation can be evaluated during the wash-in phase of the gas,
followed by the steady state and wash-out phases. This allows for analysis of lung
volumes, regional clearance rate and gas trapping.144 The effective radiation dose from
these scans ranges from 0.1-0.6mSv.

Ventilation images are often coupled with

perfusion images, which allow for the evaluation of ventilation-perfusion matching.
Perfusion images are commonly acquired following an injection of technetium-99m
(99mTc) labeled macro-aggregated albumin (MAA), which gives a measure of relative
pulmonary arterial blood flow.144 MAA has a diameter of 10-40µm, and therefore cannot
pass through the terminal arterioles; a typical dose of 200 000 particles results in a
blockage of less than 0.01% of the total number of arterioles.144 The radiation dose
associated with a perfusion scan is 1.0 mSv.144
PET provides structural and functional information using positron emitters that are
physiologically and biochemically relevant to functional lung processes, including
13
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minutes.
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Ne, and

68
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C,

Ga, with half-lives ranging from 17.4 seconds to 110

These radionuclides decay via β+ decay, and a positron is emitted.146 The

positron quickly loses its kinetic energy, and combines with an electron in an annihilation
event, simultaneously emitting two 511keV photons at 180 degrees from each other.146
PET scanners localize the location of the annihilation event through coincidence
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detection of photons in opposing detectors.146

Functional measurements using PET

19

Ne, as well as the ventilation perfusion

commonly include regional ventilation using
ratio using

13

N.147,148 The most common PET tracer is

18

F- fluorodeoxyglucose (FDG),

an analog of glucose is used as a marker of inflammation.145 In the lung, it is suggested
that the uptake of 18F-FDG is specific to neutrophilic infiltration.145
Limited studies evaluating the effect of aging on the distribution of ventilation using
nuclear medicine techniques have been performed. A PET study using

18

F-FDG-PET

found that with increased age standard uptake values in the lung increase, which may
relate to inflammation in the lung.114,145
Nuclear medicine has also been used to study COPD, more specifically to examine
ventilation perfusion patterns in these subjects with airflow limitation. SPECT studies of
COPD show two common findings in terms of ventilation; matched areas with defects in
both ventilation and perfusion, and regions that are perfused but unventilated.149,150
Ventilation studies using SPECT have also been found to correlate with FEV1.151 In
COPD, PET studies have shown there is a positive correlation between DLCO and
perfusion, but a negative correlation with the ventilation-perfusion ratio.152
Nuclear medicine, and more specifically PET in combination with CT (PET/CT), has
been heavily studied in recent years for its use in evaluating and staging lung cancer.
Using

18

F-FDG, PET studies have shown an increased specificity, sensitivity and

negative predictive values in characterizing pulmonary nodules as benign or malignant as
compared to conventional procedures (CT).153 PET/CT also aids in staging, as it is useful
for determining whether there is involvement of the thoracic wall.153 Neither SPECT nor
PET have been used to date to study the impact of lung cancer on regional pulmonary
function.
Longitudinal nuclear medicine studies by Prato and co-workers using
scintigraphy and

133

Xe ventilation

99m

Tc-MAA for evaluation of perfusion showed that the functional

parameter in the lung most affected by radiation was blood flow, which was also affected
the earliest.154

They report that blood flow changes at 60 days-post radiation are

predictive of perfusion values at 300 days, and therefore decreased perfusion as measured
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by

99m

Tc-MAA may be an indicator of patients that will go on to develop severe

pulmonary complications.154 Studies evaluating the ability of SPECT scans acquired pretreatment to determine risk of developing radiation pneumonitis post-treatment have been
performed, and to date these scans do not appear to have better predictive value than
mean lung dose or PFTs.155

One study did suggest that the presence of SPECT

hypoperfusion adjacent to a central mediastinal mass might identify patients with
improved DLCO following radiation.156

A study assessing the effects of radiation

pneumonitis using PET showed increased

18

F-FDG uptake in non-irradiated lung tissue

of approximately 80% of patients following radiation treatment for lung cancer.157

1.5.4 Magnetic Resonance Imaging
Only recently, with advances in pulmonary MRI research, has MRI been used for lung
imaging.158 MRI utilizes the magnetic properties of certain nuclei, most commonly
protons to create functional and structural images. Therefore, MRI has, until recently,
had a limited use in visualization and functional assessment of the lung primarily due to
the low water content (proton density) within the lung as visualized in Figure 1-9, as well
as secondary factors that include image degradation by cardiac and respiratory motion,
and high susceptibility artefacts at the alveolar interface.158-160 New imaging techniques
and hardware developed over the last decade have made it possible to use proton MRI to
advance the knowledge of pulmonary function. Short echo times (TE) and single shot
fast spin echo sequences have been used to probe pulmonary perfusion.160 Additionally,
oxygen-enhanced lung MRI, using inhaled molecular oxygen as a paramagnetic contrast
agent, has been used for functional lung imaging.161-163

This technique works by

shortening the longitudinal relaxation (T1) time of protons in the blood, resulting in a
reduction of measured T1 values of 7-14% depending on the exact approach used.163 This
decrease in T1 seen in normal lung tissue depends on three factors: 1) ventilation of the
lung or region of interest within the lung, 2) diffusion of the oxygen from the alveoli into
the capillaries, and 3) the perfusion of the lung tissue.161,164 The functional changes
measured with oxygen-enhanced MRI correlate with FEV1165,166, and DLCO.167
Proton MRI has been used to demonstrate changes in both the airways and parenchyma in
subjects with COPD.168,169 In emphysema the extent of tissue loss, decrease in blood

28
volume and degree of hyperinflation negatively correlate with MR signal.168,170
Additionally, in regard to the lung parenchyma, it has been reported that the difference in
parenchymal signal intensity between inspiration and expiration correlate with FEV1.171
MRI has also been used to evaluate the airways, with an MRI study of COPD revealed
bronchial wall thickening and mucus secretion.168

Using oxygen-enhanced MRI

methods, Ohno and co-workers showed that lifetime smoking exposure, FEV1/FVC,
FEV1 %pred correlate with quantitative measurements captured from this MRI
technique.166

Figure 1-9: Proton MRI of the Lung.
Historically, proton MRI has not been used for lung imaging due to the low signal related to the
lack of protons (water) within the lung. Characteristically, the lungs appear as a large regions of
signal void on MRI.

MRI applications in lung cancer have focused on detection and classification of
pulmonary nodules, as well as improvement of MR pulse sequences and contrast agents
for prospective MR application in TNM staging.172 In regard to functional lung imaging
in lung cancer, MRI has been used to assess and quantify diaphragm motion in the first
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second following maximum expiration and the total motion at end-expiration.173,174
These measurements have been shown to correlate well with FEV1/FVC in healthy
volunteers.173,174

Differences between diaphragm motion in the ipsilateral and

contralateral lungs exist in patients with stage IB tumours located in the middle and lower
lung regions, but do not exist in patients with stage IA lung cancer.173,175

1.6 Hyperpolarized Noble Gas MRI
Using inhaled hyperpolarized gas as a contrast agent, research over the past two decades
has demonstrated that MRI can be used a tool for functional imaging of the lung. This
section will discuss the development of this technique, its application in imaging healthy
young and elderly volunteers, and subjects with smoking-related lung disease. Findings
that suggest this technique might provide a sensitive, non-invasive measurement of lung
function will be discussed.

1.6.1 Development and Theory
An MR-detectable contrast agent that could be inhaled and imaged in vivo, providing
high resolution functional lung images, would present an ideal alternative to standard
proton MRI. In 1994, Albert and co-workers published the first-ever report showing that
this was indeed possible, and reported that hyperpolarized Xenon-129 (129Xe) could be
used as an inhaled contrast agent to produce MR images in an ex-vivo mouse
model.176,177 In order to produce these images, Albert and co-workers first faced the
problem that

129

Xe gas on its own would not be sufficient to produce a detectable MR

signal. Happer et al. had previously shown that noble gas nuclei can be hyperpolarized
by optical pumping techniques; increasing the polarization of the gas, and thereby its MR
detectability, by a factor of 100,000.177,178 The optical pumping technique involves a
glass cylinder filled with the noble gas and rubidium (Rb) vapour, which is illuminated
by circularly polarized laser light.177,179 The laser light is absorbed by the Rb vapour,
causing high electronic polarization in the Rb atoms.179 The polarized Rb atoms undergo
collisions with the noble gas in the glass cell, resulting in a transfer of polarization
between the atoms. This process takes 6-8 hours, and can result in polarizations of 1025%.179
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Hyperpolarized gas MRI applies specifically to the two non-radioactive noble gas
isotopes with spin-1/2 nuclei; 3He and

129

Xe. When comparing and contrasting these

nuclei to select the most suitable agent for MRI use, it is noted that 3He has a
gyromagnetic ratio (γ) 2.7 times greater than that of

129

Xe, and therefore yields a 2.7

times greater improvement in SNR177 (given that signal scales with γ2 for hyperpolarized
noble gas MRI180, and noise scales with γ). In addition, 3He has been extensively used in
the area of pulmonary function testing for the measurement of RV as well as other
medical and non-medical uses181, and therefore well characterized and widely accepted as
a safe agent for pulmonary imaging. For these reasons 3He has been the contrast agent of
choice for much of the hyperpolarized noble gas MRI research performed to date,
although supply of 3He is currently an issue.
Two years after the initial report of in vivo hyperpolarized noble gas MRI by Albert et
al., the first ventilation images in humans were published.182,183 Kauczor and co-workers
showed homogenous signal intensity across the lungs of healthy volunteers, and regions
of signal void in a subject with bronchogenic carcinoma and COPD.183 Since this time,
the technique has been widely applied in lung disease such as asthma184-190, cystic
fibrosis191-195, and lung transplant cases.196-198 Interest in this technique has grown since
these first images were produced, as they provide complimentary and alternative
information to standard x-ray and CT without the use of ionizing radiation. Furthermore,
safety data on this method is positive as indicated in a retrospective analysis by Lutey and
co-workers, who assessed the first 100 subjects (healthy and diseased) imaged using this
technique at Washington University.

They reported that the 3He MRI breath-hold

technique had no effect on vital signs and that there was only a slight decrease in SpO2 in
the first minute following breath-hold, thereby confirming the expected safety of this
technique.199
Using hyperpolarized 3He MRI two different sets of images are commonly acquired; spin
density images that provide high resolution functional information, and diffusion
weighted images (DWI) that provide structural information.

Standard spin density

images produce functional images showing the location and density of 3He gas within the
lung, thus yielding information on lung ventilation. The signal acquired in 3He MR
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ventilation images is not always homogenous, and some regions of the lung do not fill
with 3He gas at all, therefore appearing as regions of signal void. Regions of signal void
are classified as ventilation defects, and are characterized as any well defined area of the
lung showing no or low signal intensity compared with the remaining normal appearing
ventilated lung, excluding signal loss appearing due to pulmonary vasculature, heart and
mediastinum.188 To date, ventilation defects have most commonly been characterized by
radiologists using scoring methods187,188 or by estimating the percentage of the lung
occupied by ventilation defects193. One metric of quantifying lung function from 3He
MRI reported in the literature is percent ventilated volume (PVV) and has been applied
by the group in Sheffield.200 This quantitative measurement normalizes the total volume
of all reporting voxels appearing as ventilated in the 3He MR image by total volume of
the thoracic cavity as determined by conventional 1H MRI.200 Thus both ventilation
defects and regions of signal void associated with pulmonary vasculature and other
regions around the mediastinum both contribute to the PVV values of less than 100%. A
study by Altes and co-workers directly compared functional images captured with 3He
MRI to
3

133

Xe scintigraphy using ventilation defect scoring methods. The signal from all

He coronally acquired slices was summed for comparison purposes, and results showed

that in more than 60% of the lung quadrants ventilation defects identified in both sets of
images corresponded in size, conspicuity and location.201 Dynamic 3He MR images have
also been captured, allowing for visualization of 3He wash-in and wash-out in the lung,
specifically allowing for visual assessment of airway function, although methods for
quantifying these images are still under development.202-204
The second set of 3He MR images commonly acquired are DWI, which mean that in
addition to high resolution functional lung images produced, the underlying structure of
the lung can also be probed. Diffusion MR principles widely used in such areas as brain
imaging can be applied to 3He or

129

Xe MRI over short and long timescales, thereby

allowing for the evaluation of acinar size.205-209 The apparent diffusion coefficient
(ADC), calculated from diffusion weighted images, is a measure of helium diffusivity
(centimeters squared per second (cm2/s)) in the lung and is highly reproducible210,211, and
has been validated against histological212 and CT213 measurements.

32

1.6.2 Hyperpolarized 3He MRI: Research Subject Studies
Static ventilation images of healthy volunteers have been acquired and evaluated at a
handful of sites. Characteristically, as evident in Figure 1-10A, these images show
homogenous signal throughout the lung, with a minimal number of ventilation defects
observed in healthy subjects.214-216 Lee and co-workers reported that ventilation defects
observed in healthy volunteers were small; no larger than 3 cm215, while Mata and coworkers reported that they occur in the posterior and anterior portions of the lung.216
PVV was measured by Woodhouse et al. in middle-aged healthy volunteers (mean age =
51), and a mean PVV of 90% was reported.200 Structural changes in lung microstructure
occur over a lifetime in the healthy lung, and can be detected with 3He MRI. Post-natal
lung development has been probed with 3He MRI, and in subjects aged four to 30 years,
an increase of 0.003cm2/s/y was detected.217 Once the lung reaches maturity, structural
changes associated with aging occur and have been detected using 3He MRI, with results
showing an annual increase in the ADC of 0.0015cm2/s for subjects between 20 and 70
years of age.218
3

He MRI has been used to probe functional and structural changes in smokers

with179,205,210,214,219-221 and without200,222,223 COPD.
increased number of ventilation defects

214

Subjects with COPD have an

as seen in Figure 1-10B, a reduced PVV200,

and an increase in ADC219 as compared to healthy age-matched volunteers. Kauczor et
al. described the ventilation defects that occur in COPD as regions of patchy signal, or
wedge shaped regions of signal void.224 The ventilation defects that occur in subjects
with COPD are predominantly in the upper lobes of the lung.225 Measurements of PVV
in smokers with and without COPD do not correlate with spirometry measurements.200
Correlations have been reported between structural measurements of emphysema using
3

He MRI derived ADC and FEV1/FVC219,221 and DLCO.221
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Figure 1-10: Hyperpolarized 3He MRI in Health, COPD, Lung Cancer and
RILI.
Hyperpolarized 3He MRI are shown here for A. a young healthy volunteer, B. a subject with
COPD, C. a subject with lung cancer obstructing ventilation of the right lower lobe, and D. a
subject with RILI following radiation treatment for lung cancer. A homogenous signal is
observed throughout the lungs in the healthy volunteer (A), while regions of signal void and
heterogenous signal intensity are seen in smoking-related lung disease (B-D).

Limited clinical studies applying 3He MRI to lung cancer (Figure 1-10C) have been
performed. Ireland and co-workers have shown that 3He MRI can be registered with CT
scans for treatment planning purposes. This study showed, using simulated treatment
plans, that both the functional and total lung volume receiving 20Gy or greater could be
significantly reduced.226 In a subsequent study, the same group showed that registration
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accuracy of 3He MRI to CT in a group of patients with NSCLC could be improved using
breath-hold CT as compared to free-breathing CT.227

1.7 Thesis Hypothesis and Objectives
The objective of this thesis was to develop an understanding of lung function in the
context of hyperpolarized 3He MRI in healthy subjects and subjects with smoking-related
lung disease, including COPD, lung cancer, and RILI.

A method of quantifying

ventilation defects in these images was developed, and evaluated here, in regard to its
reproducibility and sensitivity in detecting disease-related changes in ventilation. The
objectives and hypotheses tested in this thesis, specific to each chapter are described here.
We first evaluated the short-term reproducibility of ventilation defect volume (VDV) in
both healthy subjects and subjects diagnosed with stage II and III COPD, and this is
described in Chapter 2. Here we tested the hypothesis that VDV has high short-term
reproducibility in healthy volunteers and COPD subjects. Eight age-matched healthy
volunteers and 16 COPD subjects were evaluated twice in one day (7 ±2 minutes) and
again 7 ±2 days later using 3He MRI at 3.0 T.
We then evaluated VDV in the context of normal aging in Chapter 3, and tested the
hypothesis that ventilation changes occurring with aging can be detected using
quantitative measures of lung ventilation from 3He MRI. Twenty-four middle aged
subjects and eight healthy elderly volunteers were imaged using 3He MRI, and VDV was
used to quantify ventilation and evaluate differences between subject groups.
Chapter 4 of this thesis evaluates the potential for quantification of ventilation
(ventilation defect percent (VDP)) in addition to structure (ADC) to classify subjects with
COPD according to the proportion of underlying functional and structural disease.
Twenty ex-smokers were evaluated at a single time point using both static ventilation
imaging and diffusion-weighted imaging. We hypothesized that differences in ventilation
patterns exist within subjects with COPD, and can be used for stratification purposes, and
tested this hypothesis in Chapter 4.
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In Chapter 5 subjects with clinically diagnosed RILI were evaluated twice within five
months to evaluate functional and structural changes that occur post-RILI diagnosis.
Seven subjects were scanned at baseline and four subjects returned for follow-up.
Pulmonary function test data was also collected and compared to 3He MRI data. In this
chapter we tested the hypothesis that lung damage occurring due to curative-intent
radiation treatment results in long-term functional changes in ventilation that can be
measured using 3He MRI.
The objective of Appendix A was to review the current state-of-the-art 3He MRI
ventilation analysis, as described in the literature, and provide an overview of potential
directions that these analysis methods might take in the future. Discussion of the current
limitations and future requirements, specifically for ventilation analysis in serial or
longitudinal image studies acquiring multiple 3He images from a single subject at
multiple time-points, is described.
A case study of a single subject imaged twice prior to Airway Bypass, and twice
following the procedure is presented in Appendix B. Here, we applied quantitative
ventilation analysis to 3He images acquired over a four year period. While 3He MRI data
was only available for a single subject, PFTs were also acquired at all four time-points
and self-reported dyspnea scores were assessed.

We hypothesized that changes in

ventilation as quantified by 3He VDP would correspond to changes in mMRC.
The overarching hypothesis tested in this thesis is that VDV and VDP are sensitive
measurements for evaluating differences in lung ventilation between subject groups and
longitudinally. This hypothesis is tested in Chapters 2-5, in healthy volunteers and
subjects with smoking-related lung disease. Chapter 6 of this thesis provides a summary
of this work and highlights the conclusions drawn from these studies. New hypotheses
generated based on the studies presented in this thesis are outlined in Chapter 6, and
future directions for quantitative noble gas MRI ventilation analysis using VDV and VDP
are described.
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CHAPTER 2: HYPERPOLARIZED
HE
MAGNETIC
RESONANCE IMAGING OF CHRONIC OBSTRUCTIVE
PULMONARY DISEASE: REPRODUCIBILITY AT 3.0 TESLA

The work presented in this chapter has been previously published in Academic Radiology
as indicated below, and is reproduced here with permission (Appendix C).
L. Mathew, A. Evans, A. Ouriadov, R. Etemad-Rezai, R. Fogel, G. Santyr, D.G. McCormack, G.
Parraga. “Hyperpolarized 3He Magnetic Resonance Imaging of Chronic Obstructive Pulmonary
Disease at 3.0 Tesla: Reproducibility at 3.0 Tesla” Acad Radiol. 2008 Oct;15(10):1298-311

2.1 Introduction
Chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death
worldwide and continues to increase in incidence, morbidity and mortality rates, as well
as direct and indirect costs.1 The increasing prevalence and economic burden related to
COPD is motivating the assessment of new ways to provide earlier diagnosis, better
patient risk assessment, and improved patient monitoring of disease progression and
treatment.

While both pulmonary function tests and high resolution computed

tomography (HRCT) have been well-established as non-invasive diagnostic tools and
biomarkers in clinical studies of COPD, some of the limitations of these approaches are
driving the development of new imaging tools that are sensitive to disease changes, that
provide regional information, and that have the appropriate specificity and precision for
use in clinical research.
Hyperpolarized 3He magnetic resonance imaging (MRI) has emerged as a radiological
research method for the evaluation of the regional distribution of anatomical and
functional lung changes associated with COPD.2-5 In particular, the measurement of the
3

He apparent diffusion coefficient (ADC)6 has been exploited to probe the lung

microstructure in patients with COPD2,3,5-7 and in ex vivo explanted lungs.8 Same-day
scanning reproducibility has also been assessed.9 Increases in ADC are consistent with
expected increases in acinar size due to destruction of alveoli accompanying
emphysema5,7,10. Furthermore, increases in ADC have been shown to correlate with
histological measurements of disease11,12 and also have been shown to correlate
positively with age.13 Parenchymal focal ventilation defects in 3He images also appear to
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be sensitive to lung ventilation changes that accompany COPD.10,14-16

The 3He

ventilation defect score correlates with both age17 and disease status providing
radiologists and respirologists with a new measurement tool for clinical studies of the
spatial and temporal changes in the lung that accompany COPD. The percent ventilation
volume18 as well as ADC measurements16 derived from 3He images have been shown to
be altered in otherwise asymptomatic smokers with normal pulmonary function values,
suggesting that these measures are sensitive to early lung changes in smokers. Finally,
safety and tolerability have been shown to be excellent across a variety of healthy and
respiratory compromised patients.19,20
While these studies have assessed the sensitivity of 3He MRI to lung differences in
COPD, the development of 3He MRI for clinical studies also requires the evaluation of
measurement precision, which is a critical consideration for clinical study design. For
example, in longitudinal clinical studies that aim to utilize 3He MRI measurements of
disease, it will be critical to understand variability that can be attributed to: 1) image
acquisition methods including those related to the scanner (field-strength, coils used) and
subject compliance (breath-hold, motion), 2) image analysis methods that are observerdependent or computationally driven, 3) center- or site-specific methodologies including
gas delivery methods, 4) potential variability differences among different disease states
including healthy age-matched control subjects, and, 5) potential physiological and/or
radiological changes that occur over short periods of time. Accordingly, the goal of this
study was to assess subjects with stage II and stage III COPD as well as age-matched
healthy volunteers at a single center using 3He MRI at 3T and the reproducibility of 3He
MRI measurements during repeated scanning visits. We present same-day and 7-day
reproducibility of 3He ADC and ventilation defect volume (VDV).

Reproducibility

measurements also allowed for the calculation of sample sizes that may aid in the design
of clinical studies of COPD utilizing 3He ADC and VDV.
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2.2 Materials and Methods
2.2.1

Study Subjects

Twenty-four subjects were enrolled from the general population of the tertiary health care
center as well as directly from the COPD clinics at the local three teaching hospitals. All
subjects provided written informed consent to the study protocol approved by the local
research ethics board and Health Canada and the study was compliant with the Personal
Information Protection and Electronic Documents Act ((PIPEDA) Canada).

COPD

subjects required a disease diagnosis of at least one year, having had a smoking history of
at least 10-pack-years and fewer than three COPD exacerbations within the last 12
months. Healthy subjects were included if they had no history of chronic respiratory
disease, less than one pack-year smoking history, forced expiratory volume in 1 s
((FEV1) greater than 80% predicted, FEV1 divided by the forced vital capacity (FVC) or
FEV1/FVC greater than 70%, and no current diagnosis or history of cardiovascular
disease. Throughout the duration of the study, COPD subjects were to be withdrawn
from the study if they had experienced a COPD exacerbation or if they experienced a
drop in arterial oxygen levels as monitored using pulse oximetry below 80% for 15
continuous seconds during MRI procedures.

COPD and healthy subjects were

categorized according to GOLD criteria.21
2.2.2

Study Assessments

After subjects provided written informed consent, they were screened for MRI and coil
compatibility and underwent a physical exam, plethysmography and spirometry.
Spirometry and plethysmography were performed in the morning after patients delayed
inhaled bronchodilators and corticosteroids for approximately 12 hours as previously
described.14 Briefly, spirometry was performed at screening and at each MRI visit using
an ndd EasyOne spirometer (ndd Medizintchnik AG, Zurich, CH) reporting forced
expiratory volume in 1 s ((FEV1) absolute and percent predicted) and forced vital
capacity (FVC). COPD subjects performed spirometry at a pre-MRI screening visit (preand post-bronchodilator) and were enrolled based on the post-bronchodilator FEV1
measurement that was furthermore required to be within 3% of pre-bronchodilator FEV1,
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which eliminated any potential subjects with underlying lung disease responsive to
bronchodialators such as asthmatics.

Whole body plethysmography (SensorMedics

VIASYS Healthcare Inc. Yorba Linda, CA USA) was also performed at the pulmonary
function laboratory at University Hospital (London Health Sciences Centre, London,
Canada) for the measurement of total lung capacity (TLC), inspiratory capacity (IC)
residual volume (RV), and functional residual capacity (FRC).
2.2.3

Safety Monitoring and Hyperpolarized 3He Administration

On both MRI visit dates, subject supine vital signs and arterial O2 levels were recorded
before pre-MRI spirometry and subjects were administered a practice dose of mixed 4Henitrogen while seated outside the scanner. Digital pulse oximetry was used to monitor
arterial blood oxygenation levels during MR scanning and all breath-hold manuevers.
Hyperpolarized 3He gas was provided by a turn-key, spin-exchange polarizer system
(HeliSpin™, GEHC, Durham, NC). In a typical study this system provided 30%
polarization in 12 hours. Doses (5 mL/kg) were delivered in 1 L plastic bags (Tedlar®,
Jensen Inert Products, Coral Springs, FL) diluted with ultrahigh purity, medical grade
nitrogen (Spectra Gases, Alpha, NJ). Polarization of the diluted dose was quantified by a
polarimetry station (GEHC, Durham, NC).

3

He MR scans were acquired during an

inhalation breath-hold after inspiration from tidal volume of a 1L 5 ml/kg dose of 3He
mixed with N2. Post-MRI spirometry was also performed for all subjects.
2.2.4

Imaging

Magnetic resonance imaging was performed on a whole body 3.0 Tesla Excite 12.0 MRI
system (GEHC, Milwaukee, WI USA) with broadband imaging capability as previously
described.14 All helium imaging employed a whole body gradient set with maximum
gradient amplitude of 19.4 mT/m and a single channel, rigid elliptical transmit/receive
chest coil (RAPID Biomedical GmbH, Wuerzburg Germany). The basis frequency of the
coil was 97.3 MHz and excitation power was 3.2 kW using an AMT 3T90 RF power
amplifier (GEHC, Wilwaukee WI USA).
The time-frame between 3He MRI scans was within 7 ± 2 minutes and again 7 ± 2 days
later. A one-week period between scanning sessions was selected to minimize subject
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inconvenience, and to model typical sources of variability stemming from the acquisition
of the images over time due to technologist changes, coil positioning, subject motion and
positioning changes and potential physiological changes.

Repeat spirometry at the

second MR visit (pre- and post-MRI) was performed to screen for exacerbations or global
disease changes that may have occurred during the one-week scanning period.
1

H scans were acquired prior to the 3He imaging with subjects scanned during breath-

hold at the top of tidal volume using a whole body radiofrequency (RF) coil and again
after 3He imaging using a 4-channel torso array coil (GEHC, Milwaukee, WI) and a fast
spoiled gradient recalled echo sequence (256x256 matrix, FOV 40x 40cm, TR= 2.7,
TE=1.3, flip angle=8 degrees).
3

He multislice images were obtained in the coronal plane using a fast gradient-recalled

echo (FGRE) method with centric k-space sampling.16

Two interleaved images

(TE = 3.7 ms, TR = 7.6 ms, 128 x 128, 7 slices, 30 mm slice thickness, FOV = 40cm x
40cm) without and with additional diffusion sensitization (G = 19.4 mT/m, rise and fall
time = 0.5 ms, duration = 0.46 ms, b value = 1.6 s/cm2) were acquired for each slice. The
first image served as a map of ventilation, while the combination of the two images was
used to compute ADC maps. All scanning was completed within approximately 10
minutes of first lying in the scanner.
2.2.5

Image Analysis

A single expert observer analyzed images for center slice ADC and another single
observer analyzed images for center slice VDV. Two observers were used to minimize
the potential for observer bias. The ADC images were analyzed by a single trained
observer in an image visualization environment (digital copy) with room lighting levels
equivalently established for all image analysis sessions. Mean ADC and ADC maps were
processed using in-house software programmed in the IDL Virtual Machine platform
(Research Systems Inc., Denver, CO) as previously described14 with b = 1.6 s/cm2.
The non-diffusion weighted images were examined in the same image visualization
environment by a single trained observer for analysis of ventilation defects in the center
coronal slice, which was defined as the slice including the carina. Three observers, in
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consensus determined the total number and location of ventilation defects at baseline
scan, same-day rescan and 7-day rescan. Images were reviewed such that all three 3He
images were visible on a digital workstation monitor system (consisting of identical 19
inch flat panel monitors). A ventilation defect was defined as previously described22 as
any well-defined area of the lung showing no signal intensity compared with the
remaining ventilated lung. Areas of absent signal associated with the pulmonary vascular
structures, heart, hilum and mediastinum were not considered to be ventilation defects.
Ventilation defect volume was manually segmented without the aid of a quantitative
signal-to-noise or spin density threshold.

After scoring ventilation defects, manual

segmentation of the defects was performed by a single observer (one of the three
consensus observers) using the non-diffusion weighted images of the center coronal slice
with the observer blinded to subject identity, disease status and scan time-point. Images
were randomized (subject and scan time) and the 32 bit image slices were imported into a
3D image visualization platform developed in our laboratory23,24 for MR and ultrasound
applications as previously described.25 Segmentation was performed using this image
visualization software which also provided a method for 2-dimensional rigid image
overlay or registration (of the center slice 1H image and the center slice 3He image),
facilitating the manual segmentation of center-slice ventilation defect volume.
Ventilation defect volume, as segmented from center slice 3He images, was computed as
the area of the segmented defect multiplied by the slice thickness (30mm).
2.2.6

Statistical Methods

Means for ADC, ADC standard deviation of center slice and whole lung as well as
ventilation defect volume of center slice were calculated. The difference in center slice
ADC values and VDV between time points was computed for every subject, and the
mean and standard deviations of these differences reported. Comparison of ADC and
VDV means was performed using the one-way analysis of variance (ANOVA) in SPSS
14.00 (LEAD Technologies, Inc., Chicago, IL). Intraclass correlation coefficients (ICC)
and Lin’s concordance correlation coefficients (CCC)26, were calculated using SPSS.
The ICC provides a way to quantify the reproducibility of the relative rankings of each
subject’s repeated scans and the CCC provides a way to show the reproducibility of both
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the relative rankings and agreement of repeated scanning results. The sample size (N)
required to detect specific volumetric changes or differences ( δ ) in ADC and VDV was
also calculated for power ß = 0.80, with α = 0.05; accordingly, Zα = 1.96, and Zß = 0.80
and N is calculated as27:
N=

2( Zα + Zβ ) 2 SD 2

δ2

2.3 Results
2.3.1

Study Subjects

Baseline demographic characteristics are provided in Table 2-1 for the 24 subjects
enrolled (15 male) with very similar mean ages and age ranges for each subgroup. Mean
body mass index (BMI) and BMI range for each subject subgroup was also very similar.
As the COPD subjects and healthy volunteers were enrolled based upon FEV1 and
FEV1/FVC according to GOLD criteria21, the mean values for FEV1 and FEV1/FVC for
each subject subgroup reflect the GOLD criteria categorization.

In addition to the

expected and significantly decreased FEV1 and FEV1/FVC for the COPD subgroups as
compared to the healthy volunteers (p<.01), baseline FRC was also significantly
increased for both COPD subject groups (p<.01) and TLC was also significantly
increased for the stage III COPD subgroup (p<.001), both findings consistent with lung
hyperinflation.
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Figure 2-1: 3He Apparent Diffusion Coefficient Maps and centre slice ADC
results.
i) ADC Maps ii) Corresponding ADC Histograms
A) Healthy Volunteer (male, age = 63 yrs, FEV1= 92% predicted)
B) Stage II COPD (male, age = 72 yrs, FEV1=62% predicted)
C) Stage III COPD (male, age = 52 yrs, FEV1= 49% predicted)
D) Stage III COPD (male, age =72 yrs, FEV1 = 49% predicted)
E) Box and Whisker plots for subject subgroups at scan, same day rescan and 7-day
rescan. Boxes represent the interquartile range (25th to 75th percentile), the whiskers
represent the minimum and maximum values and the solid line represents the median
value. Healthy volunteers n=8 (7 at 7-day rescan), stage II COPD n=9 (8 at 7-day rescan),
stage III COPD n=7 (6 at same-day rescan).
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Two subjects did not return for the second MR visit: 1) a single healthy volunteer (male,
age 72 years) did not return due to claustrophobia, and 2) a single subject with stage II
COPD (female, age 72 years), who was hospitalized due to an exacerbation of her
disease. However, both of these subjects completed both scans during their first visit,
allowing for same-day reproducibility analysis.

All subjects with stage III COPD

returned for the second MR visit, however as previously described 14, for a single subject
(the first scanned at our site with stage III COPD ) the MR images for same-day rescan
could not be evaluated. This was due to the subject’s high respiratory rate which made
the inhalation maneuver difficult. This resulted in a 3He image with low SNR (<10).
Thus in total 24 subjects were evaluable at baseline scan, 23 subjects at same-day rescan
and 22 subjects at 7-day rescan. There was a single subject with stage II COPD who
experienced three episodes of mild and transient (all < 5 seconds in duration) hypoxemia
(SpO2 dropped below 88%) sporadically before (once) and after (twice) MR scanning.
All of these episodes resolved spontaneously, and all were asymptomatic (no clinical
symptoms).

The same subject experienced shoulder pain due to restriction of her

shoulder in the rigid MR coil perhaps due to her size and shape (subject BMI=38). There
were no other scanning- or breath-hold-related adverse events reported in the study, and
no serious or severe adverse events reported related to any protocol procedure.

Table 2-1: Subject Demographics.
Healthy Volunteers Stage II COPD Stage III COPD
n=8
n=9
n=7
Age yrs (±SD) [range]
67 (6) [58-74]
68 (6) [59-74] 67 (8) [52-75]
Male Sex
5
4
6
Body Mass Index (±SD) [range]
27 (4) [24-35]
28 (5) [21-38] 27 (4) [22-34]
FEV1 %* (±SD)
106 (19)
63 (8)**
42 (7)**
FEV1/FVC % (±SD)
77 (5)
54 (11)**
38 (10)**
IC %* (±SD)
111 (16)
99 (18)
78 (17)
RV %* (±SD)
97 (10)
142 (20)
188 (55)
FRC %* (±SD)
95 (14)
116 (14)**
152 (37)**
TLC %* (±SD)
104 (19)
108 (9)
115(23)***
*Percent predicted, FEV1 = Forced Expiratory Volume in 1s, FVC= Forced Vital Capacity
FRC= Functional Residual Capacity, TLC= Total Lung Capacity
**significantly different than healthy volunteers (p<0.01), *** significantly different than healthy
volunteers (p<0.001)
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2.3.2

3

He MRI Measurements

Representative center slice ADC maps and corresponding ADC histograms are provided
for a healthy volunteer (Figure 2-1A), a subject with stage II COPD (Figure 2-1B) and
two subjects with stage III COPD, (Figure 2-1C and 2-1D). Mean ADC and mean ADC
standard deviations (SD) for all the representative subjects is provided in Figure 2-1(ii)
and in Figure 2-1E, a box and whisker plot shows the mean center slice ADC values for
each subgroup and scan time point (Scan, same day rescan and 7-day rescan). In Figure
2-2, the non-diffusion-weighted images of the diffusion-weighted pair are provided for
the same representative subjects (Figures 2-2A-D). In Figure 2-2E, a box and whisker
plot shows the mean center slice VDV values for each subgroup and scan time point
(scan, same day rescan and 7-day rescan).
Table 2-2 shows mean whole lung ADC, whole lung SD, center slice ADC, center slice
SD as well as center slice VDV for all subgroups and scan time-points. The difference in
both whole lung and center slice mean ADC between healthy volunteers and subjects
with stage II COPD was significant (p<.05) as was the difference between healthy
volunteers and subjects with stage III COPD (p<.01) at all time points. There was no
significant difference for whole lung ADC SD between any subject subgroup at any timepoint but there was a significant difference for center slice ADC SD between subjects
with stage III COPD and healthy volunteers and subjects with stage II COPD (p<.01) at
all time-points. For mean ventilation defect volume, there was no significant difference
between healthy volunteers and subjects with stage II COPD at any time point. However,
there was a significant difference between subject with stage III COPD and both healthy
volunteers and subjects with stage II COPD (p<.01) at all time-points.
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Table 2-2: Same day and 7-day Rescan ADC and VDV Measurements.
Healthy
Volunteers
n=8

Stage II
COPD
n=9

Stage III
COPD
n=7

Whole Lung Mean ADC (±SD) cm2/s
Scan
Same-day Rescan
7-day Rescan

0.27 (0.02)
0.26 (0.02)
0.26 (0.02)**

0.38 (0.09)
0.36 (0.09)
0.39 (0.08)***

0.44 (0.09)
0.42 (0.09)*
0.43 (0.09)

Whole Lung ADC SD (±SD) cm2/s
Scan
Same-day Rescan
7-day Rescan

0.18 (0.03)
0.19 (0.05)
0.16 (0.02) **

0.24 (0.07)
0.22 (0.08)
0.25 (0.08) ***

0.24 (0.04)
0.24 (0.04) *
0.24 (0.04)

Center Slice Mean ADC (±SD) cm2/s
Scan
Same-day Rescan
7-day Rescan

0.26 (0.02)
0.25 (0.03)
0.24 (0.02) **

0.38 (0.10)
0.36 (0.09)
0.39 (0.10) ***

0.47 (0.10)
0.46 (0.11) *
0.46 (0.10)

Center Slice ADC SD (±SD) cm2/s
Scan
Same-day Rescan
7-day Rescan

0.15 (0.03)
0.14 (0.04)
0.12 (0.03) **

0.19 (0.06)
0.15 (0.03)
0.19 (0.04) ***

0.26 (0.07)
0.24 (0.06) *
0.29 (0.15)

70 (40)
80 (50)
110 (70) ***

220 (160)
220 (150) *
220 (110)

Center Slice Ventilation Defect Volume
(±SD) cm3
Scan
80 (30)
Same-day Rescan
70 (30)
7-day Rescan
70 (30) **
*(n=6) **(n=7) ***(n=8)
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Figure 2-2: 3He MR Ventilation Images and Ventilation Defect Volume
(VDV) Results.
A) Healthy Volunteer (male, age = 63 yrs, FEV1= 92% predicted)
B) Stage II COPD (male, age = 72 yrs, FEV1=62% predicted)
C) Stage III COPD (male, age = 52 yrs, FEV1= 49% predicted)
D) Stage III COPD (male, age = 72 yrs , FEV1= 49% predicted)
E) Box and Whisker plot for mean VDV for subject subgroups at scan, same day rescan
and 7-day Rescan. Boxes represent the interquartile range (25th to 75th percentile), the
whiskers represent the minimum and maximum values and the solid line represents the
median value.
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2.3.3 He Measurement Reproducibility
As a reference for the measurement of 3He MRI reproducibility, repeated spirometry at
the second scanning visit showed no change for any subject or subject subgroup in FEV1
or FEV1/FVC within the 7 ± 2 days rescan period. Scan-rescan 3He MRI reproducibility
was assessed using linear regression as shown in Figure 2-3 as well as the ICC and CCC
as shown in Table 2-3. In Figure 2-3, same-day (R2 = 0.934) and 7-day rescan (R2 =
0.960) linear regression for center slice ADC was high and not significantly different and
furthermore not significantly different from same-day rescan mean VDV (R2 = 0.941). 7day rescan VDV was lower and significantly different (R2 = 0.576, p<.001).

The

corresponding Pearson correlations were also high for same-day and 7-day rescan mean
ADC (r = 0.959 and r = 0.980 respectively) as well as same-day rescan mean VDV (r =
0.970) with 7-day rescan mean VDV somewhat lower (r = 0.759).
Table 2-3 provides a comparison of same-day and 7-day ICC and CCC for FEV1, center
slice ADC and center slice VDV. ICC and CCC were both high for FEV1 and not
significantly different for same-day and 7-day repeated spirometry, or between subject
subgroups.

Center slice mean ADC for all subjects pooled together was highly

reproducible for both same-day and 7-day rescan (ICC and CCC 0.96 and 0.98
respectively). When reproducibility of mean ADC is considered for subject subgroups,
ICC and CCC was highest for subjects with stage III COPD. For center slice VDV, ICC
and CCC were high for same-day rescan for all subject subgroups and for all subjects
pooled together (ICC and CCC 0.97 and 0.98 respectively) and not significantly different
from same-day ADC reproducibility.

However, 7-day rescan ICC and CCC was

significantly lower (p<.01) than same-day rescan for all subject subgroups and for all
subjects pooled together.
In Figure 2-4, 3He images are provided to show visual evidence of the location, number
and size of ventilation defects at scan (Figure 2-4i) same-day rescan (Figure 2-4ii) and 7day rescan (Figure 2-4iii). In Figure 2-4A and 2-4B, 3He images for two representative
healthy volunteers are shown, in Figure 2-44C and Figure 2-4D, 3He images for two
representative subjects with stage II COPD and in Figures 2-4E and 2-4F, 3He images for
two representative subjects with stage III COPD are provided.
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Table 2-4 provides sample sizes that would be required to measure ADC and VDV (α =
0.05, β= 0.80) derived from the observed 7-day rescan differences. The 7-day rescan
differences were selected because they provide the most conservative estimate (based on
the fact that variability is higher at 7-days) and because for clinical trials designed to
detect disease changes, repeated scans over longer periods of time would be utilized. The
sample size required to measure a 1% / 5 % / 10% change in ADC in healthy volunteers
(0.0025 / 0.0125 / 0.025cm2/s, respectively) was 975 / 39 / 10 subjects, and in subjects
with stage III COPD (0.0047 / 0.0235 / 0.047 cm2/s) this was reduced to 69 / 3 / 1
subjects. Sample sizes calculated related to the use of VDV as an intermediate endpoint
required to measure a 5% to 10% change would be 331 to 83 healthy volunteers, 882-220
subjects with stage II COPD and 1089-272 subjects with stage III COPD.

Table 2-3: Scan-Rescan Reproducibility.
Healthy Volunteers
n=8

Stage II COPD
n=9

ICC

CCC

ICC

CCC

Stage III
All Subjects
COPD
n= 24
n=7
ICC CCC ICC CCC

Center Slice Mean ADC
(cm2/s)
Same day Rescan
7-day Rescan

0.83
0.17

0.85
0.24

0.91
0.97

0.91
0.96

0.98
0.99

0.93
0.98

0.96
0.98

0.96
0.98

Center Slice VDV (cm3)
Same day Rescan
7-day Rescan

0.91
0.56

0.90
0.57

0.94
0.59

0.94
0.62

0.96
0.63

0.96
0.58

0.97
0.74

0.98
0.75

FEV1 (%predicted)
Same Day Spirometry
7-day Spirometry

0.98
0.99

0.98
0.99

0.97
0.94

0.97
0.94

0.94
0.97

0.94
0.96

0.99
0.99

0.99
0.99

ICC is Intraclass Correlation Coefficient and CCC is Lin’s Concordance Correlation Coefficient.
Correlation coefficients represent reproducibility between baseline scan and either same-day
rescan or 7-day rescan.
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Figure 2-3: Center Slice ADC and VDV Reproducibility.
Hollow triangles represent healthy volunteers, solid squares represent subjects with stage
II COPD, and hollow circles represent subjects with stage III COPD. Dashed line
represents 95% confidence interval of regression (solid line).
A. Scan - Same day Rescan ADC linear regression: y = 0.99x + 0.016 (p<.001) Pearson r
= 0.96
B. Scan - 7-day Rescan ADC linear regression: y = 0.94x+ 0.028 (p<.001) Pearson r =
0.97
C. Scan - Same-day Rescan VDV linear regression: y = 0.98x + 4.12 (p<.001) Pearson r
= 0.97
D. Scan - 7-day Rescan VDV. Linear regression: y = 0.88x + 9.94 (p<.001) Pearson r =
0.76
ADC: R2 Same Day Rescan versus R2 7-day Rescan, p=NS
VDV: R2 Same Day Rescan versus R2 7-day Rescan, p<0.001
ADC and VDV: ADC R2 Same Day Rescan vs. VDV R2 Same Day Rescan : p=NS
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Figure 2-4: Center Slice 3He VDV Reproducibility
A) and B) Healthy volunteers at Scan (i), Same-day Rescan (ii) and 7-day Rescan (iii)
C) and D) Subjects with Stage II COPD at Scan (i), Same-day Rescan (ii) and 7-day
Rescan (iii)
E) and F) Subjects with Stage III COPD at Scan (i), Same-day Rescan (ii) and 7-day
Rescan (iii).
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Table 2-4: 3He ADC and VDV Sample Size Calculations.
Healthy
Volunteers
n= 8

Stage II COPD
n= 9

Stage III COPD
n= 7

ADC (Center Slice)
Seven Day (N)
Mean (BL and 7-day cm2/s
Difference (SDdiff) cm2/s
Sample Size 1%/5%/10% change
(n)

7
0.25
0.02

8
0.39
0.01

7
0.47
0.01

975 / 39 / 10

100 / 4 / 1

69 / 3 / 1

VDV (Center Slice)
Seven Day (N)
Mean (BL and 7-day) cm3
SDdiff cm3
Sample Size 5%/10% change (n)

7
73
17
331 / 83

8
92
35
882 / 220

7
220
93
1089/ 272

2.4 Discussion
In order to assess the feasibility of 3He MRI at 3T for use in clinical research studies of
COPD, we prospectively assessed 24 age-matched subjects, including 15 subjects with
stage II or stage III COPD. We directly assessed and compared same-day and 7-day
measurements of 3He MRI ADC and 3He ventilation defect volume. Here we provide the
quantitative results of this study performed at 3T and show: 1) high reproducibility of 3He
ADC that was not significantly different between same-day rescan and 7-day rescan, 2)
high reproducibility of 3He VDV that was significantly higher at same-day rescan as
compared to 7-day rescan, 3) significant differences in 3He ADC between healthy
subjects and those with COPD, and, 4) significant differences in 3He center slice VDV
between subjects with stage III COPD and those subjects with stage II COPD and healthy
volunteers.
The study was designed primarily to assess the reproducibility of these measurements at
3T and to compare measurement precision by assessing repeated scanning measurements
over a few minutes and over a one week period.

It is worth noting that repeated

spirometry at the second scanning visit also showed no change for any subject or subject
subgroup in FEV1 or FEV1/FVC, suggesting that no global changes in respiratory
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function had occurred during this time-frame.

For ADC, same-day reproducibility

measured using linear regression (R2 = 0.934), ICC and CCC was high (as previously
reported9) and similar to 7-day rescan measurements of ADC reproducibility and also to
same-day rescan mean VDV (R2 = 0.941), suggesting that these measurements are not
sensitive to changes in subject positioning or any scanner-coil interactions that might
change over short periods of time. However, 7-day rescan reproducibility for VDV was
lower and significantly different (R2 = 0.576, p<.001). Some explanation for this may be
derived from the fact that the measurement of VDV itself was performed by manual
segmentation and center slice VDV was represented by very small volumes in the healthy
volunteers and stage II subjects. Accordingly, the differences in VDV measured at sameday rescan and 7-day rescan as shown in Figure 2-4 were not large, with the majority of
defects having the same location and similar size in all scans.

Nevertheless, the

possibility exists that the differences measured, though small, were due to physiological
changes that occurred over a one week period. This would suggest that VDV sensitively
quantified ventilation changes resultant from airway narrowing or closure that occurred
without changes in global disease measurements such as FEV1 and FEV1/FVC or in the
3

He ADC measurements.

In addition it suggests that it is possible to measure

physiological changes that occur over short periods of time in some subjects and such
changes cannot be detected by spirometry. Sample sizes required to measure changes in
ADC and in VDV over time reflected the increased variability of the VDV measurement
as compared to ADC. It is difficult to provide an appropriate context for the potential
changes in ADC and VDV that may occur over time as a function of disease progression,
normal aging processes or COPD exacerbations. The sample size calculations may be
viewed as a guide to assist in the design of studies sensitive to morphological changes in
the lung parenchyma or airways using ADC, or studies sensitive to dynamic processes
using VDV such as those aimed at assessing ventilation changes that are dependent on
airway patency to provide gas into the lung parenchyma.

Thus, overall, if direct

measurement of airway or alveolar size changes is required, a smaller group of subjects
would be adequate, whereas precise measurement of more dynamic processes such as
those involving mucus plugging and other ventilation changes would require a larger
patient group.
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In this study we made a number of other observations that are relevant to the potential
clinical research use of 3He MRI. First, the use of 3He MRI at 3T in elderly healthy
volunteers and subjects with stage II and stage III COPD was well-tolerated. In total we
assessed repeated scanning in 24 subjects (15 scans in eight healthy volunteers and 31
scans in 16 subjects with COPD) and only a single subject (with stage II COPD and BMI
38) reported mild and transient hypoxemia with complete recovery in 5s and without
clinical symptoms. This finding, along with previously reported work at other sites and
field strengths19,20,28, supports the use of 3He MRI at 3T in longitudinal studies of older
subjects -even those with significant respiratory compromise.
We also noted the difference in mean ADC and VDV between subject subgroups which
is a measure of 3He MRI sensitivity. Mean ADC differences existed between healthy
volunteers and subjects with stage II (p<.05) and stage III COPD (p<.01), but not
between subjects with stage III COPD and those with milder disease. While the mean
ADC for stage III COPD subjects was in fact greater, a larger SD for this population
likely resulted in the difference being not statistically significant. However, the inherent
advantage of quantitative imaging is that each image voxel represents a quantitative
measure of disease; the reduction of all voxels to a whole lung mean or center slice mean
effectively masks any of the regional differences between subjects and subject subgroups.
In other words, although differences were not detected using whole lung and center slice
mean values, regional analysis30 may well show differences between subject subgroups
even with small sample sizes. ADC SD, which is a measure of the variability of the ADC
measurement over the region of interest assessed (center coronal slice), also significantly
differed (p<.01) between subjects with stage III COPD and the healthy volunteers and
subjects with less severe disease. This suggests that the stage III COPD subgroup has
higher ADC heterogeneity within the region of interest assessed which has also been
previously reported.9

For mean VDV, there was no significant difference between

healthy volunteers and subjects with stage II COPD at any time point. However, there
was a significant difference between subjects with stage III COPD and both healthy
volunteers and subjects with stage II COPD (p<.01) at all time-points. The finding of
reproducible ventilation defects (no difference in VDV between visits according to
ANOVA results) in the healthy elderly subgroup was not anticipated and suggests caution
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must be used in interpreting results from 3He studies of elderly subjects with underlying
disease. This finding also underscores the value of including a healthy elderly volunteer
control group as in this study and those planned in future that utilize 3He MRI in studies
of older COPD subjects. Perhaps as part of the normal aging processes in the lung, nonrandom airway narrowing occurs even in the absence of known or detectable respiratory
or cardiovascular disease, which may account for the VDV results shown here in healthy
elderly subjects.
The primary limitation of this study is the small sample size of each of the subgroups,
which may have limited the power to detect ADC differences between the stage II and
stage III COPD subject subgroups and to detect VDV differences between the healthy
volunteers and subjects with stage II COPD. Another limitation of this study was the fact
that we did not prospectively acquire 1H and 3He images with the same breath-hold
thoracic volumes (using the methods previously described by van Beek and coworkers18). Hence for the majority of subjects at each time point, 1H and 3He thoracic
image volumes were not well-matched, so that a reproducibility analysis of percent
ventilation volume as previously developed by van Beek18 was not possible in this study.
Nevertheless, in spite of the fact that the 3He and 1H images were acquired under similar,
but not exactly the same breath-hold volume, we were able to calculate percent ventilated
volume for 18 subjects who had well-matched 1H and 3He volumes for same-day rescan
(as assessed by a radiologist who visually compared the 3He and 1H image slices) using
manual segmentation of ventilated volumes.29 Elderly healthy volunteers (n=5) exhibited
94±20% ventilation volume, whereas subjects with stage II COPD (n=6) showed 77±19%
ventilation volume and subjects with stage III COPD (n=7) had 68±14% ventilation
volume, which is in good agreement with results of a previous study in COPD.18
Although we could not assess reproducibility of percent ventilation volume in this study,
the percent ventilation volume result for a subset of patients at a single time point using
manual segmentation suggests that this is a robust measurement that may provide
valuable measurement of airway disease in longitudinal studies. In addition, because 1H
and 3He images were not acquired with exactly matching breath-holds and very different
slice thickness, we limited the analysis of defect volume reproducibility to the center
coronal slice where the edge of the thoracic cavity and ventilation defects were most
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easily discerned. Hence in this study, center coronal slice VDV represented the area of
ventilation defect for the center slice which was then multiplied by the 30 mm slice
thickness reflecting contributions from the entire slice. Because of the rather thick slices
used, VDV as measured in this study, though precise, provides only an estimate of the
true ventilation defect volume. The use of thinner slices and 3D imaging approaches will
allow for an estimate of ventilation defect volume that is likely more accurate. Another
shortcoming of the study design was related to the fact that repeated scanning visits were
prospectively designed to assess the reproducibility of the 3He ADC. For ventilation
defect volume quantification we utilized the first of the interleaved diffusion-weighted
pair of images (typically acquired for ADC calculation) which has intrinsically lower
signal-to-noise ratio than do 3He spin density (ventilation) images. Despite this, one of
the major advantages of our approach is that a single patient breath-hold can be used to
assess both ADC value contributions from the ventilated lung and VDV contributions
from those areas of the lung that are not ventilated. The pragmatic use of a single breathhold imaging session results in an increased subject convenience and tolerability and
decreases cost and time for the subject scan, which are important considerations for
clinical studies aimed at assessing new treatments as well as longitudinal studies.
During progressive COPD, it is believed that adaptive remodeling of the lung and
thoracic gross anatomy such as the diaphragm, muscles and skeleton occurs to
accommodate the microscopic remodeling of the airways and airspaces. Clinical research
studies of COPD continue to focus on spirometric measurement of FEV1, and in some
cases high resolution or multi-detector x-ray CT methods to assess novel interventions
and disease progression. The results of the current study suggest that 3He MRI at 3T
provides another radiological tool for the assessment of both airway and airspace changes
in COPD with sufficient precision for clinical research studies. Moreover, the method
also provides a relatively rapid and safe method of visualizing and quantifying both
spatial and temporal lung structural and functional dynamics related to disease
progression or concomitant with novel treatments.
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2.5 Conclusion
In this study of a relatively small group of elderly healthy volunteers and subjects with
stage II and stage III COPD, both 3He MRI ADC and VDV measurements were highly
reproducible in repeated scans within a few minutes.

3

He MRI ADC also showed high

reproducibility at 7-day rescan and 3He MRI VDV was significantly less reproducible in
7-day rescan visits, providing evidence of spatial and temporal changes in ventilation
defect size over the seven day rescan period. In healthy age-matched elderly subjects,
3

He MRI ADC was significantly different as compared to subjects with stage II COPD

whereas 3He MRI VDV was significantly different between subjects with stage III COPD
and those without disease or with stage II COPD.
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CHAPTER 3: HYPERPOLARIZED
HE
MAGNETIC
RESONANCE IMAGING OF VENTILATION DEFECTS IN
HEALTHY ELDERLY VOLUNTEERS: INITIAL FINDINGS AT
3.0 TESLA

The work presented in this chapter has been previously published in Academic Radiology
as indicated below, and is reproduced here with permission (Appendix C).
G. Parraga, L. Mathew, R. Etemad-Rezai, D.G. McCormack. G. Santyr. “Hyperpolarized 3He
Magnetic Resonance Imaging Ventilation Defects in Healthy Elderly Volunteers: Initial Findings
at 3.0 Tesla” Acad Radiol. 2008 Jun;15(6):776-85

3.1 Introduction
New methods of pulmonary magnetic resonance imaging (MRI) with inhaled
hyperpolarized helium-3 (3He), have been shown to provide regional pulmonary 3He
ventilation maps and the location and size of ventilation changes within the lung in
asthma1-4, cystic fibrosis5-10 and chronic obstructive pulmonary disease (COPD).11-19 In
patients with respiratory disease, areas of decreased ventilation from airflow changes are
observed as “ventilation defects” that are visualized as decreased or an absence of 3He
intensity in 3He MRI spin density images.
Previously, both the size and number of these ventilation defects has been shown to
correlate with severity in asthma3,4,20,21 and in addition, exercise and methacholine
challenge has been shown to alter the size, location and number of defects that occur in
asthma.3 We have also previously described a preliminary analysis of ventilation defect
score and ventilation defect volume (VDV) in 3 subjects – one with mild-moderate
COPD, one with severe COPD and a single healthy age-matched control.17 We noted in
this study that significant ventilation defects were observed even in the healthy elderly
subject. The finding of ventilation defects in an older healthy individual who was not a
smoker, did not have asthma, or cardiovascular disease and who had normal pulmonary
function tests17 was surprising and had not been reported previously in other studies of
younger healthy volunteers.

This result challenged us to explain the physiological

mechanisms related to ventilation defects in healthy lung as well as the prevalence of
ventilation defects in older and middle-aged individuals. To try to address some of these
issues, the goal of this study was to examine and compare, with the use of 3He MRI,
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ventilation defects in elderly and middle-aged subjects who had no history of smoking,
respiratory or cardiovascular disease.

3.2 Methods
3.2.1

Study Population

Subjects were recruited from the general population by newspaper advertisement and
media coverage and they provided written informed consent to study protocols approved
by The University of Western Ontario Standing Board of Human Research Ethics and by
Health Canada. In order to qualify as a healthy subject, volunteers had no history of
chronic respiratory disease or cardiovascular disease and less than 1 pack-year of
smoking over their lifetime.

In addition, subjects were enrolled based on forced

expiratory volume in 1s (FEV1) ≥ 80% predicted and FEV1 divided by the forced vital
capacity (FVC) (FEV1/FVC) ≥ 70%, measured using spirometry, according to the GOLD
classification for healthy subjects.22

For the elderly cohort, subjects were recruited

between the ages of 50 and 75 years and enrolled between the ages of 58 and 74 years
inclusive, whereas for the younger subgroup, subjects were recruited between the ages of
18 and 60 years of age and enrolled between the ages of 23 and 57 years inclusive.

3.2.2

Spirometry

Spirometry was performed at screening and at each MRI visit using an ndd EasyOne
spirometer (ndd Medizintchnik AG, Zurich, CH) reporting forced FEV1 (absolute and
percent predicted) and FVC.

3.2.3

Magnetic Resonance Imaging

For both subject subgroups, MRI was performed on a whole body 3.0 Tesla Excite 12.0
MRS system (GEHC, Milwaukee, WI USA) with broadband imaging capability as
previously described.17 All helium imaging employed a whole body gradient set with
maximum gradient amplitude of 19.4 mT/m and a single channel, elliptical
transmit/receive chest coil (RAPID Biomedical GmbH, Wuerzburg Germany). The basis
frequency of the coil was 97.3 MHz and excitation power was 3.2 kW using an AMT
3T90 RF power amplifier (GEHC, Wilwaukee WI USA).
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The elderly subgroup was scanned twice within 7 ± 2 minutes (scan and same-day rescan)
and then again once within 7 ± 2 days (7-day rescan). All but two of the younger subjects
were scanned on a single occasion only, with two subjects being scanned up to 20 times
each within 2 years. Multi-slice 3He coronal images were obtained using a fast gradientecho method (FGRE) with centric k-space sampling (FOV 40x40cm). Two interleaved
images (TE = 3.7 ms, TR = 7.6 ms, 128 x 128, flip angle = 7 degrees, 7 slices 30 mm
thick), with and without additional diffusion sensitization (G = 19.4mT/m, rise and fall
time = 0.5 ms, gradient duration = 0.46ms, diffusion time = 1.46ms, b value = 1.6s/cm2),
were acquired for each slice with the non-diffusion-weighted image serving as a 3He
ventilation image for analysis. The total image acquisition time was 14s. Each subject
inhaled 3He gas as previously described17 from a 1 L 3He/N2 gas mixture consisting of a
dose of 5ml/kg of hyperpolarized 3He (i.e. for a 50 kg subject, 250ml would be dispensed
and diluted with medical N2 to a total volume of 1L). The 3He gas dose was administered
to subjects after completing a tidal breath exhalation and imaging was performed with the
subject in breath-hold, once the subject had completed inhaling the 1L volume of gas.
Proton imaging was performed after completion of 3He imaging and subjects were
rescanned using a 4-channel radiofrequency coil (GEHC, Milwaukee, WI) with the
subject holding their breath after completing a tidal breath inhalation. Multi-slice 1H
coronal images were obtained using a fast spoiled gradient recalled echo sequence
(256x256 matrix, FOV 40x40cm, TR= 2.7, TE= 1.3, flip angle = 8 degrees).

All

scanning was completed within approximately 10 minutes of first lying in the scanner.
Hyperpolarized 3He gas was provided by a turn-key, spin-exchange optical pumping
system (HeliSpin™, GEHC, Durham, NC) as previously described.17

3.2.4

Image Analysis

Center slice 3He images were analyzed for ventilation defect score (VDS) and ventilation
defect volume (VDV) in a dedicated radiological viewing room which provided a
constant image visualization environment with consistent (darkened) room lighting.
Ventilation defect score and volumetric segmentation were performed for the center
coronal slice only, determined by the presence of the carina, with the aid of the 1H centerslice images (also determined by the presence of the carina).

3

He center-slice images
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were visually compared alone and registered together with 1H center slice images. While
all slices were reviewed, only the center coronal slice was quantitatively assessed because
in this study, 1H image slices were not acquired with the same slice thickness or breathhold as the 3He images (slice thickness of 10mm for 1H as compared to 30mm slice
thickness for 3He).
Images were examined in the same image visualization environment by four trained
observers for analysis of ventilation defects with the observers blinded to subject identity,
disease status and scan time-point. 3He ventilation defects were identified as areas with
an absence of 3He signal with a fixed signal-to-noise (SNR) threshold of 22 and fixed
contrast level, which were empirically established after reviewing all images. Images
were reviewed such that for each subject all time points examined were displayed on a
digital workstation monitor system (consisting of identical 19 inch flat panel monitors).
Thus, all 3He images for each subject were scored together with the observers blinded to
the demographic, clinical, and spirometric information of the subjects. A ventilation
defect was defined as previously described by Altes and co-workers23 as any well-defined
area of the lung showing no or low signal intensity compared with the remaining
ventilated lung. Areas of absent signal associated with the pulmonary vascular structures,
heart, hilum and mediastinum were not considered to be ventilation defects. No lower
boundary for defect size detection or quantification was used. After scoring ventilation
defects, manual segmentation of the defects was performed on 32 bit image slices
randomized together (subject and scan time) that were imported into a 3D image
visualization platform developed in our laboratory24,25 for MR and ultrasound
applications as previously described.26 The image visualization software tool used also
provided a method for 2-dimensional rigid image overlay or registration (of the center
slice 1H image and the center slice 3He image), facilitating the manual segmentation of
center-slice ventilation defect volume even in the case where poor registration occurred
due to breath-hold mismatch. As shown in Figure 3-1, 2-dimensional image overlay (of
the center slice 1H image and the center slice 3He image) facilitated the identification and
manual segmentation of center slice ventilation defects.

3

He ventilation defects were

manually segmented, recorded and multiplied by the slice thickness (30mm) to
approximate VDV, which was recorded in dedicated source documents. Inter-scan and
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inter-observer variability was assessed using the coefficient of variation (COV), which
was calculated as the standard deviation of the difference (between scans for inter-scan
and between observers for inter-observer) divided by mean VDV.

Figure 3-1: Hyperpolarized 3He Magnetic Resonance Imaging Ventilation
Defect Volume Segmentation Approach.
A.1H thoracic cavity (i) Subject 7-1003, (ii) Subject 7-1008, (iii) Subject 6-007, (iv) Subject 6001
B. Hyperpolarized 3He Ventilation Image (i) Subject 7-1003, (ii) Subject 7-1008, (iii) Subject 6007, (iv) Subject 6-001
C. Overlay of 3He ventilation Image (yellow) on 1H thoracic cavity (grey) (i) Subject 7-1003, (ii)
Subject 7-1008, (iii) Subject 6-007, (iv) Subject 6-001
D. Segmentation of 3He ventilation defects (red) (i) Subject 7-1003, (ii) Subject 7-1008, (iii)
Subject 6-007, (iv) Subject 6-001
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3.3 Results
3.3.1

Study Subjects

Eight elderly healthy subjects (five males) were enrolled (mean age 67 ± 6 years, range
58-74 years) as well as 24 (14 males) middle-aged healthy volunteers (mean age 44 ± 10
years, range 23-57 years). Baseline subject demographic data and pulmonary function
test results are reported in Table 3-1. Both subgroups had similar baseline mean weight,
FEV1 (% predicted) and FEV1/FVC. None of the subjects had a history of cardiovascular
or respiratory disorders, obesity, sleep disorders and none of the subjects had smoked
within the last 10 years or had a smoking history of > 1 pack-year over their lifetime.
Body mass indices ranged from 24-35 for the elderly subjects and 20-24 for the middleaged subjects. The two subgroups had significantly different mean age (p<.001). All
subjects except for a single elderly subject who withdrew from the 7-day scanning visit
due to claustrophobia were able to complete all scans and visits. The single subject who
withdrew after his first scanning visit was scanned twice during his single scanning visit.
Two middle-aged healthy subjects were scanned up to 20 times each within two years.

Table 3-1: Study Subject Demographic Characteristics.

Male (n)
Age (± SD) [range] Y
Weight (± SD) kg
Body Mass Index (± SD) [range]
FEV1 % Predicted (± SD)
FEV1/FVC % (± SD)
Subjects with Ventilation Defects N (male)
Total Ventilation Defects N
Scan
Same-day Rescan
7-day Rescan
3
Mean VDV cm (± SD)
Scan
Same-day Rescan
7-day Rescan

Elderly Healthy
Volunteers
(n=8)
5
67 (6) [58-74]
76 (17)
27 (4) [24-35]
106 (19)
77 (5)
6 (3)

Middle-aged Healthy
Volunteers
(n=24)
14
44 (10) [23-57]
76 (13)
25 (3) [20-34]
101 (11)
80 (8)
0 (0)

16
15
18

0
0
0

52 (34)
53 (35)
48 (39)

0
0
0

SD is subgroup standard deviation for eight healthy volunteers
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3.3.2

Ventilation Defects and Ventilation Defect Volume

As shown in Table 3-1, none of the middle-aged healthy volunteers showed evidence of
center coronal slice 3He ventilation defects, including two of these subjects who were
scanned up to 20 times each within a two-year time frame. Although only the center slice
was quantitatively assessed, for these younger subjects, ventilation defects were not
observed in any slices. However, six of eight elderly healthy volunteers exhibited visibly
obvious 3He ventilation defects in scans acquired at baseline scan, same-day rescan and

Table 3-2: Ventilation Defects in Healthy Elderly Volunteers.
Subject 1001
Subject 1002
Subject 1003
Subject 1004
Subject 1005
Subject 1006
Subject 1007
Subject 1008
Total Sum Defects
Mean Defect Score

Scan
0
3
3
2
3
0
2
3
16
2.7

Number of Defects in Center Slice
Same-day Rescan
7-day Rescan
0
0
3
NA
3
5
2
4
2
3
0
0
2
3
3
3
15
18
2.5
3.6

NA is not assessable
7-day rescan, as results indicate in Table 3-2. Two of the eight healthy elderly subjects
had no ventilation defects in any slice during scan, same-day rescan or 7-day rescan and
these were both male subjects and the youngest in the subgroup (age 58 BMI 27 and age
60 BMI 35, respectively). For all healthy elderly subjects, the total number of center
slice defects summed across all subjects was 16 at scan, with mean VDS of 2.5. For
same day rescan, VDS was 2.7 and the sum of total defects was 15 whereas for 7-day
rescan, VDS was 3.6 and the sum of total defects was 18. Mean VDV was 52 ± 34 cm3 at
scan, 53 ± 35 cm3 at same-day rescan and 48 ± 39 cm3 at 7-day rescan. Figure 3-2
shows 3He ventilation images with defects identified with arrows (Figure 3-2(i)) and the
overlay of 3He ventilation images on the 1H thoracic cavity image (Figure 3-2(ii)) for
three representative healthy elderly subjects (ages 70, 73 and 74 years respectively).
Figure 3-3 provides representative 3He ventilation scans for three representative healthy
middle-aged subjects (ages 45, 43 and 39 years respectively). The range of signal-tonoise (SNR) for the images in both subgroups was similar.
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Figure 3-2: Elderly Healthy Volunteers 3He Magnetic Resonance Imaging.
A. Subject 7-1004 70 yr old female FEV1 = 149% predicted, FEV1/FVC=75% (i) 3He image (ii)
overlay of 3He image with 1H thorax image
B. Subject 7-1007 73 yr old male FEV1= 104% predicted, FEV1/FVC=84% (i) 3He image (ii)
overlay of 3He image with 1H thorax image
C. Subject 7-1008 74 yr old male FEV1 = 91% predicted, FEV1/FVC=79% (i) 3He image (ii)
overlay of 3He image with 1H thorax image

3.3.3

Ventilation Defect
Reproducibility

Volume

Interscan

and

Inter-observer

For all eight elderly subjects who underwent scanning, inter-scan COV for mean VDV
was 1.8% for same-day scanning and 5.3% for 7-day scanning (as compared to baseline
scan).

Figure 3-4 shows 3He ventilation images providing visual evidence of the

reproducibility of VDV for two representative elderly subjects with ventilation defects
that completed both same-day and 7-day scanning visits.

For both subjects, the

magnitude and location of many of the defects are very similar during same-day
scanning; there are a few differences in the number of defects, the location of the defects
and the size of the defects observed in the 7-day rescan. For comparison, repeated scans
of two middle-aged subjects are also provided in Figure 3-4 with rescan performed within
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8 months of baseline and the second rescan performed within 2 years of baseline. No
defects or visual differences were observed in the scans for the middle-aged subjects.
While a single observer’s results are provided for mean VDV in Table 3-1, the results for
three additional observers are provided in Table 3-3 as well as inter-observer COV,
which ranged from 10% to 12%.

Figure 3-3: Middle-aged Healthy Volunteers
Imaging.

3

He Magnetic Resonance

A. Subject 6-1001 45 yr old female
B. Subject 6-1003 42 yr old male
C. Subject 6-1010 39 yr old male

Table 3-3: Elderly Volunteer Ventilation Defect Volume Inter-observer
Reproducibility.
3

Observer 1
Observer 2
Observer 3
Observer 4
Mean Ob1-4
COV (%)

Scan
52 (34)
72 (55)
67 (43)
70 (63)
66 (8)*
12

Mean VDV cm (± SD)
Same-day Rescan
53 (35)
67 (47)
64 (42)
65 (61)
62 (6)*
10

7-day Rescan
48 (39)
60 (48)
53 (40)
46 (44)
52 (6)*
12

SD is subgroup standard deviation for eight healthy volunteers except for *SD is observer
standard deviation

COV is SD/ mean VDV for observers
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Figure 3-4: Reproducibility of 3He Ventilation in Healthy and Middle-aged
Healthy Volunteers
A.Subject 7-1005 Elderly Volunteer (i) Scan, (ii) Same-day Rescan, (iii) 7-day Rescan
B.Subject 7-1008 Elderly Volunteer (i) Scan, (ii) Same-day Rescan, (iii) 7-day Rescan
C.Subject 6-1001 Middle-aged Volunteer (i) Scan, (ii) Rescan 1, (iii) Rescan 2
D.Subject 6-1002 Middle-aged Volunteer (i) Scan, (ii) Rescan 1, (iii) Rescan 2
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3.4 Discussion
A number of important observations were made in this study. First, all subjects in this
study who were age 63 years and older displayed ventilation defects in the center coronal
slice and the number, location and size of these defects were highly reproducible for
same day scanning sessions with mean inter-scan VDV COV 1.8% and the total number
of defects at 16 and 15 for same-day scan and rescan respectively. Somewhat lower
reproducibility was observed for the 7-day scanning visit as compared to baseline with a
mean inter-scan VDV COV of 5.3% and the total number of defects scored at 18, with a
mean VDS of 3.6 defects.

However, all of the six elderly subjects who displayed

ventilation defects at baseline displayed very similar number and size of ventilation
defects at the 7-day scanning session. In addition, none of the 24 healthy volunteers in
the middle-aged subgroup displayed ventilation defects during any scanning session and
neither did the two youngest subjects in the elderly subgroup. As shown in Table 3, four
observers measured VDV over a 1.5 year period with inter-observer COV ranging from
10% to 12%. In recent work, Altes and co-workers27, have shown the association of age
and ventilatory defects which supports the finding reported here of significantly different
size and number of defects in the centre coronal slice of healthy younger and elderly
volunteers. Their previous work also reported small mean numbers (<2) of ventilation
defects in younger healthy volunteers6 when the entire lung was assessed. In current
studies of healthy volunteers at 3.0 Tesla at our site, there is little evidence of posterior or
other slice defects in healthy volunteers who have less than 1-pack-year smoking and no
evidence of cardiovascular or respiratory disease. This may be the case because 3.0 Tesla
3

He MRI at our site has been limited to <50 healthy volunteers; it is possible that with

more subjects scanned over time small mean numbers of ventilation defects will be
detected in some young healthy subjects.
A second finding from this preliminary study was that for the six elderly subjects for
whom defects were observed at baseline, there was a tendency for these to appear in the
same locations 7 days later. In some cases, the original defects were accompanied by
new defects and/or slightly altered sizes.

Regional persistence or recurrence of

ventilation defects has also been recently described in asthma by Altes, de Lange and co-
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workers28 with specific regions of the lung appearing to be more likely to display altered
ventilation patterns.

The observation in this study that regional persistence is also a

feature of ventilatory defects in healthy elderly subjects suggests that specific airways
appear to be preferentially closed in the aging lung and that these airways are more likely
to be closed on sequential days. It is important to point out that all subject scanning
sessions were scheduled for the same time of day on the second scanning visit as the first
scanning visit (±1 hour from baseline scan for each subject) and always during midmorning. Spirometry measurements were also recorded before and after each scanning
session and there was no change in spirometry measures observed for any subjects
between scanning dates or after MR scanning. Finally, obesity is a critical issue to
consider when imaging subjects in the supine position, as extra weight directly influences
respiratory mechanics in the supine and upright position. None of the subjects who
displayed ventilation defects were obese, and hence it is unlikely that any of the
ventilatory defects observed were related to BMI.
Thirdly, we observed that for the elderly healthy volunteers, all defects in the center
coronal slice appeared on the periphery of the coronal slice, which is similar to
previously published work in asthma.3,29-31 This finding of peripheral lung ventilation
defects in the elderly healthy lung and in asthma is in contrast to previously published
3

He results for subjects with COPD in our lab17 and others11-16,18,19 and in cystic fibrosis7-

10

, where numerous and large defects are observed throughout the coronal and axial plane

and not on the periphery alone.
The primary limitation of this preliminary study is the small sample size of the elderly
subject group and the fact that for the majority of the middle-aged subjects group there
was no protocol specification for prospective repeated scanning because no ventilation
defects were observed at baseline. For two middle-aged subjects, repeated scanning was
undertaken, only because these subjects were enrolled in a hardware and software
development protocol requiring multiple scanning visits to enable pulse programming
alteration assessments. Both of these subjects were scanned up to 20 times over two
years and these subjects (both with ages very close to the mean of the middle-aged group)
never displayed ventilation defects during any scanning visit.
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Another shortcoming of the study is related to the fact that subjects were scanned in a
study designed to assess the reproducibility of the 3He ADC and hence the images had
lower SNR and thicker slices than do spin density images. Nevertheless, the finding of
ventilation defects is still very evident and the difference in younger and older subjects is
significant. This suggests that the current result is robust and provides a conservative
estimate of the defects that may be observed in older subjects. Elderly subjects were
enrolled in the current study with ADC reproducibility as the primary end-point and as
such protocol utilized an optimized ADC sequence. The primary focus on ADC required
necessary trade-offs be made in the use of the non-diffusion-weighted images as a
indication of ventilation (i.e. increased TE, diffusion time). We acknowledge that the
longer TE will introduce undesirable T2* weighting into the ventilation, but expect that
this effect would lead to less than 50% signal reduction even with the largest ADC (larger
airways). Indeed, the signal in the airways is well appreciated in our images. Therefore,
we are confident that the regions of signal void in the lung parenchyma attributed to
ventilation defect in this study represent the absence of helium gas and not signal decay.
This is confirmed by the measurement of the same signal voids in T1-weighted image
(obtained on Visit 2, data not shown) which was obtained with TE of about half that of
the non-diffusion-weighted images. It may be possible that with 3He ventilation imaging,
the improvement in SNR might result in better measured reproducibility for the same-day
and 7-day scanning visits.
Another limitation of this study is the fact that 3He and 1H images were acquired at
somewhat different lung volumes and that this may have influenced the segmentation of
ventilation defects that appeared on the lung-pleura boundaries. For example, the 1H
images were acquired in breath-hold fashion after blowing out to the bottom of tidal
volume and holding their breath at the top of tidal volume. The 3He images were
acquired after blowing out to the bottom of tidal volume and in breath-hold after inhaling
1L of the 3He/N2 gas mixture. Therefore the volumes were not exactly matched and
overlay of 3He and 1H images were not perfectly registered. However, although the
images were acquired at slightly different volumes, the lung boundaries were readily
discerned when the 1H and 3He images are provided in overlay and identification of these
are facilitated in all six cases where there were clear ventilation defects at the outer
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boundary of the lungs. In addition, because 1H and 3He images were not acquired with
exactly matching breath-holds and very different slice thickness, we limited the analysis
of defect volume reproducibility to the center coronal slice where the edge of the thoracic
cavity and ventilation defects were most easily discerned. Hence, in this study center
coronal slice VDV represented the area of ventilation defect for the center slice, which
was then multiplied by the 30 mm slice thickness to reflect contributions from the entire
slice. We also point out that for some subject images, the apices of the lung have
complex ventilation patterns that might be interpreted as ventilation defects. In most
cases, the overlay of proton and helium images allows for interpretation of the irregular
shape of the ventilation image as dependent upon tissue and bone anatomy at the top of
the lung. We investigated coil coverage and found that there is excellent signal intensity
in the trachea up to and including the cricoid/larynx. We have also directly assessed coil
inhomogeneity quantitatively (ISMRM abstract 2008 #5175) and observed less than 20%
in the superior-inferior direction over a 44 cm FOV, which is likely adequate for the
imaging results we have presented here.
Why do elderly healthy volunteers display 3He MRI ventilation defects along the
periphery of the coronal plane of the lung? How is this finding related to the increased
ADC values shown previously for older subjects17,32,33 and in the six elderly subjects in
this study with ventilation defects (with mean ADC = 0.27 cm2/s)? How might this
finding be related to other measurements of pulmonary physiology that are also known to
change with aging such as FEV1 and closing volume? It is possible that along with
changes in the lung airspaces such as alveoli and acinar ducts, (as evidenced by increased
ADC) changes in airways may also occur over time, and perhaps correlated to increased
closing volumes with advancing age. In this study, the majority of defects were observed
along the periphery of the coronal slice which suggests that terminal airway closure or
narrowing may be an age-dependent pathology of the lung. Altes and co-workers have
also observed ventilation defects in healthy volunteers are positively correlated with
age27, suggesting that the finding here in a few elderly subjects should be assessed in
more volunteers in multi-center studies. While the etiology of ventilation defects is yet
unknown, we are currently assessing the presence and reproducibility of ventilation
defects in a greater number of elderly COPD subjects and elderly (age-matched) healthy
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volunteers over a five-year period in order to better understand this radiological finding.
The observation of reproducible pulmonary ventilation defects in otherwise healthy
elderly volunteers suggests caution must be used in interpreting results from 3He studies
of elderly subjects with underlying disease. This finding further suggests that inclusion
of a healthy elderly volunteer control group may be required when using 3He MRI in
treatment studies of elderly COPD, subjects in order to appropriately relate potential
treatment effects to underlying disease and not other processes related to aging. If the
results of this preliminary study are observed in the majority of elderly volunteers
scanned in our laboratory and elsewhere, this may potentially result in increased subject
sample sizes required in cohort and treatment studies of elderly subjects with respiratory
disease where 3He MRI phenotypes are used as measurements or biomarkers of disease.

3.5 Conclusion
In conclusion, the observations made in this study of a relatively small group of elderly
and middle-aged healthy volunteers indicated that regional ventilation defects within the
lung as demonstrated using 3He MRI were present in six elderly subjects aged 63-74
years. These ventilation defects were highly reproducible in size and location in repeated
scans within a few minutes and again 7 days later. These results suggest that as part of
the aging processes in the lung, non-random airway closure or narrowing occurs that is
restricted to the lung periphery and is regionally recurrent or persistent. The results
further suggest that these airway changes are occurring in the absence of known or
detectable respiratory or cardiovascular disease, perhaps as part of normal aging
processes. Further work is required to unravel the etiology of these defects in healthy
elderly volunteers.
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3
CHAPTER 4: HYPERPOLARIZED
HE
MAGNETIC
RESONANCE IMAGING: PRELIMINARY EVALUATION OF
PHENOTYPING POTENTIAL IN CHRONIC OBSTRUCTIVE
PULMONARY DISEASE

The work presented in this chapter has been previously published in the European
Journal of Radiology as follows, and is reproduced here with permission (Appendix C).
L. Mathew, M Kirby, A. Wheatley, DG McCormack, G. Parraga. “Hyperpolarized 3He Magnetic
Resonance Imaging: Preliminary Evaluation of Phenotyping Potential in Chronic Obstructive
Pulmonary Disease” Eur J Radiol. 2009 Nov 20. [Epub ahead of print]

4.1 Introduction
Chronic obstructive pulmonary disease (COPD) is the most common chronic, terminal
respiratory disease worldwide and it continues to grow in prevalence1 and yet has a very
poor prognosis, despite aggressive therapy.1-3

Although widespread pulmonary

inflammation 4,5 and diffuse lung tissue alterations are often observed5, obstruction of the
small airways (airways disease) and tissue destruction in the pulmonary parenchyma
(emphysema) are the hallmark pathologies.6 Accordingly, both airways disease and
emphysema contribute to the clinical course of COPD, although the underlying
mechanisms of both pathologies and the proportional contributions of these and their
relationship to outcomes are not completely understood.
The current functional definition of COPD7 relies on the spirometric measurement of
airflow obstruction. A fundamental limitation exists however, because the anatomy and
physiology of the lung is complex and spirometry measurements reflect the global sum of
all the different possible COPD pathologies including small airways disease, emphysema
(i.e. parenchymal destruction), chronic bronchitis (i.e. large airway remodeling), and
bronchiectasis (i.e. abnormal dilation of bronchi and bronchioles).8
The limitation of spirometry for differentiating between these pathologies or phenotypes
has severely limited the scope of basic research and clinical studies that evaluate the
relationship between these morphological phenotypes, disease pathogenesis and
progression, and patient outcomes. Accordingly, one major goal of COPD research is to
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find a way to identify patients with these different underlying pathological “phenotypes”,
which has the potential to have a profound effect on patient care and treatment options.
In this regard, non-invasive high resolution multi-detector x-ray computed tomography
(CT)9-12 has been shown to detect unique and quantitative phenotypes of both emphysema
and airway disease13-15 with the potential to determine the contributions of both airway
and airspace changes in COPD. Previously published results suggest that CT-derived
phenotypes provide evidence of underlying phenotype dominance in approximately 40%
of subjects.13
Hyperpolarized 3He magnetic resonance imaging (MRI) has emerged as research method
that is complementary to CT because it allows for simultaneous visualization of tissue
structure and regional airway function at high spatial and temporal resolution, without the
use of ionizing radiation. In particular, the measurement of the 3He apparent diffusion
coefficient (ADC)16, which is a surrogate measurement of airspace size17-20, has been
previously histologically-validated21 and correlated with CT measurements of
emphysema.22

Ventilation defects or signal voids in 3He spin density images are

hypothesized to reflect airflow limitation related to airway narrowing or closure23, but the
exact pathology underlying

3

He ventilation defects has yet to be determined.

Importantly, both 3He MRI ADC and ventilation measurements have been shown to be
highly reproducible24-26, sensitive to age27-29 and to disease-related changes.26,30-33
Here we describe the results of a proof-of-principle and hypothesis-generating
preliminary study where we explore the potential of hyperpolarized 3He MRI to classify
(or phenotype) individual COPD ex-smokers based on the relative contributions of
ventilation defect and ADC measurements. To our knowledge, this is the first study
aimed at evaluating the potential for 3He MRI to detect phenotypes based on the
proportional contributions of COPD structural and functional measurements.
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4.2 Methods
4.2.1

Subjects

Twenty subjects were enrolled from the general population of the local tertiary health
care center as well as directly from the COPD clinics at three local teaching hospitals.
All subjects provided written informed consent to the study protocol approved by the
local research ethics board and Health Canada and the study was compliant with both the
Health Insurance Portability and Accountability Act (HIPAA, USA) and the Personal
Information Protection and Electronic Documents Act (PIPEDA, Canada). Subjects were
categorized according to Global initiative for Obstructive Lung Disease (GOLD)
criteria34 and required a COPD diagnosis of at least one year, with a smoking history of at
least 10-pack-years and additional inclusion and exclusion criteria as previously
reported.26

4.2.2

Pulmonary Function Tests

Subjects were screened for MRI and coil compatibility (inner diameter of elliptical coil =
50cm) and underwent a physical exam, plethysmography and spirometry both of which
were performed according to American Thoracic Society guidelines.35

Briefly,

spirometry was performed pre- and post-bronchodilator using an ndd EasyOne spirometer
(ndd Medizintchnik AG, Zurich, CH) reporting forced expiratory volume in 1 s (FEV1)
and forced vital capacity (FVC) and a minimum of three acceptable spirometry
maneuvers were carried out with the best FEV1 and FVC selected for analysis. Whole
body plethysmography (MedGraphics Corporation, 350 Oak Grove Parkway St. Paul MN
USA) was also performed within meters of the MR scanner for the measurement of total
lung capacity (TLC), inspiratory capacity (IC), residual volume (RV), and functional
residual capacity (FRC).

4.2.3

Safety Monitoring and Hyperpolarized 3He Administration

Prior to MRI, supine vital signs and arterial O2 levels measured by pulse oximetry were
recorded, and subjects were administered a practice dose of mixed 4He-N2 gas while
seated outside the scanner. Digital pulse oximetry was used to monitor arterial blood
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oxygen levels during MR scanning and all breath-hold maneuvers. Hyperpolarized 3He
gas was provided by a turn-key, spin-exchange polarizer system (HeliSpin™, GEHC,
Durham, NC) as previously described.36

In a typical study this system provided 30%

polarization in 12 hours. Doses (5 mL/kg) were delivered in 1 L plastic bags (Tedlar®,
Jensen Inert Products, Coral Springs, FL) diluted with ultrahigh purity, medical grade
nitrogen (Spectra Gases, Alpha, NJ). The 3He gas dose was administered to subjects after
completing a tidal breath exhalation (ie. FRC) and imaging was performed with the
subject in breath-hold from FRC.

4.2.4

Imaging

Magnetic resonance imaging was performed on a whole body 3.0 Tesla Excite 12.0 MRI
system (GEHC, Milwaukee, WI USA) with broadband imaging capability as previously
described.36 All helium imaging employed a whole body gradient set with maximum
gradient amplitude of 19.4 mT/m and a single channel, rigid elliptical transmit/receive
chest coil (RAPID Biomedical GmbH, Wuerzburg Germany). The basis frequency of the
coil was 97.3 MHz and maximum excitation power was 3.2 kW using an AMT 3T90 RF
power amplifier (GEHC, Wilwaukee WI USA).
Two-dimensional multi-slice coronal 1H scans were acquired prior to 3He imaging with
subjects scanned during 1-L breath-hold of 4He/N2 from FRC using the whole body
radiofrequency (RF) coil and proton fast spoiled gradient-echo (16s total data acquisition,
repetition time (TR)=4.7ms, echo time (TE)=1.2 ms, flip angle=30°, bandwidth
(BW)=31.25, field-of-view (FOV)=40cm x 40cm, matrix 128 x 128, 14 slices, 15mm
slice thickness, 0mm gap). For diffusion-weighted 3He imaging, multi-slice coronal
images were obtained using a fast gradient-echo method (FGRE) with centric k-space
sampling. Two interleaved images (14s total data acquisition, TR=7.6 ms, TE=3.7 ms,
flip angle=8°, BW=31.25, FOV=40cm x 40cm, matrix=128 x 128, 7 slices, 30 mm slice
thickness), with and without additional diffusion sensitization (G=19.4mT/m, rise and fall
time=0.5 ms, gradient duration=0.46ms, diffusion time=1.46ms, b value=1.6s/cm2), were
acquired for each slice. For ventilation images, multi-slice coronal images were also
obtained using the same chest coil (14s total data acquisition, TR=4.3ms, TE=1.4ms, flip
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angle=7o, BW=31.25, FOV=40cm x 40cm, matrix 128 x 128, 15 slices, 10mm slice
thickness, 0mm gap).

4.2.5
3

Image Analysis

He ventilation image measurements and 3He diffusion-weighted image analyses were

performed in an image visualization environment with room lighting levels equivalently
established for all image analysis sessions as previously described.26,37 Mean apparent
diffusion coefficient (ADC) and ADC maps were processed for all slices using in-house
software programmed in the IDL Virtual Machine platform (Research Systems Inc.,
Denver, CO) as previously described36, with the trachea and main bronchi removed prior
to analysis and b = 1.6 s/cm2. 3He ventilation images were examined by a single trained
observer for analysis of ventilation defects in all coronal slices. A ventilation defect was
defined as previously described38, and manual segmentation of the ventilation defects was
performed with the observer blinded to subject identity, clinical characteristics and
disease stage. Segmentation was performed using custom-designed image visualization
software which provides for two-dimensional rigid image registration (of the 1H and 3He
slices), facilitating the manual segmentation of ventilation defects in all slices. It is
important to note that using this method and images from this dataset, intra- and interobserver coefficients of variation of <10% were previously determined (unpublished
data); inter-scan ventilation defect volume (VDV) coefficients of variation were
previously reported and were very similar.26 To generate ventilation volumes, for each
slice, the average contour area was multiplied by the slice thickness and all slices were
summed to obtain a total volume.39 As shown in Figure 4-1, manual segmentation of the
3

He signal provided a VDV while thoracic cavity volume (TV) was recorded following

segmentation of 1H images, and both were used to calculate ventilation defect percent
(VDP), or the percentage of the thoracic cavity occupied by ventilation defects.
To determine the proportional contribution of ADC to total 3He MRI measured disease,
we normalized ADC values using a linear scale. The scale ranged from 0% representing
the mean ADC for healthy age-matched (elderly) never-smoking volunteers
(ADC=0.27cm2/s)29 to 100% (ADC=0.88cm2/s) for helium in an infinitely large
container. Normalized parameters representing airway functional (VDP) and airspace
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Figure 4-1: Schematic for 3He MRI Ventilation Analysis.
3

He MRI ventilation images manually segmented to provide 3He derived ventilation defect
volume (VDV) by manual segmentation of 3He focal signal voids. 1H MRI thoracic cavity
images manually segmented on a slice-by-slice basis to provide a 1H MRI derived thoracic cavity
volume (TCV). Ventilation defect percent (VDP) is generated as VDV normalized or divided by
TCV.

structural (ADC%) measurements for the center slice (with the highest SNR) were
summed to provide a total MRI disease measurement based on the assumption of a linear
relationship between these variables.

From this total disease measurement, the

proportional contribution of ventilation defects (VDP) and emphysema (ADC%) was
evaluated for each subject.

4.2.6

Statistical Methods

Mean ADC and VDV were calculated by summing the data and dividing by the number
of subjects (n) and standard deviations were calculated as the square root of the sum of
the differences between the squared data and the squared mean, divided by n.
Comparison of ADC and VDV means was performed using the one-way analysis of
variance (ANOVA) in SPSS 16.00 (SPSS Inc., USA LEAD Technologies, Inc., Chicago,
IL).

The relationship between 3He MRI ADC and ventilation measurements was

determined using linear regression and Pearson correlation coefficients (GraphPad Prism
version 4.00, GraphPad Software Inc, San Diego California, USA). A Holm-Bonferroni
correction was applied to account for multiple comparisons.40 Classification of subjects
into three categories based on ADC% and VDP was based on the proportional
contribution of ADC% or VDP to total measurement of underlying disease pathology
using an arbitrary 2/3 threshold – indicating either ADC% or VDP was the major
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contributor to 3He MRI measured disease. A multivariate ANOVA was performed to
determine significant differences between the three groups.

4.3 Results
4.3.1

Study Subjects

Baseline demographic characteristics are provided in Table 4-1 for the 20 subjects
enrolled (13 male) by GOLD criteria.34 A single subject presented with normal FEV1 and
low FEV1/FVC (stage I) with a prior diagnosis of emphysema from thoracic CT. All
other subjects were either categorized as GOLD stage II or stage III COPD according to
post-bronchodilator spirometry performed on the same day as MRI. Mean body mass
index (BMI) and BMI range for each subject subgroup was similar. As the COPD
subjects were enrolled according to GOLD criteria34, the mean values for FEV1 and
FEV1/FVC for each subgroup reflected the GOLD categorization. In addition to the
expected and significantly decreased FEV1 percent predicted (%pred) and FEV1/FVC for
the stage III COPD subgroup, baseline FRC and RV were significantly increased and IC
significantly decreased for stage III COPD subjects consistent with lung hyperinflation.

Table 4-1: Subject Demographics.

Age yrs (±SD)
[range]
Male Sex
Body Mass Index
(±SD) [range]
FEV1 %*(±SD)
FEV1/FVC % (±SD)
IC %* (±SD)
RV %* (±SD)
FRC %* (±SD)
TLC %* (±SD)

Stage I COPD
n=1

Stage II COPD
n=9

Stage III COPD
n=10

67
1
33
90
61
128
161
139
135

68(6)
[59-74]
4
29
(4) [22-38]
61 (6)
54 (11)
95 (18)
141 (21)
118 (16)
108 (9)

68(7)
[52-75]
8
25
(4) [18-34]
39 (7)
36 (9)
59 (34)
191 (47)
164 (39)
119 (23)

Significance
Difference
SII -SIII
p
NS
NS
<.001
.003
.006
.009
.01
NS

*Percent predicted, FEV1 = Forced Expiratory Volume in 1s, FVC= Forced Vital Capacity FRC=
Functional Residual Capacity, TLC= Total Lung Capacity NS= Not significant, SII = stage II
COPD, SIII= stage III COPD.
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Figure 4-2: Linear Regression.
A) shows the relationship between FEV1 %pred and whole lung VDV (y= -0.03x + 3.01,
p=0.007). B) shows the relationship between FRC %pred and whole lung ADC (y= 0.002x + 0.18, p=0.001). Dashed line shows the 95% confidence interval.

4.3.2

3

He MRI Measurements

Table 4-2 shows mean 3He ADC as well as 3He ventilation measurements (VDV and
VDP) for the single patient with normal FEV1, and all patients with stage II and stage III
disease. No significant difference was observed for any of the 3He MR measurements
between stage II and stage III subgroups. Pearson correlation coefficients for 3He ADC
and VDV are provided in Table 4-3 which shows significant and modest correlations for
ADC and VDV with FRC %pred and significant association between TLC and ADC.
Figure 4-2 shows the relationship between FEV1 %pred and VDP (Figure 4-2A), and the
relationship between ADC and FRC %pred (Figure 4-2B). Table 4-4 shows center slice
3

He MRI measurements and the relative contributions of these measurements for each

subject. The sum of ADC% + VDP is provided for each patient in Figure 4-3, where
centre slice VDP and ADC% values are summed together and expressed as a percentage of total
3

He MRI measured disease (total sum divided by 2).

The sum of ADC% + VDP, was

statistically significantly lower (p=0.006) for subjects classified as ADC (AD) or VDP
dominant (VD) compared to the mixed group. There was also a significant difference for
FEV1%pred between subjects with a single predominant 3He MR measurement (either
ADC or VDP) and subjects in the mixed group (p=0.008). Subject classification results
based on an arbitrary 10% threshhold are shown in Figure 4-4 with the threshold denoted
as a dotted line and subjects with ADC% and VDP values close to the threshhold denoted
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with asterisks. Both the 10% threshold and 2/3 contribution to total MRI-measured
disease classified the same three subjects as VD and the same four

Table 4-2: Whole Lung 3He MRI ADC and Ventilation Measurements.
2

ADC (±SD) cm /s
2
ADCSD (±SD) cm /s
VDV (±SD) L
VDP (±SD) (%)

Stage I
n=1
0.58
0.27
0.19
6

Stage II COPD
n=9
0.42 (0.10)
0.23 (0.04)
1.07 (0.69)
22 (16)

Stage III COPD
n=10
0.48 (0.09)
0.26 (0.05)
1.74 (0.88)
28 (12)

ADC is 3He apparent diffusion coefficient, SD is standard deviation, VDV is ventilation defect
volume, VDP is ventilation defect percent

subjects as AD. The results of the multivariate ANOVA showed the VD subgroup had
significantly different, and lower ADC% values than the AD subgroup (p=0.02) and
mixed groups (p=0.008). The AD subgroup showed statistically significantly different,
lower VDP values than the mixed group (p=0.003). In Figure 4-5 3He MR ventilation
images (i), ADC maps (ii) and ADC histograms (iii) are provided for the subjects
identified by both classification methods as in the AD subgroup with high ADC pixel
values, increased mean ADC and broader ADC histograms (Subjects 2-8 (A), 2-6 (B), 36 (C) and 1-1 (D)). Figure 4-5 also shows the subjects in the VD subgroup (and one
subject on the 10% threshold) with increased ventilation defects and low ADC pixel
values, decreased mean ADC and narrow peak ADC histograms (Subjects 3-4 (E), 2-9
(F), 2-3 (G), 3-7 (H)).
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Table 4-3: Whole lung 3He MRI Correlations with Pulmonary Function.
ADC
FEV1 %pred (p)
FEV1/FVC (p)
FRC %pred (p)
IC %pred (p)
TLC %pred (p)
RV %pred (p)

-0.26 (0.27)
-0.53 (0.02)
0.68 (0.001)
-0.39 (0.09)
-0.53 (0.02)
0.43 (0.06)

Holm-Bonferroni
p value
0.27
0.12
0.012
0.27
0.014
0.24

VDV
-0.58 (0.007)
-0.54 (0.01)
0.62 (0.003)
-0.55 (0.01)
0.34 (0.14)
0.48 (0.03)

Holm-Bonferroni
p value
0.07
0.08
0.033
0.09
0.28
0.15

Figure 4-3: 3He MRI VDP and ADC% Contributions in COPD.
Center slice VDP and ADC% values are summed together and expressed as a percentage of total
3
He MRI measured disease (total sum divided by 2), where 100% disease would be 100% VDP
and ADC =0.88cm2/s. Subjects § are classified as primarily ADC by both classification methods,
whereas subjects † are classified as primarily VDP by the classification methods.
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Table 4-4: Center slice 3He Measurement Contributions by Subject.
Subject

FEV
1

1-1
2-1
2-2
2-3
2-5
2-6
2-7
2-8
2-9
2-10
3-1
3-2
3-4
3-5
3-6
3-7
3-8
3-9
3-10
3-11

90%
64%
51%
68%
62%
62%
66%
59%
68%
51%
43%
35%
41%
42%
49%
49%
32%
33%
35%
30%

FEV1/FV
C
61%
50%
41%
61%
48%
53%
77%
50%
60%
42%
29%
29%
46%
32%
42%
54%
37%
31%
23%
35%

VDP
(%)

ADC
%

ADC%+VD
P

Contribution
ADC

Contribution
VDP

2
33
52
21
25
5

54
39
33
2
20
34

56
72
85
23
45
39

96%
54%
39%
7%
44%
87%

4%
46%
61%
93%
56%
13%

21
6
18

21
13
3

42
19
21

50%
69%
15%

50%
31%
85%

64
38
25

56
38
28

120
76
53

47%
50%
53%

53%
50%
47%

12
19
8

10
33
48

22
52
56

45%
63%
86%

55%
37%
14%

29
46
37

7
33
57

36
79
94

18%
42%
61%

82%
58%
39%

33

56

89

63%

42%

26

48

74

65%

45%

Bolded subjects were classified as having a single predominant measurement by the 2/3
approach.

70
60

VDP (%)
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40
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20
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Figure 4-4: 3He MRI Classification by Thresholding.
VDP and ADC% scatter plot for all subjects with dashed line denoting 10% threshold cutoff. The
asterisks represent two subjects close to the threshold line, X represents subject 2-8, and the *
represents subject 3-4.
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Figure 4-5: 3He VDP and ADC Dominance.
A-D) ADC dominant subjects identified in both classification methods A) subject 2-8 B) subject
2-6 C) subject 3-6 D) subject 1-1
E) Subject 3-4, on the 10% threshold of mainly VDP classification
F-H) predominantly elevated VDP subjects identified in both classification methods F) subject 29 G) subject 2-3 H) subject 3-7
Predominantly ADC subject images have fewer ventilation defects (i) with brighter red/yellow
ADC maps (ii) and broader histograms (iii), whereas predominantly VDP subjects show
increased ventilation defects and darker red/black ADC maps.
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4.4 Discussion
In this pilot study of COPD ex-smokers, we made a number of important observations
that are relevant to the potential use of 3He MRI. First, although this was a relatively
small pilot study, preliminary analysis showed that there was evidence of a single 3He
measurement – either VDP or ADC providing the main contribution to 3He MRI
measured disease in a subset of subjects (35%) evaluated. In particular, some patients
reported high ADC and nearly normal 3He ventilation images with normal ADC based on
age-matched healthy non-smoker volunteers.37 Another small group of patients reported
nearly normal (age-adjusted) ADC but significantly elevated VDP (where normal VDP is
defined as equivalent to no defects, a finding in the healthy young, and some healthy
elderly subjects26). We acknowledge that these results are descriptive, the threshold
approach is simplistic, appears arbitrary, and can only be viewed as a first step towards a
more quantitative and

mathematical-based

understanding of phenomenological

observations that can be achieved when more patients are evaluated. Furthermore, we
acknowledge that this is a preliminary analysis, and that our findings are based on the
assumption that there is a linear relationship between ADC%, VDP and overall disease.
It is important to note that currently the exact relationship between emphysema, airways
disease and a “total disease index or measurement” has not been evaluated or at least
published. Therefore, our approach should be considered a first order approximation
with regard to the extent that emphysema and airways disease contribute to COPD.
Clearly, these concepts require further testing or modelling to determine the extent to
which tissue destruction and airway inflammation or obstruction contribute to overall
disease. Despite the preliminary and somewhat straightforward approach presented here,
our results support further testing of the hypothesis that non-invasive 3He MRI can
provide unique information that can be used to phenotype COPD subjects.
Second, we observed that the seven subjects with evidence of a single dominant 3He
MRI measurement had significantly higher FEV1, compared to the mixed subgroup
(n=13). This suggests that subjects with mainly elevated VDP or ADC showed decreased
disease severity measured using spirometry. Additionally, for these seven patients, the
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sum of VDP + ADC% was significantly lower than for the 13 mixed subgroup patients,
also suggesting the presence of less severe underlying disease. In a follow-up to the
analysis presented here, we will evaluate these same 20 patients over time to evaluate
VDP and ADC to help to clarify the role of disease progression and severity on subject
classification. Nevertheless this study suggests that in COPD subjects with higher FEV1
and lower 3He MRI measurements of disease there is the potential for either tissue
destruction or ventilation defects to dominate.
Third, we observed significant but modest associations between some imaging
measurements with spirometry and plethysmography, consistent with previous 3He MRI
studies of COPD.22,30-32 We note however that these associations were not strong which
is perhaps consistent with the small patient group studied, the limitations of spirometry
and plethysmography as determinants of disease classification or severity and the fact
that COPD itself is very heterogeneous.
We acknowledge that this pilot study is limited by the small number of subjects studied
and the fact that the analysis was restricted mainly to subjects with stage II and III
COPD. Therefore, caution should be exercised in extrapolating these results to the
general COPD population and more specifically to patients with stage I or IV disease.
Another shortcoming of this study is the lack of high resolution CT data with which to
directly compare the 3He MRI findings. Nakano and colleagues have already reported
CT phenotype dominance14 in COPD and it will be critical to evaluate and compare both
tools in the same patients. A further limitation of this study is that without histology, we
cannot definitively ascribe ventilation defects to specific airway pathologies such as
airway occlusion via mucous plugs, airway narrowing, airway wall thickening or bullae.
Nevertheless, regardless of the specific underlying pathology, airway changes are a likely
prerequisite for the ventilation defects that can be visualized within the time-frame of the
3

He MR breath-hold scan.
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4.5 Conclusion
In conclusion, the results of this pilot study of a small group of COPD ex-smokers show
differences in the proportional contributions of 3He ventilation defects and ADC,
suggesting a potential new role for 3He MRI in COPD studies. These findings indicate
that 3He MRI should be more extensively evaluated in a larger and more diverse group of
COPD patients, allowing for confirmation of these results with more complex statistical
analyses. Future studies should aim to address the research questions generated in this
pilot study: can 3He MRI be used to phenotype subjects in a larger COPD population
encompassing subjects across GOLD categories; does COPD, as these preliminary data
would suggest, develop as mainly ventilation defects or tissue alterations in the early
stages of disease; what is the relationship between the phenotypes detected by 3He MRI
and those determined by CT? Future evaluation of 3He MRI phenotypes of COPD will
shed light on this very important potential application for this technology.
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CHAPTER 5: DETECTION
OF
LONGITUDINAL
STRUCTURAL AND FUNCTIONAL CHANGES AFTER
DIAGNOSIS OF RADIATION-INDUCED LUNG INJURY USING
HYPERPOLARIZED 3HE MAGNETIC RESONANCE IMAGING
The work presented in this chapter has been previously published in Medical Physics as
follows, and is reproduced here with permission (Appendix C).
L. Mathew, S. Gaede, A. Wheatley, R. Etemad-Rezai, G.B. Rodrigues G. Parraga “Detection of
Longitudinal Lung Structural and Functional Changes after Diagnosis of Radiation-induced lung
injury using Hyperpolarized 3He Magnetic Resonance Imaging” Med Phys.2010 Jan;37(1):22-31

5.1 Introduction
The lung is extremely radiosensitive and therefore highly susceptible to radiation-induced
injury.1 Although radiation treatment doses for thoracic tumours are modified in order to
decrease the risk of tissue damage, radiation-induced lung injury (RILI) still occurs in as
many as 37% of thoracic cancer cases involving radiation treatment.2-5 Moderate to
severe injury occurs in about 20% of RILI cases6 and is manifested as: 1) symptoms that
significantly interfere with activities of daily life including shortness of breath, cough,
and fever, 2) the requirement for oxygen therapy or ventilatory support, and, 3) premature
death. These symptoms and adverse effects are a result of structural changes in the lung
including capillary obstruction and septal thickening7,8 resulting in smaller alveolar
spaces in the pneumonitis phase of the injury, and further septal thickening with
obliteration of the alveolar space in the fibrotic phase,8-10 all of which result in the
functional impairment of the lung.

Significant declines in pulmonary function are

typically observed in the months immediately following radiation therapy, and global
lung function measurements such as the forced expiratory volume in one second (FEV1),
and forced vital capacity (FVC) as well as the diffusing capacity of carbon monoxide
(DLCO) continue to decline even two years post-radiation treatment.11 Although these
pulmonary function measurements are often used as indicators of overall lung function,
the regional functional impact of inflammation and fibrosis in the lung over time are still
not well understood. Novel non-invasive imaging methods which provide high spatial
and temporal resolution such as hyperpolarized helium-3 magnetic resonance imaging
(MRI) may provide some clues as to where and how structural and functional changes
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occur in RILI over time. Hyperpolarized 3He MRI is being developed in a handful of
respiratory and MR imaging research centers to provide a quantitative method for the
measurement of lung function and tissue microstructure by exploiting the diffusion
properties of 3He.12 Over the past decade, this method has been pioneered to probe lung
structure and function in healthy volunteers,13-16 chronic obstructive pulmonary
disease,17-21 cystic fibrosis,22-24 asthma.25-28 and for applications in radiation treatment
planning.2930
Although 3He MRI has been explored as a potential radiation treatment planning tool,29 it
has not yet been used in clinical research to monitor RILI changes post-diagnosis, which
we believe is important to further our understanding of both the regional distribution and
functional and structural nature of changes that accompany the global decline in
pulmonary function. Accordingly, here we present the first longitudinal 3He MRI results
in a small group of patients after diagnosis of RILI.

5.2 Methods
5.2.1

Study Subjects

Study subjects were recruited and enrolled from the London Regional Cancer Program
(London, Canada) with a clinical diagnosis of RILI (symptomatic, with or without
radiological evidence) based on respiratory symptoms following radiation therapy for
lung or breast cancer. Informed consent was obtained prior to participation in this study,
which was approved by the local research ethics board and Health Canada.

5.2.2

Study Evaluations

All subjects consented to a baseline and follow-up visit prospectively planned for 20 to
24 weeks post-baseline visit to capture short-term differences in

3

He imaging

measurements of RILI diagnosed based on symptomatic evidence. At both visits, vital
signs and a short clinical history were recorded, followed by spirometry and
plethysmography performed according to ATS guidelines31. Spirometry was performed
using an ndd EasyOne spirometer (ndd Medizintchnik AG, Zurich, Switzerland) for
FEV1 and FEV1/FVC. Whole-body plethysmography was performed (MedGraphics Elite
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Series, MedGraphics Corporation. St. Paul, USA) and total lung capacity (TLC),
functional residual capacity (FRC), residual volume (RV), expiratory reserve volume
(ERV) and inspiratory capacity (IC) were recorded. The DLCO was also tested and
recorded. All pulmonary function values were recorded as absolute and normalized
percent predicted values based on sex, age and body mass index.

5.2.3

Imaging

Helium-3 was polarized as previously described19,32,33 using a turn-key, spin-exchange
polarizer (HeliSpin, GEHC, Durham, NC) and dispensed in a room adjacent to the MR
suite with a dose of 5ml/kg body weight. 3He was mixed with medical grade N2 (Spectra
Gases, Alpha, NJ) to a total volume of 1.0L.
Imaging was performed on a whole-body 3.0T MR system (Excite 12.0, GEHC,
Milwaukee, WI) as previously reported.15,32-35 Subjects were positioned supine in the
MRI scanner with arms at sides, and pulse oximetry was used to monitor blood
oxygenation throughout the course of image acquisition. All imaging was performed in a
breath-hold fashion, with subjects instructed to inhale a gas mixture from a 1.0 L Tedlar
bag (Jensen Inert Products, Coral Springs, FL) from the bottom of tidal volume, and to
hold their breath for 15 seconds.
Proton MR images were acquired in the coronal plane with patients in breath-hold (1.0L
of a 4He/N2 mixture), to mimic the 3He MRI breathhold maneuver. For proton imaging, a
fast spoiled gradient recalled echo sequence was applied with a matrix size of 256x256,
field of view (FOV) = 40 cm x 40 cm or 44 cm x 44 cm (depending on subject size), 15
slices each 10mm thick, repetition time (TR) of 2.7 seconds, echo time (TE) of 1.3
seconds and a flip angle of 8º.
A single-channel rigid elliptic transmit/receive chest coil (RAPID Biomedical GmbH,
Wuerzburg, Germany) with a basis frequency of 97.3 MHz and an excitation power of
3.2kW was used for all 3He imaging with a maximum gradient amplitude of 19.4mT/m.
Multi-slice 2-D 3He MR static ventilation images were acquired using the unweighted
image (no T1 sensitization) of a T1-weighted sequence applied following inspiration of
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hyperpolarized 3He with the following parameters: TR = 4.3s, TE = 1.4s, flip angle = 7º,
matrix = 128x128, a FOV = 40 cm x 40 cm, slice thickness = 10mm, number of slices =
15, 0 mm gap.

Following ventilation imaging, diffusion-weighted imaging was

performed as previously described19,35 with the same 3He/N2 dose and breath-hold
maneuver. 3He multislice images were obtained in the coronal plane using a fast gradientrecalled echo (FGRE) method with centric k-space sampling. Two interleaved images
(TE = 3.7 ms, TR = 7.6 ms, 128 x 128, 7 slices, 30 mm slice thickness, FOV = 40cm x
40cm) without and with additional diffusion sensitization (G = 19.4 mT/m, rise and fall
time = 0.5 ms, duration = 0.46 ms, b value = 1.6 s/cm2) were acquired for each slice. All
scanning was completed within approximately 10 minutes of the subject first lying in the
scanner.

5.2.4

Image Analysis

All image analysis was performed in a room with controlled lighting by a single expert
observer (LM). Image analysis was performed blinded to subject identity, clinical status
and timepoint. Ventilation image analysis was performed using manual segmentation of
hyper-intense 3He regions on a slice by slice basis independently for each lung as
previously described to obtain a ventilated volume (VV).32,36 In addition, proton images
were reviewed and the thoracic cavity was segmented to obtain a thoracic cavity volume
(TCV) for both the ipsilateral and contralateral lungs.

All image segmentation was

performed using an in-house image processing software platform as previously
described.37 Helium and proton image segmentation were both repeated three times and
the mean values were recorded.

For the 3He VV and 1H TCV, ipsilateral and

contralateral lung volumes were summed to obtain the totals. Percent ventilated volume
(PVV)36 was generated as the VV divided by the TCV, and was computed for each lung
independently as well as combined.
Diffusion-weighted images were analyzed by the same single trained observer in a
controlled image visualization environment (digital copy) with room lighting levels
equivalently established for all image analysis sessions. The mean apparent diffusion
coefficient (ADC) and ADC maps were generated as previously reported33,35 for the
ipsilateral and contralateral lungs independently and for the whole lung (5 center slices)
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using in-house software programmed in the IDL Virtual Machine platform (Research
Systems Inc., Denver, CO as previously described19 with b = 1.6 s/cm2. The anterior and
posterior slices were not used for analysis due to insufficient signal-to-noise ratio (SNR).

5.2.5
3

3

He – 1H Image Registration

He – 1H MR image registration was performed to facilitate the segmentation of

ventilated areas to compute a ventilated volume. Hyperpolarized 3He and 1H MR images
were imported into an in-house image processing software application as previously
described.37 Prior to importing images and image registration 3He MR images were first
viewed in ImageJ 1.33u (National Institutes of Health, USA) where the green and blue
channels in the RGB scale were set to zero to achieve a red scale image. The center slice
3

He and 1H images were viewed simultaneously and a single point rigid registration of

coronal images was performed. The carina was used for single point rigid registration for
all 3He and 1H images, and was selected as this point was consistently evident for image
registration purposes in both functional and structural MR images across all study
subjects.

3

He – 1H MRI registration accuracy was determined using the overlap

coefficient, as previously described by Ireland and co-workers,30 and modified for 1H –
3

He images. This method was adapted for image registration of the center slice only

excluding the trachea and main bronchi, and was calculated using Equation 1 where A3He
MRI is

the area of 3He MR ventilation and A1H MRI is the area of 1H MR thoracic cavity.

Ω = 100 x

5.2.6

A 3He MRI I A 1H MRI
A 3He MRI

(1)

Statistical Analysis

Mean ADC and ADC standard deviation were calculated for the 5 center slices as
previously described.35

Mean VV, TCV and PVV and standard deviations were

calculated from repeated measures for the ipsilateral, contralateral and combined lung
volume. The difference between baseline and follow-up pulmonary function test results
and MRI measurements were calculated for the four subjects returning for a second visit,
and a mean difference was reported. Differences between ipsilateral and contralateral
lung measurements were evaluated using a paired t-test. The paired t-test was also used
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to evaluate differences between parameters measured at both baseline and follow-up.
Correlations between imaging, radiation treatment and pulmonary function parameters
were assessed using Pearson’s product moment correlation coefficient. All statistical
analysis was performed using SPSS 17.0 (SPSS Inc, Chicago, IL) and results were
considered significant when the probability of making a Type I error was less than 5% (p
< 0.05).

5.3 Results
5.3.1

Study Subjects

Study subject demographics at baseline and follow-up are provided in Table 5-1. Seven
subjects were enrolled following a clinical diagnosis of RILI based on symptomatic
presentation, six after radiation treatment for lung cancer and one after breast cancer
treatment. The mean period of time between the start of radiation and the first scanning
visit was 35.1 ± 12.2 weeks, with the first scanning visit 9.1 ± 5.1 weeks following the
initial report of RILI symptoms. Four subjects returned for a follow-up visit 22.0 ± 0.8
weeks after the first visit. The three subjects who did not return for repeat scanning were
deceased (n=2) or too ill (n=1) to return for follow-up.

Five of the seven subjects had a

smoking history of >10-pack-years. Two subjects reported an FEV1 %predicted < 50% at
baseline and the single breast cancer subject reported an FEV1 %predicted > 80%. At
follow-up, three subjects reported a change in FEV1 %predicted < 10%, while one subject
reported an increase of 17%. Radiation parameters for all seven subjects are provided in
Table 5-2. Subjects were treated with a mean dose to the target of 58 ± 7 Gy, and for
those subjects treated for lung cancer the mean lung dose (MLD) was 17 ± 2 Gy and
V20Gy was 32% ± 3%, where V20Gy is the percentage of lung volume receiving at least 20
Gy. The meanV20Gy was calculated for five subjects, as one subject was imaged again
using CT for a radiation boost and calculation of an accurate V20Gy would have required
dose warping, currently not available in our centre.
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Table 5-1: Subject Demographics.

Age yrs (SD) [range]
Sex- Male
Body Mass Index (SD)
FEV1 %pred (SD)
FEV1/FVC % (SD)
IC (L) (SD)
RV (L) (SD)
FRC (L) (SD)
TLC (L) (SD)
DLCO %pred (SD)

Baseline
n=7
63 (11) [50-76]
2
28 (4)
62 (18)
70 (7)
1.4 (0.4) *
1.2 (0.6) *
2.7 (0.4) *
4.2 (0.7) *
62 (24) *

5 month Follow-up
n=4
60 (12) [51-77]
2
28 (3)
68 (17)
74 (12)
1.8 (0.7)
1.7 (0.7)
2.9 (0.5)
4.7 (0.7)
64 (26)

*n=4

Figure 5-1: Representative Baseline and Follow-up Hyperpolarized 3He
Ventilation Images, ADC Maps and ADC Histograms.
A, B and C representative subjects at Baseline (i and ii) and Follow-up (iii and iv)
(i and iii) 3He MR ventilation images at Baseline and Follow-up respectively
(ii and iv) 3He MR ADC Map and Histogram Baseline and Follow-up respectively
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Table 5-2: Radiation Parameters.
VxGY(%) is the volume of normal lung receiving xGy radiation.

Total Dose (Gy)
Dose Fraction (Gy)
Mean Lung Dose (Gy)
V5Gy (%)*
V10Gy (%)*
V13Gy (%)*
V20Gy (%)*

Ipsilateral Lung
Mean (SD)

All Subjects
N=7
Contralateral Lung
Mean (SD)

26.1 (9.9)
70.3 (22.8)
60.3 (23.3)
56.7 (23.1)
50.6 (21.5)

7.7 (5.6)
37.7 (30.6)
25.0 (21.9)
19.3 (17.0)
11.8 (10.7)

Total Lung
Mean (SD)
58.1 (7.0)
2.01 (0.2)
15.1 (5.6)
52.1 (22.7)
40.0 (17.1)
34.7 (14.4)
27.3 (10.8)

*Calculated for 6 subjects (five lung cancer, single breast cancer) only because a single lung
cancer subject underwent two separate phases of radiation with different planning CTs, and
therefore these parameters could not be obtained. Dose fraction is the dose delivered in each
treatment fraction (i.e. A dose fraction of 2Gy in 30 fractions results in a total dose of 60Gy).

5.3.2

3

He MRI

Representative baseline and follow-up center slice ventilation images as well as the
corresponding ADC maps and ADC histograms are provided in Figure 5-1 for three
representative subjects with RILI following radiation treatment for a right hilar mass
(Figure 5-1a), a right upper lobe mass (Figure 5-1b), and a left hilar mass (Figure 5-1c).
All mean 3He MRI ADC and ventilation measurements are reported in Table 5-3 for the
ipsilateral, contralateral and total lung for both baseline and follow-up visits. For the
baseline scan, a difference in the mean ADC of 0.03 cm2/s between lungs was observed,
that was not significant (p=0.053) (Figure 5-2a). As shown in Figure 5-2b, ventilation
images showed a significant difference in VV (p=0.014) and TCV (p=0.027) between
ipsilateral and contralateral lungs. PVV was significantly different (p=0.025), and 33%
lower in the ipsilateral lung as compared to the contralateral lung (Figure5-2c).
Longitudinal differences between baseline and follow-up for all parameters are provided
in Table 5-4 and Figure 5-3 for each of the four subjects returning for the second visit.
At follow-up, total mean ADC was significantly higher than at baseline (p=0.016). When
measured independently, ipsilateral mean ADC was not significantly different between
baseline and follow-up (p=0.053), while the contralateral mean ADC at follow-up was
significantly increased compared to baseline (p=0.003, Figure 5-3b). As shown in Figure
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5-3d, the contralateral lung also showed a significant increase in PVV at follow-up
(p=0.012), while no other 3He MRI measurements showed a statistically significant
change.

5.3.3 Correlations
Figure 5-4 shows a graphical presentation of the longitudinal changes in ADC and PVV
for ipsilateral, contralateral and whole lung with the V5Gy, V10Gy, V13Gy and V20Gy
identified for each of the four patients who returned for follow-up imaging. For patients
returning at follow-up Figure 5-4 Ai shows a trend towards improved PVV over time
with lower doses to the ipsilateral lung in subjects treated for lung cancer, while Figure
5-4 Cii indicates that with lower total VxGy there is a greater increase in total ADC with
time.

Figure 5-2: Baseline and Follow-up Hyperpolarized 3He MRI Measurements.
Baseline and Follow-up for the ipsilateral and contralateral lungs for all subjects.
A) mean 3He MRI ADC, B) 3He MRI VV, and C) 3He MRI PVV.
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Figure 5-3: Mean Longitudinal Differences in 3He MRI and spirometry
measurements.
Differences between Baseline and Follow-up for subjects returning for a second visit (n=4)
A) FEV1 %pred, B) mean contralateral ADC, C) mean ipsilateral PVV and D) contralateral PVV.

At baseline there was a statistically significant correlation observed for ipsilateral VV and
PVV with inspiratory capacity (R=0.97, p=0.007, R=0.89, p=0.045 respectively). DLCO
also correlated with ipsilateral VV (R=0.83, p=0.041) at baseline, while ERV correlated
with ipsilateral PVV (R= -0.89, p=0.041). Radiation parameters related to the ipsilateral
lung including MLD, V5Gy, V10Gy, V13Gy, and V20Gy correlated with ipsilateral PVV (R= 0.79, p=0.035; R= -0.83, p=0.040; R= -0.89, p=0.018; R= -0.89, p=0.018; R= -0.85,
p=0.031, respectively). No other correlations between radiation parameters and 3He MRI
measurements were observed.
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Table 5-3: 3He MRI ADC and Ventilation Measurements.

2

WL ADC (SD) cm /s*
2
WL ADC SD (SD) cm /s*
WL VV (SD) L
WL TCV (SD) L
WL PVV (SD) %

Ipsilateral
0.33 (0.06)
0.12 (0.07)
0.9 (0.5)
1.6 (0.3)
55 (29)

Baseline
N=7
Contralateral
0.30 (0.06)
0.11 (0.07)
2.1 (0.6)
2.3 (0.7)
88 (5)

Total
0.31 (0.05)
0.11 (0.08)
3.0 (0.7)
3.9 (0.8)
76 (12)

5 month Follow-up
N=4
Ipsilateral
Contralateral
Total
0.35 (0.04)
0.32 (0.04)
0.32 (0.04)
0.24 (0.02)
0.19 (0.05)
0.20 (0.04)
1.0 (0.7)
2.5 (0.7)
3.5 (0.6)
1.4 (0.2)
2.4 (0.7)
3.8 (0.5)
68 (45)
103 (5)
92 (15)

*ADC data for n=6 at baseline

At follow-up whole lung PVV correlated with IC (R=0.97, p=0.033), FVC %predicted
(R=0.99, p=0.005) and total dose (R= -0.98, p=0.021). Total dose also correlated with
the follow-up ipsilateral VV and PVV (R= -0.98, p=0.024 and R= -0.98, p=0.015
respectively). The change in ipsilateral VV between baseline and follow-up correlated
with the change in FEV1 absolute and percent predicted (R=0.98, p=0.023 and R=0.99,
p=0.009 respectively). There was no correlation between changes in spirometry values
and changes in contralateral or total lung VV or PVV.

Table 5-4: Longitudinal Differences.

FEV1 %pred
FVC %pred
FEV1/FVC
TLC (L)
DLCO %pred
Ipsilateral WL ADC
2
(cm /s)
Contralateral WL ADC
2
(cm /s)
2
Total WL ADC (cm /s)
Ipsilateral PVV
Contralateral PVV
Total PVV

002

003

004

005

Mean (SD)

-6
-2
14
ND
1
0.02

-3
1
-3
0.54
0
0.05

17
16
2
1.16
ND
0.02

9
14
-2
0.47
7
-0.01

4.3 (10.7)
7.3 (9.1)
2.8 (7.8)
0.7 (0.4)
2.7 (3.8)
0.02(0.02)

BL -FU
P
0.485
0.208
0.532
0.081
0.500
0.215

0.02

0.04

0.02

0.02

0.02(0.01)

0.003

0.02
-4
9
7

0.03
0
15
8

0.02
35
18
26

0.01
49
23
33

0.02 (0.01)
20 (26)
16 (6)
19 (13)

0.016
0.231
0.012
0.068

ND = No data for one of the two visits, BL = Baseline, FU = Follow-up
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Figure 5-4: 3He MRI longitudinal changes compared to Radiation Parameters
A) MRI measurements ipsilateral lung of four subjects returning at follow-up compared to VxGy% (the volume of normal lung receiving x Gy of
radiation).
B) MRI measurements contralateral lung compared to VxGy (%)
C) MRI measurements both lungs compared to VxGy (%) (i) PVV, (ii) ADC.

129

5.3.4 Image Registration
Image registration results are provided in Figure 5-5 showing 3He – 1H registration for subjects
002, 004, 005 and 008, with the 3He signal in red and the 1H signal in gray scale.

3

He – 1He

registration accuracy was evaluated at baseline for all seven subjects with a mean overlap
coefficient of 93.6 ± 4.6%.

Figure 5-5: Representative subjects showing 3He – 1H MR Image Registration.
Centre slice 3He – 1H image registration is shown with the 3He signal intensity in red, and the 1H signal
intensity in grey scale for a) subject 008, b) subject 005, c) subject 002 and d) subject 004.
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5.4 Discussion
In vivo imaging provides a way to quantitatively evaluate spatial and temporal changes in the

lung, post-radiation, such as consolidation within the lung visualized using CT for which various
patterns have been described38 ranging from slightly increased density to solid consolidation and
irregular bronchi. As another example, functional imaging of RILI using SPECT provides
images which can be evaluated for ventilation and perfusion defects,39-41 and while the incidence
of the latter is more common, both measurements appear to be more sensitive than CT
measurements for the detection of functional lung changes.42 Despite the development of these
important imaging approaches, and the elegant work of a number of teams using CT,38,43-45 the
temporal and spatial aspects of RILI initiation and progression are still not well understood,
partially because of the widely varying imaging protocols and a lack of intensive serial studies
reported in the literature. Emerging hyperpolarized noble gas MRI methods may provide a way
to measure specific RILI effects that are often very complex given the myriad of other
malignancy-related changes occurring prior to and after radiation. The advantage of 3He MRI
approaches for RILI may derive from the fact that the method is rapid, well-tolerated,46 provides
regional functional information with relatively high spatial resolution, and enables intensive
serial studies that could potentially identify early and late mechanisms of disease initiation and
progression, respectively. Once specific measurements and potential mechanisms are identified,
it is theoretically possible to improve the spatial resolution of therapy (guidance) and perhaps
increase doses to improve tumour response with decreased normal tissue (or at least normal
functioning tissue) damage. This is critical in the lung in particular where improvements in
radiation therapy methods have not resulted in significantly improved patient survival.47
Here in a small pilot study of RILI patients, we provide quantitative structural and functional 3He
MRI measurements in subjects after symptomatic RILI onset. Accordingly we report: 1) 3He
MRI ADC, VV, PVV and 1H MRI TCV for seven subjects approximately 8 months after
radiation therapy and again 6 months later for four of these subjects, 2) correlations between 3He
MRI measurements, well-established pulmonary function and lung volume measurements and
radiation parameters, and, 3) feasibility and implementation of functional 3He MR image
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registration with structural 1H MR images. To our knowledge, this is the first longitudinal
application of hyperpolarized 3He MRI in subjects after clinical diagnosis of RILI.
First, and as might be expected, at baseline we observed a significant difference in TCV of the
ipsilateral and contralateral lungs, suggestive of gross thoracic cavity remodelling following
radiation injury. Additionally 3He VV in the ipsilateral and contralateral lung was significantly
different, likely reflecting the decreased lung volume available for ventilation in the target lung.
Importantly, we noted a significant difference in PVV, which was higher in the contralateral
lung, suggesting that the functional capacity of the contralateral lung remained high following
radiation treatment. The lower PVV reported in the ipsilateral lung may be due to inflammation
or scarring related to the radiation dose and for some patients, due to residual tumour burden;
however, the direct cause cannot be directly ascertained due lack of histological confirmation. At
baseline, the contralateral lung reported a lower mean ADC and the difference was below the
threshold for statistical significance (p=0.053). If this result is indeed found to be significant in a
larger group of patients, this would contradict previous studies in animals48 where the ipsilateral
lung showed lower ADC (suggestive of fibrosis) than the contralateral lung. One possible
explanation for the result obtained here is that the severely fibrosed regions of the ipsilateral lung
could not be ventilated and therefore could not contribute to the ADC measurement, resulting in
an increased ADC.

Additionally, the increased contralateral lung ADC values might

alternatively reflect increased inflammation at the baseline scan, or increased alveolar
dimensions due to increased ventilation in the contralateral lung.
Second, for the small number of patients who were scanned at follow-up, there was a significant
change in the contralateral PVV and both the contralateral and whole lung 3He ADC. Both
results show that in small numbers of subjects 3He MRI can sensitively detect lung structural and
functional changes as RILI progresses. We were surprised to observe the unexpected increase in
contralateral PVV that occurred between weeks 35 and 57 post-radiation. This indicated that
although the TCV did not change over the 22 week period, the functional capacity of that volume
showed a significant increase, suggesting that functional, but not gross structural remodelling
occurred in response to the apparent loss of function in the ipsilateral lung (as evidenced by low
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ipsilateral PVV in the majority of subjects). To our knowledge this increase in functional
capacity of the contralateral lung, long after radiation treatment, and in isolation of structural
lung volume change, is a novel finding, not previously reported in the literature. The statistically
significant increase in ADC we observed (which in COPD has been validated using histology49
and CT50 as an increase of alveolar dimensions reflecting emphysema) over a relatively short
period of 22 weeks was greater than the rate previously established for healthy aging nonsmokers,

14

and therefore is unlikely related to age-related emphysema. In a previous animal

model study of radiation fibrosis, alveolar septal thickening was suggested as the explanation for
decreased 3He MRI ADC post-radiation.48

For the patients studied here, imaging was

approximately 8 months post-radiation therapy which is most likely within the radiation fibrosis
timeframe.51 Therefore, the increase in ADC observed in the contralateral lung may reflect
decreased or perhaps resolution/improvement of radiation-induced inflammation or fibrosis over
time; no change in the ipsilateral ADC was reported perhaps because of irreversible fibrosis in
that lung.
Third, correlations were observed between

3

He MRI measurements, pulmonary function

measurements and radiation parameters. The significant negative correlation between radiation
parameters (MLD, V5Gy, V10Gy, V13Gy, and V20Gy) and PVV for the ipsilateral lung is in
agreement with our understanding of the direct negative relationship between lung function and
radiation treatment.

Additionally, DLCO which is commonly impaired in subjects with

RILI,6,11,52,53 was significantly correlated with ipsilateral VV, which is in agreement with our
understanding that the lungs diminished capacity to ventilate can result in significant decreases
in gas transfer.
Finally, we showed that MR image registration was feasible in this patient group and over these
time periods. 3He–1H registration resulted in an overlap coefficient of 93.6%, likely due to the
fact that the elapsed time between scans was on the order of minutes, and subjects were not
moved between scans. This registration may be used in future to aid lung volume segmentation
and for the development of semi- and fully-automated segmentation of 3He MRI lung volumes.
Furthermore, future studies should involve registration of 3He MR ventilation images to CT
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images both pre- and post-radiation, to aid in ascertaining a direct relationship between scarring
and functional impairment in the lungs of subjects with RILI.
We acknowledge a number of specific limitations of this study, the first of which is the small
sample size at baseline (n=7) and follow-up (n=4). This may have restricted our ability to detect
other significant differences between lungs at baseline and longitudinally. In future studies with
larger sample sizes it will be important to closely monitor additional clinical factors such as
specific treatment regimes (specific chemotherapies administered concurrently), specific postradiation respiratory difficulties experienced, smoking status and O2 usage to determine whether
any of these variables directly affect the functional or structural changes reported in subjects with
RILI that could not be evaluated here due to limited sample size. We also recognize that a multimodality comparison using CT would have provided an opportunity to directly compare and
contrast the sensitivity of 3He MRI and quantitative high resolution CT which would provide
critical context for the functional and structural findings we report here.

Finally, another

potential shortcoming of this pilot study relates to the fact that we only implemented rudimentary
registration methods in this study and that in future whole lung registration should be evaluated
as well as image registration with a greater number of fiducial markers.
A previous study using 3He MRI by Ireland and co-workers29 showed that functional information
obtained prior to radiation could be used in conjunction with CT for radiation planning. Here in
this small pilot study of seven patients, we add to this significant body of work and show that
3

He MRI provides quantitative and regional measurements of RILI post-diagnosis and

longitudinally for the target and non-target lung.

5.5 Conclusion
In conclusion, hyperpolarized 3He MRI provides a way to acquire quantitative lung functional
information as well as a method to measure 3He diffusion to probe airway and airspace sizes.
Furthermore, for the first time we showed that lung function in the contralateral lung
significantly increased over time following the onset of symptomatic RILI, likely to compensate
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for the radiation-induced functional damage that was largely restricted to the ipsilateral lung and
constant over the time course of this study.
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CHAPTER 6: CONCLUSIONS AND FUTURE DIRECTIONS
6.1 Overview and Summary
The development of new, sensitive and precise measurements of lung function are critical for a
better understanding of the structure-function paradigm that exists in the lung in both the normal
and disease states.1,2

Currently, the gold standard method for evaluating lung function is

spirometry. Specifically FEV1, measuring airflow limitation, is influenced by both regions of
functional impairment and anatomical changes in the lung tissue microstructure and airway
calibre. Thus, FEV1 is a good indicator of disease presence, but cannot provide any information
on the contribution of underlying structural impairments or ventilation abnormalities that
contribute to airflow obstruction. Furthermore, it does not give any indicator of the regional
burden of disease, which is important for disease classification and guiding interventions and
treatments. Therefore, when airflow limitation is detected further examination is often required.
Chest x-rays are most commonly used for subsequent evaluation, but provide extremely limited
quantitative information.

CT is often the imaging modality of choice for high resolution

pulmonary imaging.3 Using CT, it is possible to evaluate the lung microstructure by way of lung
attenuation measurements3-6 and to evaluate the airways through measurements of the airway
wall7-10, but the relationship these structural measurements have with lung function is often not
clear. Moreover, CT is associated with significant increase in radiation exposure compared to
chest x-ray, and because of the high radiation dose, serial CT exams over short time frames and
longitudinal studies are not practical or safe even in elderly subjects. Thus, using clinically
available imaging tools, lung structure can be probed without any information on the functional
impact of structural abnormalities observed.

Nuclear medicine techniques could fill this

functional imaging gap, but they too are associated with radiation dose, suffer from poor
resolution, and deposition of tracer particles in the central airways.11,12 Given that loss of lung
function often occurs regionally within the lung, and may be associated with changes in lung
microstructure, airway remodelling, or both, an ideal imaging tool would allow for quantitative
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measurements of functional impairments in both cross-sectional and longitudinal studies, in
conjunction with measurements of underlying lung structure.2
It is in this context that we embarked on developing quantitative measurements of lung function
derived from hyperpolarized

3

He MR images.

In this thesis we evaluated

3

He MRI

measurements of lung function in cross-sectional and longitudinal studies of healthy volunteers
and subjects with smoking-related lung disease. In regard to these measurements, we tested the
following hypotheses: 1) metrics for quantifying 3He MR ventilation images have high shortterm reproducibility 2) changes in lung function occurring with normal healthy aging can be
detected using measurements of functional 3He MR images, 3) functional and structural 3He MRI
measurements of COPD subjects, taken together, can be used to stratify disease, and, 4)
radiation-induced lung injury results in long-term changes in lung function that can be measured
using 3He MRI.
In Chapter 2, the same-day and seven-day reproducibility of VDV was evaluated from 3He MR
images acquired at 3.0T. Twenty-four age-matched subjects were imaged with 3He MRI twice
within 7 ± 2 minutes and again 7 ± 2 days later. Same-day and seven-day reproducibility were
evaluated using ICC, CCC and linear regression. Same-day VDV was highly reproducible for all
subjects (ICC = 0.97, CCC = 0.98, r2 = 0.94), while seven-day VDV was significantly lower
(p<0.01, ICC = 0.74, CCC = 0.75, r2 = 0.58). Over the seven day time period there were no
significant differences in FEV1 and FEV1/FVC. ADC, derived from diffusion-weighted 3He
MRI, was also evaluated for reproducibility over the same time period.

ADC was not

significantly different at the seven minute or seven day time mark, and was found to be highly
reproducible at both time points (same-day r2 = 0.93, seven-day r2 = 0.96). This is the first study
to report the reproducibility of VDV, and more importantly, the first to report on the
reproducibility of any method for quantifying ventilation defects with 3He MRI. Additionally,
this is the first study to report on the reproducibility of 3He MRI evaluated at 3.0T. Overall, in
Chapter 2 we demonstrate that 3He MRI VDV has high short-term reproducibility, and therefore
has potential as a non-invasive quantitative marker of lung function for use in clinical trials
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evaluating new treatments, as well as in longitudinal and cross-sectional research studies of
smoking-related lung disease.
In Chapter 3, 3He MRI VDV was measured in a group of young healthy volunteers (mean age =
44), and another group of elderly healthy volunteers (mean age = 67). Images were acquired
twice in one day, and again one week later to evaluate the inter-scan VDV variability. Images
were scored and analyzed by four trained observers to assess the inter-observer variability of
VDV. No ventilation defects were observed in the younger subjects, while in the older subject
group, six of eight subjects had ventilation defects, with a mean VDV = 52 ± 34 cm3. Same-day
and seven-day COVs were 1.8% and 5.3% respectively, while the inter-observer COV ranged
from 10-12%. Overall, this study demonstrates that there are ventilation defects present in
healthy elderly adults that are quantifiable using VDV, and that these age-related changes in lung
function are highly reproducible over short time periods.

Smoking-related lung disease,

specifically COPD, tends to occur in elderly individuals, and thus it will be important in future
studies quantifying lung function using 3He MRI to differentiate between 3He MRI VDV likely
related to age alone, and volumes likely related to both age and COPD in this elderly diseased
population.
In Chapter 4, functional and structural 3He MRI measurements were captured and used to stratify
subjects with COPD according to the proportional contribution of these measurements to the
overall sum of disease. Twenty former smokers with mainly stage II and stage III COPD were
imaged using 3He MRI at a single time-point. Based on the relative contribution of normalized
ADC and VDP, there was evidence of a predominant measurement in seven of the twenty
subjects, three having mainly ventilation defects and four having mainly emphysema.
Additionally, those with a predominant measurement had less overall disease, suggesting that
mainly ventilation defects or tissue destruction develop early in the disease, with both being
present at later stages. This was the first study to explore the potential of 3He MRI derived
measurements to stratify subjects with COPD, and results suggest that 35% of subjects had a
single predominant measurement – which is in agreement with previously published CT data.9
Further studies with increased sample size should be performed to evaluate 3He MRI based
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measurements as a tool for phenotyping COPD. With further validation, 3He MRI VDP and
ADC phenotypes may allow for identification and selection of COPD subjects based on their
baseline 3He MRI-derived phenotype for clinical studies. Potential new treatments could then be
evaluated in a specific 3He MRI phenotype, and specific underlying changes in lung function and
structure evaluated.
In Chapter 5, 3He MRI derived measurements of lung function were used for the longitudinal
evaluation of subjects with a clinical diagnosis of radiation-induced lung injury.

Static

ventilation and diffusion-weighted MR images were acquired 35 ± 12 weeks after radiation
therapy began and again 22.0 ± 0.8 weeks later. At baseline, PVV was significantly lower
(p<0.05) in the ipsilateral diseased lung. In four subjects returning for follow-up evaluation
significant differences in both PVV and ADC were reported. 3He MRI PVV increased by 16% ±
6% (p<0.05), and 3He ADC increased by 0.02 ± 0.01 cm2/s (p<0.01). Hyperpolarized 3He MRI
was well tolerated in all subjects with moderate to severe RILI. Functional improvements and
microstructural changes were observed in the contralateral lung, while the ipsilateral lung
remained stable, suggesting that functional compensatory changes may have occurred in the
contralateral lung due to ipsilateral radiation-induced lung injury. These findings highlight the
sensitivity of 3He MRI VDV to changes in lung function, and for the first time provide evidence
of functional changes in the fibrotic stage of RILI. Specifically, this is the first report to suggest
that the lung has the ability to compensate for a severe, local functional injury by increasing its
functional capacity in other regions.
In Appendix A current methods for analyzing static ventilation images found in the 3He MRI
literatre were described along with their limitations. Specific needs for 3He MRI ventilation
analysis were addressed, and most importantly methods needed for quantitative comparative
analysis of 3He MR ventilation images acquired from the same subject at multiple time-points
were described. Requirements for image analysis include registration, signal normalization, and
image subtraction for regional difference analysis. Development of these quantitative tools will
further establish the potential of 3He ventilation image-derived measurements as sensitive
markers of regional lung function that can be used as an analysis tool in clinical trials.
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Appendix B described a case study of a single subject imaged pre- and post-Airway Bypass
(AB). The subject was imaged over a four year time-period; at baseline, two years later, and
again six and twelve months following AB. In the two years between baseline and first followup visit, there was a decrease in VDP that corresponded to a visually apparent worsening on the
3

He MR images. Following the AB procedure VDV and VDP improved, which corresponded to

a self-reported improvement according to the mMRC scale, along with an improvement in cycle
ergometry test time. Although the subject reported feeling better and visually apparent changes
in ventilation were observed and quantified, there were minimal change in PFTs. While this is
the only subject in the Broncus AB study to have 3He MRI data, quantitative 3He ventilation
results following therapeutic intervention showed an improvement, were reflective of the
improvement in dyspnea scores (while PFTs did not show any change), and therefore highlight
the potential of this technique as a sensitive measure of lung function in clinical trials.
Here in Chapter 6 the conclusions that can be drawn from the studies presented in this thesis are
addressed, as well as the limitations of these studies and possible future work that will expand on
the work presented in Chapters 2-5. The conclusions of this thesis are addressed in section 6.2,
the limitations of the current studies and solutions are presented in section 6.3, and possible
future studies are detailed in section 6.4.

6.2 Summary of Conclusions
Overall, we have presented a new method for quantifying 3He ventilation defects present in static
ventilation MR images. Measurements of ventilation defect volume are shown to have high
same-day and moderate seven-day reproducibility in healthy volunteers and subjects with COPD.
Furthermore, they are sensitive to changes in ventilation that occur with aging in healthy
individuals. The quantification of ventilation changes that occur with age is important, as lung
diseases typically occur in elderly individuals, and it is important to differentiate between
functional changes occurring due to age, and those occurring due to lung disease. COPD, the
most common smoking-related lung disease, is known to be a heterogenous disease and we have
shown here that the quantification of ventilation defects in conjunction with the quantification of
underlying microstructural abnormalities measured using 3He MRI can be used to stratify
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subjects according to the proportion of these functional and structural measurements to the
overall sum of 3He MRI measured disease. This initial report suggests that 3He MRI may have a
role to play in phenotyping COPD for treatment, and additional larger-scale studies will be
needed to confirm this result. Additionally, in a small group of subjects diagnosed with RILI
post-radiation therapy, functional and structural changes were observed and quantified in the
contralateral lung. The improvement in contralateral lung function observed suggests that there
is a compensatory effect following severe radiation injury to the ipsilateral lung. Furthermore,
the changes in contralateral lung microstructure observed over 22 weeks in this very small group
of RILI subjects speaks to the sensitivity of 3He MRI ADC for detecting differences in lung
microstructure longitudinally.
In summary, we have provided: 1) evidence that VDV derived from 3He MRI images has high
short-term reproducibility, 2) evidence of reproducible ventilation defects in healthy elderly
subjects, not present in their younger healthy peers, 3) a new method for stratification of subjects
with COPD based on 3He MRI derived VDP and normalized ADC, and, 4) evidence of
longitudinal changes in function and structure of the contralateral lung in subjects clinically
diagnosed with RILI.

6.3 Limitations of Current Tools and Solutions
The limitations of the studies presented in this thesis are discussed in this section, along with
recommended solutions to address these limitations in future studies. A number of limitations
addressed in this section are common to multiple studies described in this thesis, while others are
study specific. This section begins by addressing the study-specific limitations in sub-section
6.3.1, while general limitations are discussed in section 6.3.2.

6.3.1

Study Specific Limitations

In Chapter 2 and 3, VDV was measured from hyperpolarized 3He MRI. One of the primary
goals of the initial 3He MRI study of healthy elderly subjects and subjects with COPD was to
assess the reproducibility of 3He MRI measurements of the ADC; measurements of ventilation
derived from these images was a secondary marker and therefore did not drive the data collection
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scheme/MR pulse sequence design. The ADC is calculated from DWI, which have inherently
thicker slices than 3He MR spin density images for the same breath-hold/imaging time, given
that a diffusion and non-diffusion weighted image are captured for each slice of the DWI series.
For the calculation of VDV the first of the interleaved diffusion-weighted pair of images was
used. The thickness of the slices was 30mm, and therefore the ventilation defect area segmented
was multiplied by 30mm, representing signal contribution from the entire slice. Given the slice
thickness of the images used for image analysis, it is possible that the VDV values presented
over-estimate the true ventilation defect volume, and thus should be taken as an estimate of the
true VDV of the lung. Additionally, the use of DWI results in images with a lower signal-tonoise ratio than would be obtained had spin-density images been acquired for VDV
measurements.

Thus, acquiring a spin-density image set or perhaps a three-dimensional

volumetric image set would allow for thinner slices and an improved signal-to-noise ratio. It will
be important to evaluate thinner slices using spin density images, especially in a young healthy
volunteer cohort to determine whether this group truly did not have any ventilation defects, as
reported, or whether the thick slices and increased SNR perhaps mask the very small ventilation
defects that have been reported in the literature in groups of similar age and health status.13,14
A second limitation present in Chapters 2 and 3 is that proton images acquired just prior to 3He
MRI were not bag-matched to the 3He MRI breath-hold scans. In follow-up studies 1H scans
were acquired following inhalation of 1.0 L of 4He/N2 at the same dosage used for 3He/N2
ventilation imaging. This approach allowed for rigid registration of proton and helium scans,
allowing for clear delineation of the thoracic cavity border, and aided in ventilation defect
segmentation. However, this was not the approach used in Chapter 2 and 3, when proton images
were acquired during a breath-hold at peak-tidal volume. Therefore, the VDP measurement used
in Chapter 4, and PVV measurement used in Chapter 5 and pioneered by Woodhouse and coworkers15, could not directly be assessed. In subjects with COPD, proton and helium images
were registered, and despite these differences in image acquisition techniques, 3He MR images
visually appeared to have good registration in most COPD subjects, while healthy elderly
subjects had poorer registration on visual inspection making ventilation defect delineation
difficult.

Without a normalized measurement such as VDP or PVV, a true inter-subject
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comparison of the extent of ventilation defects in the lung was not possible. In all future studies,
this limitation was addressed by acquiring bag-matched 1H MRI.
One of the major limitations of the work presented in Chapters 2-5 is the small sample size, each
with a study specific impact. In Chapter 2, the group of healthy volunteers had eight subjects,
while the Stage II and III groups had nine and seven subjects respectively. The small sample
size was selected to detect between group differences in ADC, and was calculated based on ADC
and ADC standard deviation (SD) results published by Salerno and co-workers16. This sample
size may have limited the power necessary to detect differences between VDV in the elderly
healthy volunteer and stage II COPD subgroups, which in this study were not statistically
significant. However, it is also possible that the reported VDV in subjects with stage II COPD is
not due to COPD, but rather predominantly due to aging. Another possibility that would explain
the large VDV SD is related to underlying 3He MRI phenotypes in the stage II COPD
population; a subset of the stage II subjects were likely ADC dominant, having a VDV was due
to age alone while another subset had elevated VDV due to both age and COPD (VDP or mixed
phenotypes). In Chapter 3, the small sample size of the elderly subgroup may have resulted in an
over- or under-estimation of true population ventilation defect volume; however, it is clear that
ventilation defects do occur in the elderly, and these defects should not be confused with
functional abnormalities related to COPD or other lung diseases. The small sample size in
Chapter 4 of twenty subjects resulted in stage II and stage III COPD subjects forming the basis
of the COPD group evaluated (one subject with stage I disease was included). The limited
sample size evaluated, made up of a small group of mainly stage II and III COPD, indicates
caution should be exercised in extrapolating the results presented in this chapter to the general
COPD population, and more specifically, more advanced or less severe COPD groups (stage
I/IV). In Chapter 5, the small sample size at baseline (n=7) and follow-up (n=4) may have
restricted the detection of differences in functional measurements acquired longitudinally in the
ipsilateral lung. Additionally, an increase in sample size in this study may have allowed for the
detection of a significant difference in ADC between lungs at baseline (p=0.053 in seven
subjects), and longitudinal change in ADC in the ipsilateral lung. Thus, increasing sample size
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in future studies using 3He MRI will increase the power and likely lead to an increase in the
number of differences detected between subject groups.
A further limitation in Chapter 3 is the lack of follow-up data for the younger subgroup. Because
no defects were present at baseline in any subjects in this young healthy subgroup no follow-up
data was acquired. Therefore, it is not known what the short-term reproducibility of this finding
is. However, in two young healthy subjects imaged at multiple time points as part of a hardware
and software development protocol no ventilation defects were observed in any of the scans
collected. Despite this observation, it would be valuable to continue scanning younger healthy
volunteers, and to evaluate the short-term reproducibility of ventilation images in these subjects
given that previous reports of young healthy volunteers do report the presence of ventilation
defects.13,14
One specific limitation present in Chapter 5 is the lack of other clinical parameters collected for
study purposes. Subjective information regarding post-radiation respiratory difficulties was not
obtained, and would have been useful in evaluating the impact of functional changes measured
with 3He MRI on quality of life scores. Additionally, information related to treatment regime,
specifically course of chemotherapy, smoking history and use of oxygen post-treatment, if
collected, could give further information in relation to the functional changes reported in this
study.

6.3.2

General Limitations

One major limitation of the studies presented in this thesis is the lack of data collected from other
imaging modalities in conjunction with 3He MRI, specifically CT data that could have been used
for validation purposes. CT has largely been used both clinically and as a research tool for
quantifying attenuation, related to the lung parenchyma3-6, and airway wall dimensions.7-10
Although a limited number of studies have compared ADC measured from diffusion-weighted
3

He MRI to attenuation on CT17, to date there has not been a direct comparison of 3He ventilation

defect measurements to airway wall dimensions. It is hypothesized that 3He MRI VDV in
subjects with COPD is the result of underlying airways disease, and therefore measurements of
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airway dimension on CT would provide important complimentary information on airway
structure leading to the ventilation defects that could be used to test this hypothesis. In relation
to the work presented in Chapter 4 regarding the classification of COPD based on 3He MRI
measurements, similar work has been done by Nakano and co-workers using CT9, and a direct
comparison of these two techniques in the same COPD subject group would provide further
insight into the surrogate measures of underlying emphysema and airways disease captured by
these respective imaging modalities. Additionally, the registration of 3He MRI to CT data in
Chapter 5 could have potentially been used to correlate regions of ventilation defect with areas of
fibrosis on CT, providing a direct link to the etiology of these regions of signal void on 3He MRI.
Furthermore, in all studies presented here, registration of 3He MRI with CT images would allow
for a breakdown of ventilation defect analysis by lobe. In Chapter 2, the measurement of lobar
VDV could be evaluated for reproducibility, which would have the potential to further solidify
3

He MRI as a highly reproducible technique for evaluating regional pulmonary ventilation.

Overall, CT data collected in conjunction with 3He MRI would aid in validating 3He MRI
measurements against more established CT images, and potentially provide some explanation as
to the underlying structural abnormalities that result in diminished ventilation. Finally, nuclear
medicine techniques would have been valuable for cross-comparison purposes, especially in
Chapter 5, where blood flow measurements would have provided important complimentary
information to the ventilation results. We hypothesize in Chapter 5 that the increase in PVV in
the contralateral lung may be due to a compensatory increase in ventilation due to the diminished
ventilation in the ipsilateral lung. Measurements of blood flow from PET would show whether
this ventilation improvement translates to a true improvement in contralateral lung function due
to a corresponding improvement in blood flow, or whether the increase in ventilation is not
mirrored by an increase in blood flow, simply resulting in a ventilation-perfusion mismatch in
the contralateral lung.
The second overall limitation is that the etiology of ventilation defects is currently unknown.
While we hypothesize that VDV is reflective of underlying airways disease in subjects with
COPD, closing volumes in healthy elderly subjects and radiation fibrosis in subjects with RILI,
to date there is no direct evidence to affirm these hypotheses. There is also the possibility that
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ventilation defects occur in COPD due to bullous disease, representing structural changes in lung
parenchyma rather than the hypothesized changes in lung airway structure, or a combination of
the two. Without knowing the underlying cause of the ventilation defect, it is difficult to
determine whether 3He MRI is truly sensitive to underlying changes in airway structure that may
be associated with aging, COPD or fibrosis. Therefore, histological data is necessary to ascertain
the direct cause of ventilation defects observed and measured using 3He MRI. Given that this is
a potentially difficult task to accomplish in humans, a secondary method of validation would be
through multi-modality imaging studies. High resolution CT can provide structural information
regarding both airway dimensions and lung parenchyma, and thus could be used in conjunction
with 3He MRI to correlate ventilation defects to regions of inflamed, thickened airways, bullae,
or fibrosis.
Finally, one major limitation of all studies presented here is the limited translation of this
technique for more widespread research investigating lung diseases in both the research setting
and for use in guiding therapy or as an endpoint in clinical trials. There is an extremely limited
supply of helium-318,19, and therefore further follow-up studies stemming from the studies
presented here may not be possible.

It has been pointed out in previous paragraphs that

increased sample sizes are needed in future studies to expand on the promising results of these
small studies, which will likely not be possible given the current gas supply.

Therefore,

validation of this technique may not be necessary, but rather these studies should be reproduced,
perhaps on a larger scale, with

129

Xe, which is set to replace 3He as the noble gas contrast agent

for hyperpolarized gas MRI.20-22

Thus, previous solutions for limitations addressed in the

previous paragraphs would be better suited using
translational value in the clinical research setting.

129

Xe, which is likely to have increased
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6.4 Roadmap for Future Studies
6.4.1

Quantification of Lung Disease in Patients Diagnosed with NonResectable Lung Cancer using Hyperpolarized 3He MRI

Combining the work presented in Chapters 4 and 5, we are currently evaluating potential
functional and structural measurements derived from 3He MRI to be used as predictors of
radiation-induced lung injury. Lung cancer and COPD are both diseases of tobacco smokers,
thus many patients diagnosed with lung cancer will also have underlying, and potentially
undiagnosed COPD. Inflammation is the hallmark of both COPD and RILI and we hypothesize
that imaging measurements of airway function (airway disease or inflammation) and airspace
structure (emphysema) provide a way to predict the enhanced and prolonged inflammatory
response to radiation. Previous studies however have failed to establish that spirometric (FEV1)
and other standard measurements of COPD severity are predictive of RILI23, likely because
spirometry provides a global measurement of disease, and thus tumour burden and underlying
COPD have a confounding effect on results. Therefore, in a study currently underway, we aim
to evaluate measurements of airway function and tissue destruction typical of COPD in the
contralateral lung only using 3He MRI, to determine whether they may be useful for predicting
RILI onset. The findings presented in Chapter 4, demonstrating the potential of 3He MRI to
categorize subjects into subgroups according to predominant measures of underlying disease,
have led to the current study using hyperpolarized 3He MRI to measure the contribution of ADC
and VDP to total disease measured in the contralateral lung of patients prior to radiation and
evaluate these phenotypes as predictors of RILI. In this study, we hypothesize that quantification
of ventilation using 3He MRI in patients with advanced lung cancer scheduled for radiation
therapy can be used to quantify underlying lung disease, and will be predictive of treatment
outcomes.
To date, 17 subjects recruited from the London Regional Cancer Program scheduled for radical
radiation therapy (>60Gy) have enrolled in the study, and provided informed consent.
Pulmonary function tests including spirometry, plethysmography and DLCO were performed,
followed by MRI in a single study visit as described in Chapters 2-5, prior to the first scheduled
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radiation treatment. MRI images were analyzed, and VDP and ADC% were measured in the
contralateral lung independently (to avoid confounding results due to tumour burden) according
to the methods outlined in Chapter 4. Briefly, ADC measurements taken from the contralateral
lung were scaled from 0-100% using an ADC range of 0.24cm2/s to 0.88cm2/s, based on the
expected healthy ADC value of the youngest subject (47 years old) based on results published by
Fain and co-workers24, and the maximum ADC value for helium in an infinitely large
container.25 The scaled ADC% values and VDP values were summed to obtain an overall 3He
MRI total disease measurement. CT data collected for diagnosis, treatment planning and followup as part of standard care were acquired for interpretation of radiological changes following
radiation therapy. CT images will be evaluated for radiological evidence of RILI by a radiologist
specializing in thoracic imaging, and a radiation oncologist with an expertise in lung cancer,
according to criteria previously published by Palma and co-workers.26
Results to date indicate that 9 of 17 subjects (53%) were VDP dominant, while the remainder
had mixed disease according to 3He MRI VDP and ADC% measurements. Interestingly, no
subjects had ADC dominant disease according to 3He MRI measurements of the contralateral
lung. Representative VDP dominant subjects are shown in Figure 6-1, representative mixed
subjects are shown in Figure 6-2 and all subjects ranked by total disease are shown in Figure 6-3.
Total disease (sum of ADC% and VDP) was significantly different (p<0.001), and greater in the
subjects with mixed disease. Additionally, linear regression showed relationships between VDP
in the contralateral lung and FEV1%pred (r2=0.57, p<0.001), FEV1/FVC (r2=0.36, p<0.05), and
DLCO (r2=0.50, p<0.01), while contralateral ADC showed a linear relationship with the same
pulmonary function test measurement (FEV1 %pred r2=0.45, p<0.05; FEV1/FVC r2=0.63,
p<0.001; DLCO r2=0.69, p<0.001). Future analysis will determine if these underlying phenotypes
play a role in RILI development.
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Figure 6-1: Representative 3He VDP dominant subjects
Static ventilation images are shown in (i), and ADC maps are shown in (ii) for subjects 016 (A), 018 (B)
and 015 (C) for lung cancer subjects classified as VDP dominant according to 3He MRI measurements of
the contralateral lung (left lung in all cases shown).

Figure 6-2: Representative 3He mixed subjects
Static ventilation images are shown in (i), and ADC maps are shown in (ii) for subjects 013 (A), 005 (B)
and 017 (C) for lung cancer subjects classified as having mixed disease according to 3He MRI
measurements of the contralateral lung (left lung in A and B, right lung in C).
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Figure 6-3. 3He MRI VDP and ADC% contribution in the contralateral lung of Lung Cancer Subjects
VDP and ADC% values are expressed as a percentage of the total 3He MRI disease. * are VDP dominant.

Overall, VDP and ADC% measurements may provide sensitive and specific markers for
predicting the development, severity and progression of RILI, with the potential to effect patient
care by allowing for radiation treatment planning evaluation in identified high risk patients.

6.4.2

Ventilation Defect Etiology

In this thesis we demonstrated that VDV and VDP measured from hyperpolarized 3He MRI are
sensitive and highly reproducible markers of lung ventilation.

3

He derived measurements of

VDV and VDP have potential as a novel marker of regional pulmonary ventilation abnormalities
in longitudinal and cross-sectional studies of lung disease in clinical trials aimed at evaluating
new therapeutics. Before this goal can be reached, the etiology of ventilation defects needs to be
determined.
To determine the etiology of ventilation defects, there are a number of potential studies that
could be performed. Histological validation would of course provide concrete evidence as to the
underlying pathology leading to regions of signal void on 3He MRI in the lung.

3

He ADC has

been validated in histological studies in canines and humans27,28, and should be extended in
future studies for evaluating ventilation defect etiology. Woods and co-workers performed the
first and only human study assessing 3He gas diffusion in patients prior to lung transplantation,
with subsequent morphological analysis in the explanted human lung.28 To evaluate the cause of
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ventilation defects, a study following the same protocol should be performed, with 3He spin
density images replacing the DWI, and used to guide the histological sampling of areas
surrounding the defect and within the area of the ventilation defects. Sampling areas within the
ventilation defects would allow for the evaluation of the parenchyma in the region of the defect,
to determine whether or not bullae were present and might have contributed to the region of 3He
signal void. Areas of the lung preceding the ventilation defect should also be sampled and
evaluated with specific attention on the small airways leading to the ventilation defect. Hogg
and co-workers have carefully characterized small airways disease in COPD using histology, and
this seminal work should be used to help guide the airways analysis.1,29 Histological analysis
using the techniques described here should be performed in a subject cohort with well described
ventilation defects prior to lung transplantation.
Additionally, multi-modality studies should be performed using CT and 3He MRI. These studies
should evaluate associations between airway dimensions preceding ventilation defects in the
airway tree, and quantification of areas of low attenuation within the ventilation defect. Coxson
and co-workers as well as Nakano and co-workers have probed airway dimensions using CT in
previous studies of COPD.5,7,9,30 The measurements they have previously employed could be
applied in a multi-modality study incorporating 3He MRI.

Such a study would require

registration of 3He MRI to CT images, and would also require that CT images be collected in a
similar breath-hold fashion to mimic the 3He MRI scan, thus emulating the conditions of the
airways and parenchyma during the 3He MRI scan. Association between airway dimensions,
3

He VDV and a regional overlap analysis of bullae and ventilation defects should provide further

insight into the etiology of the signal void on 3He MRI.

6.4.3

Hyperpolarized Noble Gas MRI Phenotypes of COPD

Another key future study that should be performed is a follow-up to the study presented in
Chapter 4, using measurements derived from 3He MRI to classify patients with COPD according
to the proportion of 3He MRI measured disease. The follow-up study should begin with a large
cross-sectional sample of subjects with COPD, with cohorts of subjects from all four stages of
disease. This diverse population will aid in understanding potential underlying phenotypes that
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exist across all stages of COPD, detectable through measurements derived from 3He MRI. A
larger sample size than previously studied will allow for more sophisticated statistical analysis,
such as principal component analysis, probing underlying COPD phenotypes detected using 3He
MRI. Furthermore, this will enhance our understanding of the proportion of subjects with
ventilation defect dominant, ADC dominant and mixed disease based on 3He MRI in early stages
of COPD as compared to the proportion of each subgroup in the later stages of disease.
Additionally, these subject cohorts should be followed longitudinally to determine how
individuals progress from one classification to another, and how changes in disease severity
effect 3He MRI disease classification.

6.4.4

Hyperpolarized 129Xe MRI: Ventilation Defects in Health and Disease

Finally, and as previously eluded to, there is a shortage of 3He that limits the future translation of
this technique. Currently, studies are underway to evaluate

129

Xe as a 3He replacement for

hyperpolarized noble gas MRI in human studies.20-22,31-33 Initial studies using

129

Xe MRI in

humans have been completed, and the results from these studies are promising.20,31-33 Studies
presented in this thesis should be repeated using 129Xe, to evaluate the short-term reproducibility
of VDV and VDP measured from
from

129

129

Xe MR images, as well as the sensitivity of VDP derived

Xe MR images to age- and disease-related changes.

129

Xe will not only be able to probe

alveolar diffusion and ventilation, but it also has the advantage of being a probe for
transmembrane diffusion.21,31-33

129

Xe is soluble in blood and tissue, and during MR imaging,

exhibits a readily discernible frequency shift and retains longitudinal relaxation times of several
seconds.31-33 Thus, using hyperpolarized 129Xe as an inhaled contrast agent for MR imaging, the
intraalveolar diffusion, ventilation and transmembrane diffusion can all be evaluated. Future
studies using 129Xe will be particularly useful in the evaluation of RILI. Probing the transfer of
129

Xe from the alveolar spaces into the capillaries provides information on the thickness of the

tissue barrier separating the air spaces and capillaries. Differences detected in thickness of the
alveolar tissue, especially thickening in regions will likely be associated with regions of inflamed
and fibrosed tissue following radiation therapy. Overall, the addition of xenon transfer constant
measurements that accompany

129

Xe MRI may have a potential role in RILI as an early marker
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of injury onset. This will largely depend on the sensitivity of 129Xe MRI xenon transfer constant,
which will require evaluation in preliminary studies of this technique.
Overall, studies of lung function using surrogate measurements of ventilation derived from
hyperpolarized gas MRI should be further developed. VDV and VDP hold promise as noninvasive, sensitive markers of lung function that will be useful in longitudinal and cross-sectional
studies of lung disease, specifically in research studies evaluating the functional burden of
structural disease changes and clinical trials evaluating new therapeutics.

6.5 Impact and Significance
Overall, in this thesis we have introduced a novel method for quantifying regional and total lung
ventilation from 3He MR static ventilation images.

VDV and VDP, with high short-term

reproducibility, are sensitive to age-related differences in lung ventilation, and changes in lung
function following treatment in subjects with lung cancer. Furthermore, they can be used to
phenotype subjects with lung disease according the magnitude of functional impairment and the
magnitude of structural impairments. The results of studies presented in this thesis provide a
foundation for future studies using 3He MRI aimed at evaluating longitudinal or treatment related
changes in lung function in subjects with smoking related lung disease. Additionally, VDV and
VDP measurements are translatable, and can be used to quantify lung function from

129

Xe MR

images. 3He MRI derived VDV and VDP are sensitive metrics of lung function and can be used
both independently and in conjunction with structural 3He MR imaging measurements to gain a
more complete understanding of the lung in health and disease.
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Appendix – A: Hyperpolarized 3He Magnetic Resonance
Pulmonary Imaging: Image Processing Tools for Clinical
Research
The work presented in this chapter has been previously published in Conference Record on the
Forty-Second Asilomar Conference; Signals, Systems and Computers as follows.
L. Mathew, A. Wheatley, DG McCormack, G. Parraga. “Hyperpolarized 3He Magnetic Resonance
Pulmonary Imaging: Image Processing Tools for Clinical Research” Conference record on the Fortysecond Asilomar Conference Signals, Systems and Computers, 2008.

A.1 Introduction
Chronic obstructive pulmonary disease, (COPD) is a leading cause of death worldwide1, and
continues to grow in prevalence.2 The worldwide Burden of Obstructive Lung Disease (BOLD)
study recently reported that 10% of the world’s adults 40 years and older have clinically relevant
COPD.3,4 Surprisingly, the world-wide COPD prevalence in never-smokers was between 6 and
15%, only slightly lower than for tobacco smokers.5
Despite decades of active research, as well as the staggering and growing societal burden of
COPD, therapeutic breakthroughs have not occurred, largely because of: 1) inadequate patient
phenotyping of underlying pathology, 2) an incomplete understanding of COPD pathogenesis,
and, 3) a scarcity of sensitive tools that can track disease changes. These limitations are critical
considerations when treating patients and evaluating clinical trials because the intermediate
endpoints currently in use (such as lung function measured using spirometry) are poor surrogates
for long-term outcomes -the ultimate target of new treatments.

In response to these serious

limitations, non-invasive imaging techniques have been recently proposed by Hogg6 as potential
solutions, because they may provide in vivo phenotypes of lung pathology and function that can
be used for testing new treatments and to personalize patient therapy.
Computed tomography (CT) has emerged as a research and clinical tool because it provides high
resolution images of pulmonary anatomy, and quantitative information about lung tissue
structure. However, CT is also associated with a small, but potentially significant radiation
burden that limits “dynamic” imaging of the lung and longitudinal imaging in certain patients.
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Hyperpolarized helium-3 (3He) magnetic resonance imaging (MRI) has recently emerged as
another research approach7-11 for the non-invasive measurement of lung structure and function,
including conduction of gas through airways and into airspaces. Preliminary studies suggest that
3

He MRI may be ideally suited for longitudinal respiratory research, which is a likely target
3

application of this novel technology.

He MRI provides a complementary and alternative

method for evaluating respiratory disease and may be superior to CT because it allows

simultaneous visualization of both airway and airspace structure and function at high spatial and
temporal resolution. Two major pathological phenotypes that can be directly measured in
respiratory disease involve changes in the airways and airspaces, which in COPD are reflected in
emphysema and airways disease.12

Emphysema is defined histologically as an abnormal

permanent enlargement of the lung parenchyma (or airspace) beyond the terminal bronchioles
with destruction of the alveolar walls.13

Hogg and coworkers14 have recently identified that

pulmonary inflammation is associated with both tissue proliferation in the airways (manifested
as airways disease) and tissue destruction in the respiratory bronchioles (manifested as
emphysema), these sites separated by only a few micrometers. In this regard it is important to

note that a major goal of COPD research in particular and respiratory research in general is to
find a way to differentiate patients with these underlying disease pathological “phenotypes”
because the treatments required for the different pathologies are conceptually and practically
very different. For decades, the concept of pathology-based respiratory treatments has been
explored with the notion that this could result in more efficacious and personalized patient care.
However, it remains difficult, if not impossible, to phenotype (i.e. measure the physical or
pathological characteristics of) patients in vivo based upon underlying disease pathology.
A handful of research centres world-wide have pioneered the use of inhaled hyperpolarized
noble gases such as 3He for lungs imaging.7,9-11,15-20 The images acquired provide both
anatomical and functional information of the respiratory system that have never before been

attained.

Of the numerous and novel hyperpolarized 3He MRI measurements that can be

obtained, the 3He ventilation defect and ventilation volume provides an opportunity to visualize
(with 1x1mm in-plane resolution and 15-mm slice thickness) and quantify those areas of the lung
that participate in ventilation and those that do not. As shown in Figure A-1, in healthy young
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adults, a single inhalation of hyperpolarized 3He gas results in homogeneous signal suggesting
that all areas of the lung are participating equally in ventilation. In contrast, characteristic
volumetric “focal” defects are observed in COPD, corresponding to areas of the lung that are not
ventilated or are poorly ventilated within the time-course of a typical 8-16s breath hold scan.

Figure A-1: Clinical Hyperpolarized 3He Magnetic Resonance Imaging.
A. functional imaging in a healthy volunteer during a 15 second 3He breath hold, no ventilation defects
are seen B. a subject with stage III COPD with large regions of signal void (ventilation defects), and C. a
subject with exercise induced asthma showing focal ventilation defects.

As shown in Figure A-2, scoring methods have been developed and used to provide quantitative
regional 3He ventilation defect scores21,22 whereby focal ventilation defects are counted and a
defect score/slice is generated. For example, one of the currently used tools for quantifying
regions void of 3He signal team of radiologists to count them on a slice by slice basis, and
dividing by the total number of slices to get the mean number of ventilation defects per slice
(VDS). 21,22 Another method shown in Figure A-3 relies on defect scoring by consensus, whereby
a group of three radiologists would review all slices of the 3He MRI and estimate the percentage
of the lung that appears not to be ventilated.23 These techniques are subject to interpretation,
observer bias and potentially less sensitive to the physiological changes that appear to take place
in the lung. In addition, in longitudinal studies where focal ventilation defects often change in
size as compared to the number of defects, consensus defect and ventilation scoring methods
often fail to reveal physiological truth because we and others have observed that ventilation
defects often grow in volume as compared to number over time.
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Figure A-2: Ventilation Defect scoring of 3He MRI.
Ventilation defect scoring of the center slice is shown for A. asthma subject at baseline, B. asthma subject
5 minutes post-exercise, C. asthma subject 55 minutes post-exercise. This demonstrates the lack of
information VDS yields- specifically changes in size and location of defects.

Therefore, in order to accelerate the use of 3He MRI in clinical longitudinal research, new image
analysis, image visualization and processing/segmentation tools are required that account for the
physiological changes that potentially can occur and that provide appropriate continuous
statistical endpoints. We hypothesize that 3He MRI can be analyzed to provide information
about how lung regions which are not receiving ventilation change over time, and how potential
treatments will affect these unventilated regions. In order to do this, tools that can quantify
differences in ventilation are needed, which are both sensitive and specific to regional changes in
ventilation over time. These types of tools will have the capability to assess not only regions of
signal void, but also regions that are decreasing in ventilation over time- possibly predicting the
location of a future ventilation defect. Hyperpolarized 3He MR ventilation images contain the
information necessary to quantify regional changes in lung function, and thus the aim of this
paper is to outline the exact tools needed for this to occur. Here we propose preliminary results
of novel image processing tools we have designed to account for these differences and address
the outlined image processing needs are described below.

A.2 Methods
Subjects with asthma and stage II and stage III COPD were recruited for various studies at our
site. All subjects provided written informed consent to the study protocols approved by the local
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ethics board and Health Canada. Longitudinal time points ranged from same-day rescan to a 2year follow up study.

Figure A-3: Ventilation Defect Evaluation: Estimation by Consensus.
Ventilation defect estimation by consensus is shown in the centre slice for A. asthma subject at baseline,
B. asthma subject 5 minutes post-exercise, C. asthma subject 55 minutes post-exercise. Binning of
ventilation abnormalities into groups such as mild-moderate and severe is shown to be an insensitive
technique for assessing ventilation and ventilation differences.

A.3 Results
A.3.1 Image Visualization
Image analysis was performed in a controlled lighting environment.

For the purposes of

visualizing and scoring images at baseline and follow-up, images from each visit were compared
visually on side-by-side monitors. For direct visualization of differences in signal intensity in
baseline and two year follow-up images were changed to red and blue colour scales respectively.
These images were previously registered based on main airway anatomy as described below. Red
baseline and blue follow-up images were then summed on a pixel-by-pixel basis, with the
resulting image showing the contribution of each scan as visualized through the pixel hue.

A.3.2 Image Registration
Hyperpolarized 3He MR images acquired at different time points require image registration
before they can be directly compared. This may be possible by rigid registration of points
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surrounding the trachea, right and left bronchi, and carina. In order for registration to be
successful points used must be present at each time point. Image registration in this preliminary
study was performed using a manual image registration of specified points- most consistently the
carina, but also points along the perimeter of the trachea. An expert observer selected points in
images acquired at each time point and then manually aligned them using in-house software.

A.3.3 Signal Normalization
Following image registration 3He signal normalization is necessary. This is due to the fact that
there are both physiological and non-physiological reasons for differences in signal intensity of
pixels in images from the same subject at different time points. Differences in 3He signal
intensity due to physiological reasons such as changes in disease should be measured, but prior
to this non-physiological reasons for differences in 3He signal intensity must be accounted for.
These reasons include minor differences in absolute polarization of the 3He when it leaves the
polarizer, and differences in the amount of time that it takes to get the 3He from the polarizer and
into the patient. Finally non-physiological differences in signal intensity may be due to the exact
amount of gas inhaled, as subjects with severe disease may struggle to inhale the complete 1.0L
of gas while in the supine position.
For all images the mean and standard deviation of the background noise was computed from four
30x30 pixel regions of interest. A threshold of the mean background noise plus two standard
deviations of the background noise was applied. In this preliminary study, no signal
normalization was performed and window and leveling was not changed to account for nonphysiological differences in signal intensity.

A.3.4 Image Subtraction
Once image registration was complete image subtraction was performed using two different
methods. First, the absolute signal intensity difference was calculated on a pixel-by-pixel basis.
Baseline visit images were subtracted from follow-up visit images. Results were displayed in
colour showing a full range of differences in intensity from -255 to +255. Second, normalized
image subtraction was performed to show the percentage change from baseline as shown in
Figure A-4 and Figure A-5 for subjects with COPD and radiation-induced lung injury
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respectively. This was done by dividing the absolute subtraction image pixel values by baseline
image pixel values. Pixels resulting in the normalized subtraction image were calculated on a
pixel-by-pixel basis. If the absolute difference between pixels was zero, normalization values
were automatically set to zero. In cases where the follow-up pixel intensity was not equal to zero
and the corresponding baseline pixel signal intensity value was equal to zero, the normalized
value was set to positive or negative 110% based on the follow-up pixel value. In order to
visualize regions of change less than 100%, output image normalization values greater than
110% were scaled to 110%. This enabled visualization of minor ventilation differences.

A.4 Conclusion
3

He MRI measurement precision, sensitivity and specificity are required in order to translate

these surrogates as intermediate endpoints in clinical research. To accomplish this, novel image
registration, signal normalization and image subtraction methods are under development for
asthma, COPD, cystic fibrosis and radiation-induced lung injury.
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Figure A-4: Image Processing for a Subject with Stage III COPD.
A. baseline, B. two-year follow-up, C. image addition – baseline is red and two-year follow-up is blue, D. absolute image subtraction
(baseline – follow-up) on a pixel-by-pixel basis, E. normalized image subtraction ((baseline – follow-up)/baseline) on a pixel-by-pixel
basis.

Figure A-5: Image Processing for a Subject with Radiation-induced lung injury.
A. baseline, B. five month follow-up, C. image addition – baseline is red and two-year follow-up is blue, D. absolute image subtraction
(baseline – follow-up) on a pixel-by-pixel basis, E. normalized image subtraction ((baseline – follow-up)/baseline) on a pixel-by-pixel
basis. Mis-registration is evident in the lower right lobe, suggesting that registration based on points beyond the trachea and main bronchi
may be necessary.

169

A.5 References
(1) Murray CJ, Lopez AD. Alternative projections of mortality and disability by
cause 1990-2020: Global Burden of Disease Study. Lancet. 1997;
349(9064):1498-1504.
(2) Global strategy for the diagnosis, management, and prevention of chronic
obstructive pulmonary disease. NHLBI/WHO Workshop Report Update. 2701.
2003.
(3) Buist AS, McBurnie MA, Vollmer WM et al. International variation in the
prevalence of COPD (the BOLD Study): a population-based prevalence study.
Lancet. 2007; 370(9589):741-750.
(4) Menezes AM, Perez-Padilla R, Jardim JR et al. Chronic obstructive pulmonary
disease in five Latin American cities (the PLATINO study): a prevalence study.
Lancet. 2005; 366(9500):1875-1881.
(5) Menezes AM, Perez-Padilla R, Jardim JR et al. Chronic obstructive pulmonary
disease in five Latin American cities (the PLATINO study): a prevalence study.
Lancet. 2005; 366(9500):1875-1881.
(6) Hogg JC, Chu F, Utokaparch S et al. The nature of small-airway obstruction in
chronic obstructive pulmonary disease. N Engl J Med. 2004; 350(26):2645-2653.
(7) Albert MS, Cates GD, Driehuys B et al. Biological magnetic resonance imaging
using laser-polarized 129Xe. Nature. 1994; 370(6486):199-201.
(8) Yablonskiy DA, Sukstanskii AL, Leawoods JC et al. Quantitative in vivo
assessment of lung microstructure at the alveolar level with hyperpolarized 3He
diffusion MRI. Proc Natl Acad Sci U S A. 2002; 99(5):3111-3116.
(9) Mills GH, Wild JM, Eberle B et al. Functional magnetic resonance imaging of the
lung. Br J Anaesth. 2003; 91(1):16-30.
(10) Kauczor HU, Hofmann D, Kreitner KF et al. Normal and abnormal pulmonary
ventilation: visualization at hyperpolarized He-3 MR imaging. Radiology. 1996;
201(2):564-568.
(11) de Lange EE, Mugler JP, III, Brookeman JR et al. Lung air spaces: MR imaging
evaluation with hyperpolarized 3He gas. Radiology. 1999; 210(3):851-857.
(12) Hogg JC, Chu F, Utokaparch S et al. The nature of small-airway obstruction in
chronic obstructive pulmonary disease. N Engl J Med. 2004; 350(26):2645-2653.
(13) Fabbri LM, Hurd SS. Global Strategy for the Diagnosis, Management and
Prevention of COPD: 2003 update. Eur Respir J. 2003; 22(1):1-2.

170
(14) Hogg JC. Pathophysiology of airflow limitation in chronic obstructive pulmonary
disease. Lancet. 2004; 364(9435):709-721.
(15) Kauczor HU, Ebert M, Kreitner KF et al. Imaging of the lungs using 3He MRI:
preliminary clinical experience in 18 patients with and without lung disease. J
Magn Reson Imaging. 1997; 7(3):538-543.
(16) MacFall JR, Charles HC, Black RD et al. Human lung air spaces: potential for
MR imaging with hyperpolarized He-3. Radiology. 1996; 200(2):553-558.
(17) Tooker AC, Hong KS, McKinstry EL et al. Distal airways in humans: dynamic
hyperpolarized 3He MR imaging--feasibility. Radiology. 2003; 227(2):575-579.
(18) Wild JM, Paley MN, Viallon M et al. k-space filtering in 2D gradient-echo
breath-hold hyperpolarized 3He MRI: spatial resolution and signal-to-noise ratio
considerations. Magn Reson Med. 2002; 47(4):687-695.
(19) Van Beek EJ, Wild JM, Kauczor HU et al. Functional MRI of the lung using
hyperpolarized 3-helium gas. J Magn Reson Imaging. 2004; 20(4):540-554.
(20) Van Beek EJ, Wild JM. Hyperpolarized 3-helium magnetic resonance imaging to
probe lung function. Proc Am Thorac Soc. 2005; 2(6):528-532.
(21) de Lange EE, Altes TA, Patrie JT et al. The variability of regional airflow
obstruction within the lungs of patients with asthma: assessment with
hyperpolarized helium-3 magnetic resonance imaging. J Allergy Clin Immunol.
2007; 119(5):1072-1078.
(22) de Lange EE, Altes TA, Patrie JT et al. Evaluation of asthma with hyperpolarized
helium-3 MRI: correlation with clinical severity and spirometry. Chest. 2006;
130(4):1055-1062.
(23) van Beek EJ, Hill C, Woodhouse N et al. Assessment of lung disease in children
with cystic fibrosis using hyperpolarized 3-Helium MRI: comparison with
Shwachman score, Chrispin-Norman score and spirometry. Eur Radiol. 2007;
17(4):1018-1024.

171

Appendix – B: Hyperpolarized 3He Magnetic Resonance
Imaging Biomarkers of Bronchoscopic Airway Bypass
in COPD
The work presented in this chapter has been submitted to Journal of Magnetic Resonance
Imaging for publication (submission # JMRI-10-0886).
L. Mathew, M. Kirby, D. Farquhar, C. Licskai, R. Etemad-Rezai, DG McCormack, G. Parraga
“Hyperpolarized 3He Magnetic Resonance Imaging Biomarkers of Bronchoscopic Airway Bypass
in COPD” Submitted to J Magn Reson Imaging, January 2011.

B.1 Introduction
Pulmonary functional imaging using hyperpolarized helium-3 magnetic resonance
imaging (3He MRI) provides quantitative regional pulmonary functional information with
high sensitivity to longitudinal changes in chronic obstructive pulmonary disease
(COPD).1 In the case of lung functional changes in COPD after drug2 or direct airway
interventions3 a discordant relationship has been previously reported between
symptomatic improvements measured using quality of life scores, and pulmonary
function tests.4 Until very recently, the use of pulmonary imaging methods has been
limited to the evaluation of structural lung changes. Here, we report the first case of an
elderly ex-smoker with severe emphysema who was monitored longitudinally for 2 years
before, and 1 year after bronchoscopic Airway Bypass (AB) using 3He MRI for the
quantitative evaluation of functional lung changes.

B.2 Case Report
A 73-year old male ex-smoker with GOLD stage III COPD underwent AB in February
2009 as part of the Exhale Airway Stents for Emphysema (EASE) Trial. AB is an
investigational procedure that involves Doppler-guided transbronchial delivery and
airway insertion of drug-eluting stents (Exhale® Drug-Eluting Stent, Broncus
Technologies, Inc., USA) with the aim being connection of the segmental airways to
adjacent lung tissue allowing trapped gas to be exhaled. Written informed consent was
provided to a Health Insurance Portability and Accountability Act (HIPAA) compliant
protocol approved by a local ethics board, and Health Canada. Thirty-two months prior
to AB (June 2006), he reported a 70-pack-year smoking history, having ceased smoking
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approximately 13 years earlier, and was enrolled in a longitudinal hyperpolarized 3He
MRI study that also included same day spirometry and plethysmography. As shown in
Table B-1, at 32 months pre-AB forced expiratory volume in one second (FEV1) was
1.2L (32%pred), and residual volume (RV) to total lung capacity (TLC) ratio was 0.62.
Hyperpolarized 3He ventilation and diffusion-weighted MRI was performed on a 3.0T
scanner (Excite 12.0, GEHC, Milwaukee, WI) as previously described5 in a breath-hold,
after inspiration of 1.0L of 5mL/kg 3He mixed with N2 gas from functional residual
capacity (FRC). Proton images were also acquired as previously described6 within 3
minutes of 3He MRI, with the same breath-hold volume from functional residual capacity
(FRC) (1.0L of 4He/N2 mixture) to obtain a structural image of the thorax allowing for
clear delineation of the thoracic cavity.

3

He ventilation MRI (Figure B-1A, 32 months

pre-AB) shows a heterogeneous distribution of gas with large ventilation defects, and in
regions of gas distribution, heterogeneous signal intensity - both of which are the
hallmark of COPD. Upon returning for follow-up imaging 24 months later in June 2008
(8 months pre-AB Figure B-1B) 3He MR images showed a decrease in ventilation of the
right upper and lower and left upper lung regions (Figure B-1B). Quantitative analysis of
the 3He ventilation distribution (Table B-1) resulted in a 3He MRI ventilation volume
(VV) decrease of 3.8L over the two year period, corresponding to a decrease in the
percentage of ventilated lung volume (PVV) from 73% to 26% and an increased
ventilation defect percent (VDP).

The functional imaging changes observed were

concomitant with a decrease in FEV1 and FVC and an increase in RV/TLC (Table B-1)
during the follow-up period. There were no exacerbations or hospitalizations reported
during the follow-up period.
At this time the subject was enrolled in a randomized double-blind study evaluating the
safety and efficacy of AB in subjects with homogeneous emphysema and severe
hyperinflation (RV/TLC≥0.65).

For 6 weeks prior to AB, the subject underwent

pulmonary rehabilitation, and four days prior to AB his self-reported dyspnea rating was
2 on the modified Medical Research Council (mMRC) scale and his St George’s
Respiratory Questionnaire (SGRQ) score was 65. In February 2009 four stents were
placed; two in the right lower and two in the left upper lung. The subject returned for
follow-up evaluation one, three, six and twelve months post-stent, with 3He MRI at the
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six month (Figure B-2A) and twelve month (Figure B-2B) time points. At 6 months postAB, the subject reported an increase in forced vital capacity (FVC) ≥ 12% and therefore
failed to achieve responder status and was subsequently categorized as an AB nonresponder.

Table B-1: Pulmonary function test and 3He MRI results pre- and post-AB.
Months
32
FEV1 (L)
FEV1 (%pred)
FVC (L)
FVC (%pred)
FEV1/FVC (%)
RV (L)
RV (%pred)
TLC (L)
TLC (%pred)
RV/TLC
IC (L)
DLCO
(ml/min/mmHg)
DLCO (%pred)
mMRC
6MWD (m)
SGRQ
CE (s)
WL TCV (L)
WL VV(L)
WL PVV (%)
WL VDV (L)
WL VDP (%)
WL ADC (cm2/s)

1.2
32
3.2
66
37
5.2
193
8.4
111
0.62
1.8

7.3
5.4
73
2.0
27
0.47

Pre-Airway Bypass
8
2
0.8
23
2.3
49
34
5.2
200
8.0
107
0.65
1.6

6.3
1.6
26
4.7
74
0.49

Post-Airway Bypass
3
6

0.1

1

0.9
27
2.6
57
35
5.6
213
8.6
115
0.65
1.6
9.2

1.1
32
3.2
68
35
4.4
169
7.8
104
0.57
2.1
9.9

1.2
34
3.6
77
32
5.0
190
8.2
114
0.60
2.3
14.6

1.2
35
3.6
78
33
4.5
169
8.2
110
0.55
2.3
16.9

1.1
33
3.5
76
32
4.7
169
8.3
108
0.56
1.8
14.6

1.2
35
3.8
81
31
5.0
189
8.5
114
0.58
2.8
18.7

26

28
2
288
65
750

42
1
315
27

48
0
330
27

42
1
366
27
1084
8.5
4.8
57
3.6
43
0.48

53
1
330
31

Note: the dashed line separates pre- and post-AB results
FEV1 = forced expiratory volume in one second, FVC = forced vital capacity, RV = residual
volume, TLC = total lung capacity, IC=Inspiratory Capacity, DLCO=Carbon Monoxide Diffusion
Capacity of the lung, mMRC = modified medical research council, 6MWD = six minute walk
distance, SGRQ = St. George’s research questionnaire, CE = cycle ergometry,
TCV = thoracic cavity volume, VV = ventilated volume, PVV = percent ventilated volume, VDV
= ventilation defect volume, VDP = ventilation defect percent, ADC = apparent diffusion
coefficient.

In contrast, at 6 months post-AB, very obvious changes in 3He MRI were observed
throughout the right lung and in the left upper lobe at six months (Figure 2A) with further

12

8.1
5.8
72
2.4
28
0.49
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improvements, specifically in the right lower lung observed at twelve months (Figure 2B)
post AB. Such visual changes did appear to generally correspond with stent placements
in the right lower and left upper lung lobes. These gas distribution improvements that
occurred after stent placement corresponded to 3He MRI VV increases of 3.2L at 6
months and 4.2L, 1 year after the AB procedure. As noted in Table B-1, the thoracic
cavity volume (TCV) measured using 1H MRI increased approximately 2.0L between the
8 month pre-stent visit and the 6 and 12 month post-stent visits. Taken together, the
increase in VV and TCV resulted in an improved PVV 6 months post-stent that persisted
at the 1 year post AB time-point. At the same time, other surrogate measures of lung
functional capacity including the six minute walk distance (6MWD), SGRQ score and
cycle ergometry (CE) time showed improvements post-AB 6MWD increased by 78m,
SGRQ score decreased by 38, and CE time improved by 334s. During this same time
period an increased diffusing capacity of carbon monoxide (DLCO) was measured with
3

He MRI whole lung ADC remaining unchanged.

Figure B-1: 3He MRI registered to 1H MRI Prior to Airway Bypass.
3

He MRI registered to 1H MRI of GOLD stage III COPD ex-smoker A) 32 months prior to AB
and B) 8 months prior to AB. Heterogeneous 3He signal intensity and large ventilation defects
are visualized in both scans, with 3He MRI VV decreased by 3.8L during this two year time
period.
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B.3 Discussion
Bronchoscopic lung volume reduction methods provide a minimally invasive alternative
to lung volume reduction surgery with the goal of improving COPD quality of life,
pulmonary function and survival.7-9

Unfortunately, for many of these approaches,

including AB10, significant improvements in the established intermediate endpoints such
as FEV1 and RV/TLC have not been realized post-intervention3,4 and sometimes these
results are discordant with measures of symptoms or functional improvements. In these
studies lung imaging has been used only as a structural tool to capture lung volumes
using CT.

Figure B-2: 3He MRI registered to 1H MRI Following Airway Bypass.
3

He MRI registered to 1H MRI of GOLD stage III COPD ex-smoker A) 6 months post-AB and B)
12 months post-AB after insertion of two stents left upper lung and two stents right lower lung.
Improved gas distribution post-AB is suggested with new regions of 3He ventilation and
increased 3He signal intensity and VV at both time points post-AB.

3

He MRI has emerged over the last 10 years as a highly reproducible and sensitive

research tool for the evaluation of COPD in cross-sectional and longitudinal
studies1,5,11,12. Here we show hyperpolarized 3He MRI in a COPD ex-smoker on 4
occasions – twice before AB (32 and 8 months prior) and twice after AB (6 and 12
months post) and the results suggest significant improvements in gas distribution (3He
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VV increase of over 3L) 6 months and 12 months after AB. These imaging results
cannot be explained by the small changes in spirometry and plethysmography results but
they are in agreement with post-AB changes (improvements) in the 6MWD, SGRQ and
mMRC.
In summary, we report changes in 3He MRI VV for a COPD ex-smoker following AB
that are similar to changes in quality of life measurements but not reflected in FEV1,
FVC, IC or RV/TLC. Potential explanations for these findings include higher sensitivity
of 3He MRI to functional lung changes than traditional pulmonary function tests. This
discordance in outcome measures, in the only EASE Trial subject for whom 3He MRI
was performed, highlights the utility of functional lung imaging in COPD interventional
trials, and suggests this high resolution functional imaging method may offer insight into
underlying regional physiologic changes in COPD patients following treatment.
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